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ABSTRACT
As most adaptive clinical trial designs are implemented in stages, well-understood meth-
ods of sequential trial monitoring are needed. In the frequentist paradigm, examples of
sequential monitoring methodologies include the p-value combination tests, conditional er-
ror, conditional power, and alpha spending approaches. Within the Bayesian framework,
posterior and predictive probabilities are used as monitoring criteria, with the latter being
analogous to the conditional power approach.
In a placebo or active-contolled dose response clinical trial, we are interested in achieving two
objectives: selecting the best therapeutic dose and confirming this selected dose. Traditional
approach uses the parallel group design with Dunnett’s adjustment. Recently, some two-
stage Seamless II/III designs have been proposed. The drop-the-losers design considers
selecting the dose with the highest empirical mean after the first stage, while another
design assumes a dose-response model to aid dose selection. These designs however do not
consider prioritizing the doses and adaptively inserting new doses. We propose an adaptive
staggered dose design for a normal endpoint that makes minimal assumption regarding the
dose response and sequentially adds doses to the trial. An alpha spending function is applied
in a novel way to monitor the doses across the trial. Through numerical and simulation
studies, we confirm that optimistic alpha spending coupled with informative dose ordering
jointly produce some desirable operating characteristics when compared to drop-the-losers
and model-based Seamless designs. In addition, we show how the design parameters can
vii
be flexibly varied to further improve its performance and how it can be extended to binary
and survival endpoints.
In a biosimilarity trial, we are interested in establishing evidence of comparable efficacy be-
tween a follow-on biological product and a reference innovator product. So far, no standard
method for biosimilarity has been endorsed by regulatory agency. We propose a Bayesian
hierarchical bias model and a non-inferiority hypothesis framework to prove biosimilarity.
A two-stage adaptive design using predictive probability as early stopping criterion is pro-
posed. Through simulation study, the proposed design controls the type I error better than
the frequentist approach and Bayesian power is superior when biosimilarity is plausible.
Two-stage design further reduces the expected sample size.
viii
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1Chapter 1
Rise of Adaptive Methods in Clinical Trials
1.1 Introduction
Society and government regulatory agencies have high expectations for the production of
safe and efficacious drugs from the pharmaceutical industry. However, the success rate of
new drugs remains low or may even be in decline. In the past decade, the submission rate
of new drug applications in the United States has shown a downward trend while the in-
vestment cost has risen (Woodcock and Woosley, 2008). In 2004, the U.S. Food and Drug
Administration (FDA) launched the Critical Path Initiative, a project that is intended to
improve the drug and medical device development processes, the quality of evidence gener-
ated, and the outcomes of clinical use of these products. This has generated considerable
discussion and debate among drug developers, academics, and patient advocacy groups.
After extensive consultation with stakeholders, the FDA issued the Critical Path Report
and List in 2006. This report enumerated several important areas of scientific improve-
ment - development and utilization of biomarkers, modernizing clinical trials processes and
methodologies, aggressive use of bioinformatics, and improvement in manufacturing tech-
nologies. In the clinical trial community, it has been interpreted as encouragement for the
use of innovative adaptive design methods.
Recent achievements in the methodology of adaptive designs provide new ways of drug
2development that have the potential to improve quality, speed, and efficiency of decision
making. By introducing adaptivity into trial design, this approach saves resources through
identifying failures early and increases efficiency through focusing precious patient resources
on treatments that have higher probability of success. While clearly this is advantageous
to the drug development program, this is also ethically appealing as it restricts patient
exposure to ineffective treatments (Dragalin, 2006).
By definition, an adaptive design of a clinical trial is a design that allows adaptations or
modifications to some aspects of the trial after its initiation without undermining the valid-
ity and integrity of the trial (Chow, Chang, and Pong, 2005). Maintaining validity requires
ensuring consistency between different stages, minimizing operational bias, and providing
correct statistical inference; maintaining integrity requires providing convincing results to
the broader scientific community. An adaptive design requires the trial to be conducted
in multiple stages with convenient access to the accumulated data so that prospectively
planned adaptations can be readily implemented after interim data are examined. It is im-
portant to emphasize that adaptations that are not prospectively planned are not by design
but ad hoc adaptations and they are neither recommended nor encouraged. According to
Chow and Chang (2008), modifications can be applied to either trial or statistical proce-
dures. Examples of trial procedures include eligibility criteria, study endpoints, or treat-
ment duration while those of statistical procedures are randomization schedule, hypotheses,
sample size, or analysis plan. The following sections briefly describe these adaptations.
1.2 Types of Adaptive Methods
1.2.1 Stopping Rule
Stopping rules are intended to protect patients from clearly unsafe or ineffective treatments
or to hasten the approval of a beneficial treatment when overwhelmingly strong evidence
of efficacy is observed. Many stopping rules are constructed based on boundary-crossing
3methodology. The classical group sequential method is the most representative of this
type of adaptation. At any stage in the trial, a test statistic is calculated and compared
with the given stopping boundaries. If the boundary is crossed, the trial is stopped and
the corresponding conclusion is drawn; otherwise, the trial will continue to the next stage.
Armitage, McPherson, and Rowe (1969) showed that repeating tests of significance at a fixed
level on accumulating data increase the probability of getting a significant result under the
null hypothesis. Jennison and Turnbull (2000) offered a comprehensive treatment on group
sequential methodology. For example, for a two-arm K-stage group sequential design, if Zk
is the standardized test statistic comparing the two treatments at the kth interim analysis,
then given the set of efficacy stopping boundaries, b = (b1, b2, ..., bK)′, and futility stopping
boundaries, a = (a1, a2, ..., aK)′, the probability of rejecting the null hypothesis when it is
true at the kth interim is ψk = Pθ=0(a1 < Z1 < b1, ..., ak−1 < Zk−1 < bk−1, Zk > bk) and
the probability of accepting the null hypothesis when there is a true treatment difference δ
is ξk = Pθ=δ(a1 < Z1 < b1, ..., ak−1 < Zk−1 < bk−1, Zk < ak) . Since Z = (Z1, Z2, ..., ZK)′
follows multivariate normal distribution, the boundary sets can be calculated numerically
by controlling the overall type I error, ΣKi=1ψk 6 α and type II error, ΣKi=1ξk 6 β. Very
often, a flexible alpha spending function α(t) is used to monitor the type I error, and a
beta spending function β(t) is used to monitor the type II error, where t is the information
fraction (Lan and DeMets, 1983).
1.2.2 Sampling Rule
Sample size adjustment involves the re-calculation of the sample size for subsequent stages.
This can be based on an interim estimate of a nuisance parameter such as the variance, or
based on an interim estimate of the treatment effect. For most practical purposes, this is
performed in a two-stage design in which sample size for the second stage is re-estimated
using data from the first stage. However, this can also be performed in a multiple-stage
design. There are many approaches to sample size adjustment. Blinded sample size re-
4estimation uses the estimate of the nuisance parameter without unmasking treatment codes
(Proschan, 2005; Bauer and Kieser, 1999). This is less controversial than unmasking to
obtain the pooled variance or the estimated treatment differences. In this case, the sample
size for the next stage is determined by either the estimated effect size or the conditional
power. Cui, Hung, and Wang (1999) proposed increasing the sample size based on interim
estimate of treatment difference as well as a new group sequential test procedure by changing
the weights used in the traditional repeated significance two-sample mean test. The new
test can provide a substantial gain in power with the increase of sample size while keeping
overall type I error at target level. For a two-stage design, conditional power is defined
as the probability of rejecting the null hypothesis at the end of study conditional on the
observed test statistic from the first stage. Denne (2001) shows that the conditional power
CP for a two-stage sample size re-estimation design is given by
CPθ(n2, c2|Z1 = z1) = 1− Φ
c2√n2 − z1√n1 − (n2−n1)θ√2σ2√
n2 − n1

where θ is the treatment effect of interest; n1 and n2 are the first-stage sample size and
cumulative total sample size respectively; z1 is the observed value of the standardized test
statistic Z1 in the first stage; c2 is the critical value for the overall standardized test statistic
Z2; and σ2 can be replaced by the sample variance in the first stage, s21. The value of n2
can be calculated to ensure CP = 1− β.
1.2.3 Adaptive Model-Based Dose Finding
The main goal of an early-phase dose finding study is to establish the dose response rela-
tionship, which in turn provides estimates of the maximum tolerated dose (MTD) or the
minimum effective dose (MED). This is also known as a dose escalation study, since the
decision to escalate the experimental dose for subsequent cohorts of patients is based on the
observation of dose limiting toxicity (DLT). A commonly used method is the rule-based 3+3
5conventional design. However, a more efficient method is to assume a prior dose response
model such as a logistic model and use data from each cohort of patients to continuously
update this model until the target dose is estimated with specified accuracy. This design is
sometimes referred to as the Continuous Reassessment Method (CRM), originally proposed
by O’Quigley, Pepe, and Fisher (1990). Denoting the dose levels as xi (i = 1, 2, ..., k), and Yj
as the binary toxicity response for the jth patient, a one-parameter monotonic dose response
model can be E(Yj) = ψ(xi, a). We are interested in estimating x∗ such that ψ(x∗, a) = θ
where θ is the target probability of toxicity. Usually using a Bayesian framework, a prior
distribution is elicited for a such as pi(a), then it is updated continuously with accumulat-
ing data, Y, to obtain the posterior distribution, pi(a|Y) such that x∗ can be estimated
accordingly. A number of improved versions of CRM such as the CRM − Escalation with
Overdose Control (Babb, Rigatko, and Zacks, 1998) have also been proposed.
1.2.4 Seamless Designs
A seamless design combines two trials into one single trial and achieves objectives normally
achieved in separate trials. For example, a seamless Phase 2/3 design is characterized by a
single trial with a learning stage followed by a confirmation stage (Jennison and Turnbull,
2007). Maca et al. (2006) described it as a fusion of treatment selection techniques and
hypothesis testing for integration, both operationally and inferentially, of phase 2 and 3
into a single trial. This type of design may incorporate elements of several adaptation rules.
There are advantages in combining two trials into one. Seamless designs can substantially
reduce time by eliminating the wait between two trials, and gain efficiency with a smaller
sample size than that for two trials. However, feasibility may only be restricted to a primary
endpoint with relatively short follow-up time. As for inference, the P-value Combination
Test has been proposed to combine data from both stages (Posch et al., 2005). Denoting p1
as the p-value based on data from the first stage, if p1 6 a, then null hypothesis is rejected
early, or if p1 > b, then null hypothesis is accepted due to futility. If we let p2 be the p-value
6based only on the second stage data, and C(p1, p2) be the combination function, then the
null hypothesis is rejected if C(p1, p2) 6 c and therefore we have
a+
∫ b
a
∫ 1
0
I[C(x,y)6c] dy dx = α
where I is an indicator function. Examples of combination functions are (1) the method of
product of p-values (MPP), C(p1, p2) = p1p2, which is also known as the Fisher’s criterion,
(Bauer and Kohne, 1994) (2) the method of sum of p-values (MSP), C(p1, p2) = p1 + p2
(Chang, 2007), and (3) the method of weighted inverse normal combination of p-values
(MINP), C(p1, p2) = 1−Φ[ω1Φ−1(1− p1)− ω2Φ−1(1− p2)] where ω21 + ω22 = 1 (Lehmacher
and Wassmer, 1999). The conditional power approach can be used to evaluate and compare
the operating characteristics of these methods.
1.2.5 Decision Rule
This category summarizes any additional decision rules such as changing test statistic, re-
designing multiple endpoints, selecting which hypothesis are to be tested (e.g. switching
from superiority to non-inferiority), changing the hierarchical order of hypotheses, or chang-
ing the study population as the trial continues. Lang, Auterith, and Bauer (2000) proposed
a two-stage adaptive trend test with scores corresponding to the unknown shape of a dose
response curve updated using data from the first stage. Another example of adaptive mod-
eling is choosing the right covariate at interim stage to be included at interim stage which
can increase the precision of estimating treatment effects (Wang and Hung, 2005). Hommel
(2001) investigated how one can modify the hypotheses in a trial after an interim analysis.
He suggested possible modifications such as reducing the set of hypotheses, changing the
weights of hypotheses, changing the a priori order of the hypotheses, or even adding new
hypotheses. Jenkins, Stone, and Jennison (2011) proposed a seamless phase 2/3 design
with a subpopulation selection at interim. Many of these adaptive decision rules require a
learning stage before adaptations are planned and implemented for the subsequent stages.
71.2.6 Allocation Rule
Randomization or random allocation of patients is used to maximize balance of all known
and unknown, observed and unobserved covariates (prognostic factors) at baseline between
treatments. Fixed allocation rule uses allocation probabilities that are determined in ad-
vance and are not changed during the trial. However, an adaptive allocation rule dynami-
cally alters the allocation probabilities to reflect the accruing data on the trial. Response-
adaptive allocation uses interim data to modify the allocation probabilities in favor of the
treatment arms showing superior outcomes. The earliest application of this method in a
clinical trial is the play-the-winner rule proposed by Zelen (1969), although this was first
studied by Robbins (1952). In some situations, the allocation rule removes inferior treat-
ment arms completely from a further randomization schedule.
In summary, although statistical methods have been developed to allow for these types of
adaptations, these methods should never be used as a substitute for careful planning in the
statistical design of a clinical trials. Before the trial, an adaptive design must be detailed
in the protocol to avoid the introduction of bias.
1.3 FDA Perspectives
1.3.1 Major Concerns
In response to the increasing popularity of adaptive methods in clinical trials, the FDA
released a draft guidance titled “Guidance for Industry - Adaptive Design Clinical Trials
for Drugs and Biologics” in February 2010 to unfold the agency’s current perspectives
on adaptive designs and to invite comments and suggestions from stakeholders. Gallo
et al. (2010), members of the Pharmaceutical Research and Manufacturers of America
(PhRMA), have delineated their viewpoints on the document in a white paper. These
authors recognized the concerns raised by FDA and proposed recommendations to promote
8discussion and learning between leaders from the drug development industry and from the
regulatory authority.
In Section V of the document, the FDA encourages adaptive approaches that they described
as well-understood. These approaches include adaptive exploratory studies on patient char-
acteristics such as enrollment rate or eligibility criteria, adaptations that use only blinded
interim data, interim analyses on an outcome unrelated to efficacy, and the classical group
sequential methods. However, in Section IV of the document, the FDA cautions several
areas of challenges in using adaptive design in drug development. First, adaptive design
has the potential to increase the chance of a false positive conclusion. It is possible, dur-
ing the adaptation process, for operational bias to be introduced. This operational bias is
due to subjective decision-making during the course of a trial. One well-known example is
selection bias. This type of bias is difficult to quantify and renders the study result dif-
ficult to interpret. Statistical bias due to statistical procedures such as selecting the best
performing treatment out of many, by random chance, that is more favorable than the true
value, can also over-estimate the true effect. Without proper control, the type I error can
be inflated. Second, adaptive design, by shortening the trial duration or eliminating the
wait time between trials such as in seamless combining of two traditionally separate trials,
can limit identifying gaps in knowledge. Lack of extended time allocated to fully explore
the data between trials may also lead to inadequate recognition of safety issues. On the
other hand, a seamless design may allow longer follow-up time for safety assessment using
subjects enrolled in the first stage, particularly when these safety issues are rare and take
longer time to appear. Third, complex adaptive designs may potentially increase the trial
planning time. Fourth, trial analyses and revisions that are not prospectively planned have
the potential to increase false positive rate and difficulty in interpreting the study result.
Any unplanned revisions to the conduct and analysis of the trial may result in a trial that
is different from the one originally planned and may not answer the originally stated objec-
tives and questions. Some adaptive methods that are prone to the above pitfalls are listed
in Sections VI and VII. These methods that are all based on unblinding at interim in order
9to estimate comparative treatment effects are termed as less well-understood designs. Cited
examples of these less well-understood designs are outcome-adaptive randomization, sam-
ple size adjustment based on interim effect size estimate, modification of patient population
enrolled, and endpoint selection based on interim treatment effect estimate.
1.3.2 Recommendations
Although the document made cautious statements regarding the application of adaptive
methods, the FDA encourages their use in exploratory studies which have less impact on
regulatory approval decisions and where type I error is of lesser importance. The remaining
sections of the document attempt to provide constructive guidelines for scientists or trialists
to consider when planning an adaptive clinical trials. Some of these suggestions are:
• Thorough understanding of the statistical properties and operating characteristics
of the proposed adaptive design. This can be achieved through extensive computer
simulations which are intended to characterize and quantify the level of statistical
uncertainty in each adaptation and its impact on type I error, power, and bias.
• Early interactions with the FDA when planning and conducting an adaptive design.
Sponsors who have questions about the adaptive designs should seek the FDA feedback
and review comments from FDA.
• Adequate documentation of adaptations in a protocol, statistical analysis plan (SAP),
and supportive documents. The SAP for an adaptive trial is likely to be more detailed
and complex than for a non-adaptive trial.
• Prospective specification of study design and analysis, particularly where unblinded
interim analyses are planned. Any ad hoc or retrospective adaptations will likely risk
the inflation of type I error.
In the past few years, much statistical research has been conducted by statisticians from
both academia and industry to characterize different types of adaptive designs. In addi-
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tion, a surge in journal submission on the topics of adaptive designs was also observed,
however extensive applications of adaptive methods still remain low. Kairalla et al. (2012)
has attributed this slow absorption of adaptive methods into common practice to the lack
of infrastructure and software implementation. This is clearly an area that may require
arduous future effort.
11
Chapter 2
Approaches to Sequential Clinical Trial Monitoring
2.1 Introduction
In Chapter 1, we presented a brief overview on the various types of adaptive methods in
clinical trials. A distinctive and common feature of these adaptive designs is that a trial
is monitored sequentially in stages when inspection of the interim data is carried out. The
primary purpose for monitoring clinical trials is to provide an ongoing evaluation of risk-
to-benefit profile that addresses the uncertainty necessary to continue. Some of the reasons
that may lead to early termination of a clinical trial are (1) experimental treatment is
found to be convincingly better than the control, (2) experimental treatment is found to be
convincingly worse than the control, (3) side effects or toxicity are too severe to continue, or
(4) study integrity has been undermined. Therefore, interim monitoring is usually carried
out by an independent and impartial group called the data and safety monitoring board
(DSMB) or simply data monitoring committee (DMC).
Much methodological research on adaptive methods has mainly focused on proving early
efficacy. In order to control the overall type I error, many methods of hypothesis testing
have been proposed to achieve the objectives of a trial while preserving this error rate under
a specified α level, whether the analytical approach is frequentist or Bayesian. The following
sections will be devoted to review the statistical methods, both within the frequentist and
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the Bayesian paradigms, that are used to sequentially monitor a clinical trial.
2.2 Frequentist Approaches to Sequential Monitoring
As seen in Section 1.2.4, the different types of combination tests described provide additional
flexibility and adaptability to allow for trial monitoring based on independent stage-wise p-
values, calculated using data from sub-samples. Another approach is the conditional power
monitoring approach (Lan, DeMets, and Halperin, 1984). In this approach, a trial can be
terminated based on the promising conditional power calculated using the interim statistic
as defined in Section 1.2.2. Lan and Wittes (1988) transformed the Z-statistic into a statistic
that is independent of the sample size, but is only dependent on the information fraction, and
this statistic is called the B-value, which is used in the evaluation of the interim conditional
power. Proschan and Hunsberger (1995) proposed the use of an increasing conditional error
function which is based on the interim data. It specifies the amount of conditional type
I error for the next stage and therefore, the average conditional error is controlled under
α level. If the conditional error function is the same as the combination function, it is
essentially the same as the combination test.
Another prominent and flexible approach to clinical trial monitoring is the use of the alpha
(or error) spending plan which was proposed by Lan and DeMets (1983). As introduced in
Section 1.2.1, an alpha spending function distributes the total probability of false positive
risk as a continuous function of the information time or fraction in a sequential trial. In
this case, the test statistic of choice can be the normal Z-statistic, stochastic increment
W-statistic, or independent p-values. The corresponding stopping boundary values for a
K-stage trial can be computed based on the distribution of the chosen statistic and the alpha
spending function. The Haybittle-Peto boundary, which fixes a constant p-value for the first
K − 1 stages, can be used to monitor the p-values across the stages (Haybittle, 1971). The
fixed boundary methods consider a shape parameter that determines the boundary shape.
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The O’Brien-Fleming-type boundary and the Pocock-type boundary are examples of the
fixed boundary method (O’Brien and Fleming, 1979; Pocock, 1977). Finally, the most
flexible approach is the error spending function. The error spending function is usually
expressed in term of the information fraction, t. The Lan-DeMets spending function (1983)
has two forms:
α(t) =
 2− 2Φ
(
Zα/2√
t
)
for one-sided test
4− 4Φ
(
Zα/4√
t
)
for two-sided test
α(t) = α ln (1 + (e− 1)t)
where α is the overall level the trial type I error is controlled at. The first form resembles the
O’Brien-Fleming-type boundary while the second one resembles the Pocock-type spending.
The Gamma spending function was proposed by Hwang, Shih, and DeCani (1990). The
functional form is
α(t) =
 α
(1−e−γt)
(1−e−γ) if γ 6= 0
αt if γ = 0.
Negative values of γ yield convex spending functions that increase in conservatism as γ
decreases, while positive values of γ yield concave spending functions that increase in ag-
gressiveness as γ increases. The choice of γ = 0 spends the error linearly. When γ = −4, it
resembles the O’Brien-Fleming boundaries, while γ = 1 produces boundaries that resemble
those of Pocock. Power (also known as Rho) spending function was first proposed by Kim
and DeMets (1987), and was further generalized. The function form is simply represented
as
α(t) = αtρ, ρ > 0.
When ρ = 1, the corresponding stopping boundaries resemble the Pocock stopping bound-
aries, but when ρ = 3, the boundaries resemble the O’Brien-Fleming boundaries. Large
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values of ρ yield increasingly conservative boundaries, while 0 < ρ < 1 gives aggressive
boundaries. These methods ensure the false positive rate is controlled under the α-level.
2.3 Bayesian Approaches to Sequential Monitoring
Bayesian methods for statistical monitoring of clinical trials have a growing appeal in the
biopharamceutical industry and among clinicians. The theories of Bayesian inference are
also well-established, but applications to modern clinical trials are still rare. Spiegelhalter,
Freedman, and Parmar (1994) argued that “the Bayesian approach allows a formal basis
for using external evidence and provides a rational way for dealing with issues such as the
monitoring of accumulating data and the prediction of the consequences of continuing a
study.” Using a Bayesian inferential framework, there are two main methods in monitoring
clinical trials, (1) posterior probability, and (2) predictive probability. Thall and Simon
(1994) illustrated the use of posterior probability for a binary outcome xi (i = 1, 2, ..., n)
to monitor a single-armed Phase 2 clinical trial with null hypothesis H0 : piE 6 piC + δ
comparing the experimental treatment E to control treatment C. After prior distributions
are elicited for the probabilities of a response (piE , piC), the decision rule of the trial at
interim stage k is based on posterior probability such that
P (piE > piC + δ|x) > θU : reject H0 and terminate trial to declare success
P (piE > piC + δ|x) 6 θL : accept H0 and terminate trial to declare futility
θL < P (piE > piC + δ|x) < θU : continue to next stage
where δ is the minimum difference in the probabilities and (θL, θU ) are the stopping bound-
aries.
Dmitrienko and Wang (2006) described another approach to interim monitoring, the poste-
rior predictive probability or simply the predictive probability. This method is also known
as the Bayesian stochastic curtailment because it is analogous to the conditional power
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approach in the frequentist paradigm (Spiegelhalter, Freedman, and Blackburn, 1986). The
predictive probability is the probability of a successful trial if the trial hypothetically con-
tinues to the end, conditional on the current interim data. Since the predictive samples are
not yet observed, the predictive probability is defined as an average over all possible values
of the predictive samples. Using the same notation in the previous example, the predictive
probability P ∗ is defined as
P ∗ =
∫
I {P (piE > piC + δ|x,x∗) > η)}P (x∗)dx∗
where I{.} represents an indicator function, x∗ as the future samples, P (x∗) as the joint
probability of the future samples, and η as a high pre-specified cutoff such that η ∈
[0.85, 0.95], for instance. If P ∗ is greater than a upper stopping boundary θU , then the
trial can be stopped based on convincing early evidence of efficacy, otherwise the trial can
continue until it reaches the planned end if interim monitoring fails to reject the null hy-
pothesis. Based on this definition, the monitoring using predictive probability has a similar
interpretation of the conditional power, given the strength of the currently observed data.
It is important to emphasize that the stopping boundaries (θL, θU ) need to be calibrated
through simulations to achieve desirable trial performance such as control of Bayesian type
I error.
In the following sections, we will discuss two types of confirmatory clinical trials: multi-arm
dose response trial and biosimilarity trial. After that, we will briefly introduce how selected
sequential monitoring techniques described earlier can be applied to these two types of trials
to achieve their respective trial objectives.
2.4 Multi-Arm Dose-Response Clinical Trials
During the development of a new drug, a phase 2 trial with multiple treatment arms consist-
ing of a control dose (usually an active control) and a few experimental doses is conducted
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to determine the therapeutic dose of the drug for a phase 3 confirmatory clinical trial. Note
that we use the term dose interchangeably with treatment arm. The objectives of a phase
2 trial are to examine (1) whether the population means for the primary endpoint increase
monotonically with the doses, (2) the shape of the dose-response function, and (3) what dose
is appropriate as a therapeutic dose for use in a confirmatory trial (Wakana, Yoshimura,
and Hamada, 2007). Selection of one or more doses to carry into confirmatory phase 3 trials
is one of the most difficult decisions that needs to be made during drug development.
When multiple doses are considered, statistical methods have been proposed to combine
both the objective of selecting one or more therapeutic doses and the objective of confirming
these selected doses. Many of these designs are carried out in stages. Some of these designs
extend the two-arm group sequential design to multiple arms with a control. Follmann,
Proschan, and Geller (1994) proposed a design to monitor multi-armed clinical trials that
strongly controls the type I error rate. At any interim stage, there is a collection of pairwise
test statistics and critical values. Based on this information, the decision to retain or drop
individual arms or to stop the trial entirely is made. At the end of the trial, it is possible
more than one arm can be selected. When only one stage is considered, this procedure is
reduced to the standard Dunnett’s adjustment design. A more recent multi-armed group
sequential drop-the-losers design is given by Chen, DeMets, and Lan (2010). In addition
to the use of non-binding futility boundary, they suggested two methods of calculating the
efficacy boundaries. The first approach is called joint monitoring in which all dose-control
comparisons are monitored simultaneously by using one single alpha spending function,
α∗(t), where t is the information fraction, 0 < t < 1. Under the global null hypothesis,
P


Z1(t1) < c1, Z1(t2) < c2, ..., Z1(tk−1) < ck−1
Z2(t1) < c1, Z2(t2) < c2, ..., Z2(tk−1) < ck−1
· · ·
ZJ(t1) < c1, ZJ(t2) < c2, ..., ZJ(tk−1) < ck−1

⋂ J⋃
j=1
(Zj(tk) > ck)

= α∗(tk)− α∗(tk−1)
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is assumed for J treatment arms at the kth interim stage where j = 1, 2, ..., J and k =
1, 2, ...,K. The second approach is called marginal monitoring where a marginal alpha
level αj and an alpha spending function αj(t) for each dose-control comparison is specified.
Therefore, each dose j is monitored independently by its own alpha spending function. For
example, under null hypothesis, Hj0:
P (Zj(t1) < c1, Zj(t2) < c2, ..., Zj(tk−1) < ck−1, Zj(tk) > ck) = α∗j (tk)− α∗j (tk−1)
for k = 1, 2, ...,K and j = 1, 2, ..., J . For both approaches, numerical integration is used
to calculate the stopping boundaries (i.e. critical values) since the joint standardized test
statistics follow multivariate normal distribution. This design allows more than one dose to
be selected at the end of the trial.
When a trial design has two stages, with the first stage selecting doses and the second stage
confirming the selected doses, it is sometimes known as the Seamless Phase 2/3 design or
the drop-the-losers design described in Section 1.2.4. Sampson and Sill (2005) described a
drop-the-losers design for a normal endpoint. In the first stage, n1 subjects are randomized
to each of the J experimental treatments and a control. At the end of the first stage,
the sample means xj are computed. The dose j∗ that shows the empirically largest mean
xj∗ = x(1) = max(x1, x2, ..., xJ) will be selected for continuation into the second stage and
n2 subjects are randomized to the selected treatment and control. Final inference on the
selected dose is based on the data from both stages.
In order to improve the selection of the minimum effective dose (MED) to be confirmed in
the second stage, some methods assume a dose response model in the first stage and select
the dose based on the estimated model. An example is given by Huang, Liu, and Hsiao
(2011). These authors suggested estimating a linear dose response model at the end of the
first stage such as
E(Yji) = β0 + β1dj
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and test if β1 > c where c is a specified threshold. The dose that achieves an effect compared
to a control dose by at least a magnitude of δ will be selected for the second stage.
2.5 Biosimilarity Clinical Trials
The second type of clinical trial we want to consider here is a biosimilarity trial. In 2010,
the passage of the Biologics Price Competition and Innovation Act (BPCI) created an ab-
breviated licensure pathway in section 351(k) of the Public Health Service Act (PHS). This
new law allows for an expeditious approval process for a generic follow-on biological product
shown to be biosimilar to a licensed reference biological product. Due to their large and
complex molecular structures, biological products are fundamentally disparate from small
synthetic drugs, and so are their mechanisms of action. Traditional statistical methods
used to test for bioequivalence as in a generic drug development may not be the most ef-
ficient way to establish biosimilarity. The FDA has released a guidance document called
“Scientific Considerations in Demonstrating Biosimilarity to a Reference Product” in 2012.
This document provides the definition of biosimilarity and some philosophical guidelines
for the biopharmaceutical community in developing statistical methods for proving biosim-
ilarity. Two important principles were suggested by the document: (1) totality of evidence
approach, and (2) step-wise approach. This is often interpreted by the scientific commu-
nity as a series of pre-clinical and clinical studies to show the plausibility of biosimilarity.
A thorough review of the literature on recently proposed statistical methodologies can be
found in Chapter 5.
2.6 Direction of Thesis
In this dissertation, we want to develop an innovative trial design for a multi-arm dose-
response clinical trial as described in Section 2.4. The objective of this trial is to select the
maximum biological dose (MBD) based on a dose response model and to increase efficiency of
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the trial. However, when some prior qualitative knowledge of the dose response relationship
is given such as from prior animal dose response studies, we can design a trial that allows
the explicit prioritization of doses as clinicians may not consider all doses to be equally
effective. In addition, we want to design this trial such that doses are added or inserted to
the trial only if previous doses do not show statistical evidence of efficacy. This feature of
adaptively adding doses may reduce the expected sample size needed since not all doses are
used in the trial. We explore the operating characteristics of this adaptive design using a
normal endpoint in Chapter 3. Under this design, we are able to show that by pre-specifying
the order of the doses or hypotheses in decreasing order of efficacy, we can employ an alpha
spending function that favors earlier doses to select the efficacious doses earlier. We also
show how the design parameters can be flexibly varied and that it can be extended to both
binary and survival endpoints in Chapter 4. When we allow more doses to be explored per
interim stage or when we reduce the number of stages per dose, we may be able to gain
better statistical power or to reduce the expected sample size.
Finally, we want to look into developing a testing framework for establishing biosimilarity in
a confirmatory clinical trial. Since historical trials are involved in designing a biosimilarity
trial as the reference innovator biological product was approved in the past, a Bayesian
framework will be a logical choice to allow the synthesis of historical and current evidence.
We propose an adaptive two-stage design that uses predictive probability as a monitor-
ing criterion. We show that it provides better control of type I error than the frequentist
approach even when the constancy assumption is slightly violated and that it gives bet-
ter power than frequentist approach when biosimilarity is highly plausible. This will be
presented in Chapter 5.
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Chapter 3
Adaptive Staggered Dose Design for a Normal End-
point
3.1 Introduction
Clinical drug development usually follows distinct phases and in each phase one or more
trials are conducted to answer a specific set of questions. For example, within phase 2, a
small phase 2A study such as a proof-of-concept study is conducted to establish the dose to
efficacy relationship. If efficacy is established, a phase 2B dose-ranging study is conducted
to estimate the shape of the dose to efficacy relationship and to find an optimal dose that
can be carried to a phase 3 confirmatory trial. However, in most practical situations, when
there is still uncertainty about the efficacy and safety of this one dose, due to the use of
surrogate endpoint in dose-ranging study, the investigational team may be more inclined
to keep several potential doses rather than only one definitive dose. In other situations,
the team may want to compare several drug schedules or regimens instead of doses. In this
case, a single trial design that combines both the selection of a dose from multiple doses as
in a dose-ranging trial and the confirmation of the selected dose as in a confirmatory trial
is desirable.
This idea has given rise to the development of a class of adaptive trial designs that seamlessly
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combines both the selection of a therapeutic dose out of multiple doses and the confirmation
of the selected dose. This type of trial design is sometimes referred to as the Seamless Phase
2/3 design (Gallo et al., 2006; Maca et al., 2006). These designs allow trial adaptation such
as selection of hypothesis, subpopulation, or treatment after the first stage and aim at
controlling the experiment-wise type I error as required in a confirmatory trial. In our
present context, we focus only on the seamless designs that select treatment at interim.
One of the many approaches is the two-stage ranking and selection procedure and is some-
times called the drop-the-losers design, first described by Sampson and Sill (2005). In this
design, k experimental treatments and a control are administered in the first stage. At
interim, the empirically best treatment is selected for continuation into the second stage,
along with the control. At the end of the second stage, inference comparing the selected
treatment and the control is conducted using the data from both stages. More recently,
other two-stage designs were also proposed (Li et al., 2009; Wang et al., 2011). Depending
on the ranking results at the end of the first stage, these designs allow the selection of more
than one dose to be carried to the second stage. They also allow for early termination of
the study if at least one dose shows statistical significance at the end of the first stage.
Another approach is the multi-stage group sequential procedure. These are designs that
drop inferior treatments based on testing at interim. Follmann, Proschan, and Geller (1994)
extended the two-arm group sequential design to multiple arms and provided critical values
that could strongly control the type I error. Other similar designs that used the efficient
score statistics developed by Whitehead (1997) also appeared in the literature. These
designs allowed for sequential monitoring for any type of outcome - binary, normal, and
survival (Stallard and Todd, 2003; Stallard and Friede, 2008). The major challenge in
implementing multi-stage group sequential methods involves the calculation of stopping
boundaries. The most recent design by Chen, DeMets, and Lan (2010) suggested two
methods of calculating the efficacy boundaries. The first approach is called joint monitoring
in which all dose-control comparisons are monitored simultaneously by one single alpha
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spending function. The second approach is called marginal monitoring where a marginal
alpha level and an alpha spending function are specified for each dose-control comparison.
Computation of stopping boundaries remains intensive in this approach.
Besides ranking and hypothesis testing as methods of interim treatment selection, other
innovative approaches were also found in the literature. Kimani, Stallard, and Hutton
(2009) considered the selection of dose in a Seamless Phase 2/3 trial using criteria that
incorporated both efficacy and safety. They proposed a Bayesian method that used prior
distribution of dose response relationship to inform the selection of dose for the confirmation
stage. Huang, Liu, and Hsiao (2011) considered estimating and testing for a linear dose
response model to inform the selection of the best dose for the second stage. Wang and
Cui (2007) applied outcome-adaptive randomization to dose selection. The allocation ratio
is continuously updated based on calculation of conditional power with higher probability
of assigning subjects to dose groups with higher conditional power. Friede et al. (2011)
designed a seamless design that used early surrogate endpoint to aid treatment selection.
Bretz, Pinheiro, and Branson (2005) proposed combining multiple comparisons and para-
metric modeling techniques in selecting both a model and a dose that gives a desired level of
efficacy. Although the above adaptive approaches have made significant strides in improving
statistical power and reducing the expected sample size, the derivation of the distribution
of test statistics and the computation of stopping boundaries remain intensive, particularly
for the rank-based selection procedure. Here we are proposing a staggered dose design that
starts off with only one or a subset of the doses, and depending on interim results, remain-
ing doses may be added to the trial if the previous doses do not show evidence of efficacy.
This design is proposed for meeting the objectives of late phase 2 and confirmatory phase
3. It actively incorporates information from previous dose-ranging studies and allows for
the prioritization of doses, while keeping type I error under nominal level of α.
It is important to note that, when planning a trial, sometimes the clinical team may not
consider all candidate doses to be of equal importance, but would be interested in exploring
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these doses one after the other starting with doses with assumed better responses and
proceeding to doses with uncertain responses if the earlier doses do not show statistical
evidence of efficacy. This is especially true when some prior qualitative evidence of dose
response relationship exists, and investigators are willing to consider J doses which can
be arranged in decreasing order of priority. We can let j = {1, 2, 3, ..., J} be this order of
priority with one being of the highest priority and J the lowest priority. We can represent
the actual prioritized dose levels as d1, d2, ..., dJ . There is a need to emphasize that this
order of priority does not necessarily imply an increasing (d1 < d2 < ... < dJ) or decreasing
(d1 > d2 > ... > dJ) order of dosage. This a priori ordering that is based on previous
knowledge offers additional flexibility for the team to explore the doses one after the other
knowing that we only have a limited number of patients in a dose selection and confirmation
trial. Traditional fixed dose parallel group design and some adaptive designs treat all doses
to be equally important and the experiment randomizes patients equally to all of the doses.
These designs may be inefficient when an informative prior model on the dose response
relationship exists. The designs reviewed earlier, although making improvement in dose
selection, do not consider the option of adaptively inserting new doses.
By adaptively allowing the option of adding new doses, we propose a design that can start
off with fewer doses and sequentially drop inferior doses and add new doses at the same
time. This new design, adaptive staggered dose procedure, may further reduce the expected
sample size while gaining information about the efficacious doses more quickly. One major
condition is that the clinical team has to provide an assumed best case of dose ordering
by ranking the candidate J doses in decreasing order of priority based on their clinical
judgment or previous evidence on dose response. The gain in design efficiency necessitates
this assumed dose ordering because potentially better doses will be studied earlier. We
define the optimal dose as the biological dose that has the highest efficacy. If the ordering
is right, this design may perform better than both the current drop-the-losers design and
the fixed dose parallel group design in terms of reduced expected sample size and perhaps
experimental time. If the a priori ordering is weak, this proposed design can perform as
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good as the drop-the-losers design but generally still better than the fixed dose parallel
group design in most scenarios under some assumed conditions.
The following sections are organized as follows. A general version of the proposed adaptive
staggered dose design will be described in Section 3.2.1. We will illustrate this design using
a specific version in Section 3.2.2. In Section 3.3, we expound more on other important
design considerations such as futility, type I error control, and error spending functions.
The operating characteristics of this proposed design will be examined in detail in Section
3.4. Based on the simulation results, we will discuss the strengths and weaknesses of this
design and recommend its suitable applications in Section 3.5
3.2 Adaptive Staggered Dose Design
3.2.1 General Design
As a motivating example, we can consider a topical ophthalmic solution containing a new
histamine receptor antagonist to prevent ocular itching due to allergic conjunctivitis. A
trial is conducted to select one from several safe dosages (e.g. 0.15%, 0.2%, 0.25%, and
0.3%) and to confirm the strength of the selected dosage against its placebo vehicle (0%).
The primary efficacy endpoint is an Ocular Itching Score (OIS) at 7-minute post-dosing
after ocular allergen challenge (CAC). For illustration purpose, we assume higher score
corresponds to symptom improvement, i.e. lessened itching. Therefore a trial design that
selects one or two optimal doses from J possible doses for late-phase pivotal trials will be
useful. These J doses can be arranged by the investigators in the order of decreasing priority
j = 1, 2, ..., J as {d1, d2, ..., dJ}. It is worth-noting that {d1, d2, ..., dJ} are not necessarily in
increasing or decreasing order of dosage. It is generally assumed that these doses are well
within the range of acceptable safety. Acceptable safety may refer to adverse events that
are mild and reversible or that are not related to treatment. Although if the team decides
that it is important to escalate the doses for simultaneous assessment of safety and efficacy,
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a dose escalation order can be adopted, and in this case, d1 < d2 < ... < dJ . In addition, we
want to compare these doses with a control dose d0 (j = 0) and adopt a randomization ratio
of 1 : R for control to each of the experimental doses. The primary clinical endpoint such
as OIS above is assumed to be normally distributed with known common variance (σ2 = 1)
across dose groups. We can let Yji represent the endpoint in the ith subject receiving dose
dj such that
Yji ∼ N(µj , 1). (3.2.1)
If µ is related to d, then a dose response function may exist such that µj = f(dj). However,
f(dj) may or may not be a monotonic function.
In this design, we consider looking at a maximum of D experimental doses (D < J) at
each of the K global stages. Therefore, we do not start off with all J doses but a subset
containing the first D doses, {d1, d2, ..., dD}. Depending on the assessment of efficacy at
interim stages, we drop doses from the D doses that show convincing futility or lack of
efficacy and simultaneously add the next doses from the pre-specified dose ordering to
maintain D current doses in the next interim stage. If the interim results demonstrate that
at least one dose shows evidence of efficacy, the trial can be stopped early and no more
doses will need to be added. Therefore, a maximum of D doses may be selected before or
at the final (Kth) stage or none of the J doses shows efficacy at the final stage. If no dose
is selected and confirmed at the end of the experiment, this drug development program will
halt. We restrict the number of patients allocated to each experimental dose by setting the
same minimum and maximum numbers of subjects allocated. For example, if we let c be
the cohort size per dose and per stage, then the minimum number of subjects will be c and
the maximum number of subjects will be cM , where M is the maximum number of per-dose
stages. However, the control dose will always have c/R subjects randomized per stage. It is
important to emphasize that only the control subjects that are randomized simultaneously
with the corresponding experimental dose are compared to the experimental subjects. This
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ensures the control subjects and the experimental subjects are comparable in all known and
unknown prognostic factors except the doses assigned.
3.2.2 Specific Version of Design
To illustrate the decision rule of this design, we consider a specific version of the design where
we study one dose at a time (D = 1), with a maximum of two per-dose stages (M = 2),
and the maximum number of global stages of K = 2J . Setting K = MJ = 2J allows the
experiment to fully explore each of the doses with an equal amount of information, if added
to the trial. Figure 3.1 graphically illustrates this specific adaptive staggered dose algorithm
for J = 4 and a control to dose randomization ratio of 1 : R at each stage. The number
of global stages K is necessarily bounded, J 6 K 6 MJ . The lower bound J ensures that
each of the J doses will have at least one per-dose stage, while the upper bound ensures
that each dose will have at most M per-dose stages. If the set of one-sided hypotheses are
Hj0 : µj 6 µ0, Hja : µj > µ0 (3.2.2)
for j = 1, 2, ..., J , then the standardized test statistic for dose dj , conditioned on the out-
comes of previous doses, will be
Zjm =
Y jm − Y 0m√
R+1
cm
(3.2.3)
where Y jm =
∑cm
i=1 Yji/(cm) and Y 0m =
∑(cm)/R
i=1 Y0i/( cmR ) for m = 1, 2. It is important
to stress that Y0i’s are the responses only for control subjects that are randomized simul-
taneously with the experimental subjects for dose dj . The control subjects randomized
simultaneously with subjects to the previous doses, d1, ..., dj−1, will not be included in the
calculation of this test statistic since they may not be comparable in prognostic factors.
The conditional distributions of these statistics are
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Zj1 ∼ N
µj − µ0√
R+1
c
, 1
 , (Zj1, Zj2)′ ∼ N2


µj−µ0√
R+1
c
µj−µ0√
R+1
2c
 ,Σ =
 1 1√2
1√
2 1

 . (3.2.4)
Figure 3.1: A graphical illustration of the proposed adaptive staggered dose procedure with
J = 4, D = 1,M = 2, R = 2 and K = 2J = 8.
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Under this specific design, the decision rule for dose dj at the kth interim is described as
follows.
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1. If, whether m = 1 or 2, the test statistic for dose dj is Zjm > bk where bk is the efficacy
boundary for the kth interim analysis, then it is declared statistically significant and
Hj0 is rejected. This trial will stop and the remaining doses {dj+1, ..., dJ} will not
enter the trial.
2. If, when m = 1, the test statistic for dose dj at its first per-dose interim is ak < Zj1 6
bk, where ak (ak < bk) is the futility boundary for the kth interim analysis, then it will
continue to its second per-dose stage with an additional cohort of c subjects allocated.
If, when m = 2, the test statistic is Zj2 6 bk+1, where ak+1 = bk+1, then this dose
has reached its maximum allowable samples of 2c and it will be dropped due to lack
of efficacy. At the same time, a new dose dj+1 in the next priority will be added to
the experiment.
3. If, when m = 1, the test statistic for dose dj is Zj1 6 ak, then it is dropped due to
convincing futility and Hj0 is accepted, and a new dose dj+1 in the next priority will
be added to the experiment.
Therefore, at any global stage k, only one dose is being considered. This trial design allows
early termination if (1) any one dose is declared efficacious, (2) all of the J doses are declared
futile, or (3) no dose is declared efficacious at the end of the Kth (final) stage.
Under this staggered dose selection procedure, we can achieve greater gain in design ef-
ficiency if we have strong prior knowledge about the dose response relationship. In this
adaptive staggered dose design, we do not need to assign patients to all of the doses at the
beginning. At the end of the trial, if we cannot select a significantly efficacious dose, then
this drug development program will stop. Since the trial can stop at any global stage for
futility or efficacy, the number of stages the trial goes through before stopping is therefore
a random variable and so is the sample size used. For a pre-specified K, the total number
of planned subjects for this entire trial is therefore equal to cK( 1R + 1). The operating
characteristics of this proposed design will be examined in the next sections.
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3.3 Other Design Considerations
3.3.1 Futility Analysis
In the specific design described in Section 3.2.2, we want to drop the interim analysis of
futility at the moment and focus only on the proof of efficacy. In this case, we let ak = −∞
and hence P (Zjm 6 ak) = 0 for all j and m = 1. Therefore, each dose will always go
through all M per-dose stages if no statistical evidence of efficacy is shown at interim
stages. Investigators can still drop a dose before its Mth per-dose interim stage, if safety
issues arise, without inflating the family-wise type I error, and this can provide additional
flexibility. In this setting, dose dj is considered at only two global interim stages: k = 2j−1,
if k is odd, or k = 2j if k is even (see Figure 3.1). The general form of the type I error at
the kth stage will be derived in the next section.
3.3.2 Family-wise Type I Error
For this specific design without futility analysis, we denote the probability of rejecting the
null hypothesis Hj0 for dose dj at the kth interim as ψj,k. Under Hj0, the standardized test
statistics for dose dj , using (3.2.4) for all j, will have the following distributions:
Zj1 ∼ N (0, 1) , (Zj1, Zj2)′ ∼ N2

 0
0
 ,Σ =
 1 1√2
1√
2 1

 . (3.3.1)
Since these distributions, under null hypothesis, are the same for all doses, we can simply
replace Zj1 with Z and (Zj1, Zj2) with (Z1, Z2). As we have seen, when no futility analysis
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is performed, the probability of rejecting Hj0 given it is true can be given by
ψj,k =

P (Z > bk) if k = 1
P (Z1 6 bk−1, Z2 > bk) if k = 2(∏ k−12
i=1 P (Z1 6 b2i−1, Z2 6 b2i)
)
P (Z > bk) k = 2j − 1(∏ k−22
i=1 P (Z1 6 b2i−1, Z2 6 b2i)
)
P (Z1 6 bk−1, Z2 > bk) k = 2j.
(3.3.2)
This follows from the design setting that the test statistics Zjm’s for any given dose dj
are calculated only using the responses from the control cohort that are randomized simul-
taneously with this dose but not the responses from previous doses, they are considered
independent from the test statistics of previous doses. The family-wise type I error under
the global null hypothesis for this trial is therefore given by
ψ =
J∑
i=1
(ψi,2i−1 + ψi,2i) (3.3.3)
and we are interested in keeping it under a target alpha level, Supψ 6 α. The next section
will discuss how the set of efficacy stopping boundaries (b1, b2, ..., bK) is derived.
3.3.3 Alpha Spending Functions
Classical group sequential methodology employs flexible alpha spending functions to monitor
the trial’s test statistic as multiple interim looks during a trial can cause inflation of type
I error (Armitage, McPherson, and Rowe, 1969; Lan and DeMets, 1983). However, it
is important to distinguish the use of alpha spending function in the traditional group
sequential setting versus in this adaptive staggered dose design setting. In the traditional
two-arm trial setting, alpha spending function is applied to monitor the test statistic of one
dose-to-control comparison as information accrues through the stages in order to control
type I error. However, in this adaptive staggered dose selection design, since earlier doses are
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investigated at earlier stages and later doses at later stages, the use of one alpha spending
function across all global stages monitors test statistics of the dose-to-control comparisons
in a staggered fashion. Therefore, this design presents a novel application of the alpha
spending function. For the kth interim, if α(t) represents the alpha spending function
with t (0 < t < 1) being the information fraction, then the doses and their corresponding
hypotheses can be monitored through
ψj,k = α(tk)− α(tk−1) (3.3.4)
where α(0) = 0, α(1) = α, tk = k/(2J), and k = 1, 2, ..., 2J since c, the cohort size per stage
and dose, is a constant. Alternatively, one can flexibly re-define the cohort size parameter c
as information fraction tc during the first interim stage given a maximum samples allowable
for each dose. For either parameterization method, the efficacy stopping boundary values
can be computed via numerical method using the null distributions in (3.3.1).
Some of the common alpha spending functions used in traditional group sequential designs
such as the Pocock, O’Brien & Fleming, Lan & DeMets and the Rho alpha spending func-
tions can be used in this adaptive design. Rho alpha spending scheme, a one-parameter
function, offers more flexibility by simply adjusting the parameter ρ in
α(t) = αtρ. (3.3.5)
If ρ < 1, it allocates more alpha to earlier stages, hence favoring earlier doses; while for
ρ > 1, it allows more alpha spent at later stages, and thus favoring later doses by pushing
the trials to later stages. In fact, Pocock’s approach is similar to the former and O’Brien
& Fleming’s approach to the latter. The choice of a suitable value for ρ reflects how
optimistic or conservative the investigators are toward the ordering of the doses, as well as
how informative the dose response relationship µj = f(dj) they are willing to assume.
It is important to emphasize that once a dose is accepted or its null hypothesis is rejected, the
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remaining doses cannot enter the trial nor their hypotheses be tested as this may inflat the
type I error. It is because the stopping boundaries derived are based on the condition that
the previous doses do not cross their respective stopping boundaries. Under this design, we
can assert that by controlling the probability of a false positive conclusion under the global
null hypothesis, that is, when all Hj0’s are true, we have strong control of the family-wise
type I error. This assertion is proved in Section 3.6.4 of the Appendix.
Another alternative to jointly monitoring using one global alpha spending function is to
allow different alpha spending functions αj(t)’s for different doses dj ’s since we know exactly
which dose is investigated at the kth stage. In this case, the stopping boundaries for dose
dj will not only depend on the alpha spending function specified for dose dj , which is αj(t),
but also on the specified alpha levels of the previous doses, (α1, α2, ..., αj−1). This will be
explored in Chapter 4.
3.3.4 Efficacy Stopping Boundaries
Given the general form of the type I error in (3.3.2), and a chosen alpha spending func-
tion in (3.3.4), we can numerically solve for the set of efficacy stopping boundaries, b =
(b1, b2, ..., bk, .., bK) using the null distributions in (3.3.1). Numerical methods to evaluate
probabilities of multivariate normal distributions have been proposed, such as the GenzBretz
method proposed by Genz et al. (2011) implemented in the R package, mvtnorm.
3.3.5 Expected Stages and Sample Sizes
One of the major advantages of this adaptive staggered dose procedure is stopping the trial
early if a dose showing evidence of efficacy is selected. In addition, the doses following the
selected dose under the given dose ordering do not have to enter the trial, and therefore,
saving patients from further allocation to potentially inferior doses. Under the proposed
design, the number of stages the trial goes through before stopping for efficacy, K, is a
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random variable. The expected number of stages is given by
E(K) = 2J −
J−1∑
j=1
((2J − 2j + 1)ξj,2j−1 + (2J − 2j)ξj,2j)
− ξJ,2J−1 (3.3.6)
where ξj,k is the probability of rejecting the null hypothesis Hj0, evaluated under the alter-
native hypothesis Hja. In other words, ξj,k is the statistical power for testing dose dj against
the control dose at the kth interim stage. The mathematical forms of ξj,k and E(K) are
given in Sections 3.6.2 and 3.6.3 of the Appendix. We can see from (3.3.6) that E(K) 2J
if the stopping probabilities, ξj,k’s are large. The sample size S for this specific design is
also random and its expectation is given by
E(S) = c
( 1
R
+ 1
)
E(K), (3.3.7)
since the control arm will always require an allocation of c/R subjects per stage. Table 3.1
summarizes the six design parameters of a general version of this staggered dose design.
Table 3.1: Definitions of design parameters of the adaptive staggered dose procedure
Parameter Definition
J Total number of experimental doses considered in the entire trial
D Maximum number of experimental doses under study at each interim stage (D < J)
M Maximum number of interim stages allowable to each experimental dose (i.e. per-dose stage)
c Cohort sample size allocated to an experimental dose per interim stage
K Total number of interim stages including final stage of the entire trial (i.e. global stage)
R Randomization ratio of control dose to experimental dose is 1 : R
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3.4 Simulation Study
3.4.1 Simulation Plan
In this section, we want to investigate the operating characteristics of this proposed adaptive
staggered dose procedure using extensive simulations. We consider the specific trial design
illustrated in Figure 3.1 using the same design parameters. In this specific procedure, we
have four experimental doses (J = 4), maximum of eight global stages (K = 2J = 8) and
only one dose being compared to the control at each interim stage (D = 1). Each experi-
mental dose will have a maximum of two per-dose stages (M = 2). A fixed randomization
ratio of 1 : R = 1 : 2 is used for the control dose to each of the experimental doses through-
out the trial. In other words, if c is the cohort size for each experimental dose per stage,
then the control will have a cohort of c/2 per stage.
For operating characteristics, we are interested in evaluating, for a given dose response
model, the cohort size c required to attain statistical powers of 0.8 and 0.9 under different
combinations of dose orderings and error spending schemes. This cohort size c can be eval-
uated numerically using the mathematical form of statistical power stated in Section 3.6.2
of the Appendix. This cohort size c will guide the research team to decide and plan for the
recruitment of the total sample size for the entire trial under given pre-specified scenarios.
As we have seen earlier, this design allows for early stopping when an experimental dose is
selected due to statistically significant evidence of efficacy. Therefore, the number of global
stages the trial goes through before stopping for efficacy is a random variable and so is the
sample size used. Therefore, we want to know the expected number of global stages and
expected trial sample size using the cohort size corresponding to each of the dose orderings
and error spending schemes. Also, the experimental doses will be selected with different
probabilities under different dose orderings and error spending schemes. We also want to
characterize the variation of these dose selection probabilities, particularly the probability
of selecting the dose with best efficacy.
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We choose the following dose levels, d = 0, 2, 4, 6, and 8 for illustration. They can correspond
to studying 0%, 0.15%, 0.2%, 0.25% and 0.3% concentrations in our previous example of
topical ophthalmic drop for ocular itching. The first dose level of zero refers to the control
dose, d0, with µ0 = f(d0 = 0) = 0 and the second to fifth are the four increasing levels
of the experimental drug. We consider four dose response models - Flat, Linear, Emax,
and Umbrella, for the alternative hypothesis. Table 3.2 describes these four dose response
curves, E(Yji) = µj = f(dj). These four curves are chosen because they are the commonly
assumed dose response models in clinical trials (Bornkamp et al., 2007; Antonijev et al.,
2010). Although not common, non-monotonic umbrella dose response has been observed in
the therapeutic targeting of angiogenesis in cancer (Reynolds, 2010). Also when doses are
high, downturn in response is common when cytolethality occurs (Simpson and Margolin,
1986; Combes, 1997).
Table 3.2: Four dose response models with µ0 = f(d0) = 0
Dose Response µj = f(dj) f(d0, d1, d2, d3, d4) = f(0, 2, 4, 6, 8)
Flat µj = 0.35 (0.000, 0.350, 0.350, 0.350, 0.350)
Linear µj = 0.04375dj (0.000, 0.088, 0.175, 0.263, 0.350)
Emax µj = 0.4375 dj2+dj (0.000, 0.219, 0.292, 0.328, 0.350)
Umbrella µj = 0.117dj − 0.0097d2j (0.000, 0.194, 0.311, 0.350, 0.311)
We consider looking into three ordering schemes for the four experimental doses - dose
escalation, informative, and uninformative orderings. In dose escalation ordering, these four
experimental doses are ordered in increasing dosage such that (d1, d2, d3, d4) = (2, 4, 6, 8).
In this case, the trial proceeds from the lowest dose to the highest dose. If a strong dose
response model based on pre-clinical or earlier clinical experience exists, we can adopt an
informative ordering. In informative ordering, we arrange the doses in the presumed order
of decreasing priority. For example, for the umbrella dose response model described above,
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we can order the four experimental doses such that the best dose is explored earlier, then
(d1, d2, d3, d4) = (6, 4, 8, 2). In this case, we prefer to study f(d1 = 6) = 0.35 first and
f(d4 = 2) = 0.194 last. In uninformative ordering, we will use all of the 24 (J ! = 4!)
permuted orderings and take the average of all the calculated cohort sizes. This is the
expected cohort size required if we randomly pick an ordering out of the 24 permuted
orderings with equal probabilities. This simulates the situation when there is no prior
knowledge of the dose response relationship.
Next, we select eight different error spending plans. We include the Pocock, O’Brien &
Fleming error spendings, Rho error spendings with parameter ρ pre-specified at 0.3, 0.5, 1, 2,
and 3, and a final error spending that fixes a constant efficacy stopping boundary bk across
all K = 8 stages. For Rho error spending, we choose the above values of ρ to study how a
wide spectrum of error spending can affect the cohort size, the expected number of stages
to stop the trial and the probabilities of dose selection. The family-wise type I error is set
at one-sided α = 0.05 for all of the selected error spending plans. The objective of this part
of the simulation study is that we can compare the operating characteristics for different
dose orderings and error spending plans for a given dose response model.
In the next part of the simulation study, we would like to compare this adaptive staggered
dose design with three comparator designs: the traditional parallel group design using Dun-
nett’s adjustment (Dunnett, 1955), the two-stage drop-the-losers (pick-the-winner) design,
and a two-stage seamless design with dose selection based on an informative dose response
in the first stage. We use the expected trial sample size evaluated under uninformative
ordering for a given dose response model and a given error spending plan attaining power
of 0.9 as the trial sample size to simulate the statistical power of the first two comparator
designs. We denote the expected trial sample size as E(S) as in (3.3.7). When simulating
the statistical power of the last comparator design, the two-stage dose-response informed
seamless design, we use the expected trial sample size evaluated under informative ordering
for the proposed adaptive procedure since we assume informative prior dose response model
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here. The simulated powers for the three comparator designs can be compared to the target
power of 0.9 under the proposed adaptive procedure.
In the parallel group design, we use balanced allocation ratio for the control dose and the
four experimental dose groups. Therefore, each arm will receive E(S)/5 subjects. If at least
one dose is found to show statistical evidence of efficacy under the Dunnett’s multiplicity
adjustment with one-sided α = 0.05, then the trial will be declared a success. For the
drop-the-losers design, we have two stages. In the first stage, balanced allocation ratio is
used for the control dose and the four experimental dose groups with each group receiving
w subjects. At interim, the experimental dose, which demonstrates the largest sample
mean, will continue to the second stage with the control dose, while the remaining three
experimental doses will be dropped from the trial without further randomization. This
second stage will use balanced allocation ratio to randomize the remaining subjects to both
the selected dose and the control dose, with each receiving another w subjects. Therefore,
w is equal to E(S)/7. There is no testing of hypothesis at the first interim stage, but only
dose selection. However, the test statistic at the final stage comparing the selected dose
and the control dose will use all 2w subjects allocated in both stages. The efficacy stopping
boundary for the final stage, evaluated by simulation, will keep the family-wise type I error
at one-sided α = 0.05. If this selected dose shows evidence of efficacy, then this drop-the-
losers trial is a success. For the two-stage dose-response informed design, similar to the
drop-the-losers design, w = E(S)/7 subjects will be randomized to each dose. At the end
of the first stage, the parameters of the dose response curve, which is assumed to be known,
will be estimated using linear or non-linear regression analysis. The dose with the highest
estimated mean response based on the dose response model estimated using the data from
the first stage will be selected for the second stage. Only the selected dose and the control
will continue to the second stage for further randomization. Observed responses from both
stages will be combined for final analysis. However, no hypothesis testing is performed at
the end of first stage as the first stage is the learning and dose selection stage. If the selected
dose demonstrated evidence of efficacy over control at the end of second stage, the trial is
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considered a success. Lastly, we will simulate data from normal distribution with common
known unit variance (σ2 = 1) and the number of simulated trials is 10,000 unless otherwise
stated. All of the simulations are conducted in R software.
3.4.2 Efficacy Stopping Boundaries
Table 3.3 shows the stage-wise efficacy boundaries and their corresponding alphas spent us-
ing the eight selected error spending plans under the global null hypothesis. These bound-
aries values are evaluated numerically. We have seen earlier that, without futility analysis
at interim stages, dose d1 is studied at interim stages k = 1, 2; dose d2 at k = 3, 4 and so on.
The constant efficacy boundary scheme offers similar αk spent for each of the four doses.
Dose d1 gets an alpha of 0.0127, d2 of 0.0126, d3 of 0.0124 and d4 of 0.0122. In this case,
we are not showing strong favoritism to any of the doses.
Table 3.3: Eight alpha spending schemes and their corresponding stage-wise efficacy stop-
ping boundaries (bk) and errors (αk) for J = 4, D = 1,M = 2, R = 2, and K = 2J = 8.
Family-wise type I error is controlled at one-sided α = 0.05. No futility is adopted, ak = −∞
for all k.
Error Spending Scheme k 1 2 3 4 5 6 7 8
1. Constant efficacy boundary bk 2.442 2.442 2.442 2.442 2.442 2.442 2.442 2.442
αk 0.0073 0.0054 0.0072 0.0054 0.0071 0.0053 0.0070 0.0052
2. Pocock-type boundary bk 2.337 2.291 2.451 2.399 2.534 2.480 2.599 2.544
αk 0.0097 0.0081 0.0070 0.0061 0.0055 0.0049 0.0045 0.0041
3. O’Brien & Fleming-type boundary bk 5.421 3.750 3.015 2.600 2.426 2.220 2.232 2.078
αk 2.96e-08 8.84e-05 0.0013 0.0042 0.0076 0.0104 0.0125 0.0139
4. Rho error spending ρ = 0.3 bk 1.930 2.277 2.619 2.613 2.755 2.728 2.837 2.802
αk 0.0268 0.0062 0.0043 0.0034 0.0028 0.0024 0.0022 0.0020
5. Rho error spending ρ = 0.5 bk 2.104 2.273 2.526 2.493 2.625 2.577 2.685 2.632
αk 0.0177 0.0073 0.0056 0.0047 0.0042 0.0038 0.0035 0.0032
6. Rho error spending ρ = 1.0 bk 2.498 2.407 2.493 2.402 2.489 2.397 2.484 2.392
(i.e Constant error spending) αk 0.0062 0.0063 0.0063 0.0063 0.0063 0.0063 0.0063 0.0063
7. Rho error spending ρ = 2.0 bk 3.163 2.797 2.659 2.474 2.451 2.289 2.310 2.151
αk 0.0008 0.0023 0.0039 0.0055 0.0070 0.0086 0.0102 0.0117
8. Rho error spending ρ = 3.0 bk 3.725 3.190 2.901 2.638 2.512 2.289 2.236 2.016
αk 9.77e-05 0.0007 0.0019 0.0034 0.0060 0.0089 0.0124 0.0165
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Under Pocock-type boundary set, we are favoring the earlier doses by spending more alphas
in the earlier stages, while under O’Brien & Fleming-type boundary set, we are doing the
opposite by spending more alphas in later stages. The boundary sets under Rho error
spendings with ρ = 0.3 and 0.5 have similar properties to the Pocock-type boundary set,
while those with ρ = 2 and 3 are similar to the O’Brien & Fleming-type boundary set.
Similar to the constant boundary set, the boundary set under Rho error spending with
ρ = 1 also has the same αk spent for each of the four doses. Each dose gets an alpha
spending of 0.0125. This is almost similar to the constant efficacy boundary scheme except
for the fact that constant efficacy boundary favors the first per-dose stage m = 1 slightly
more than the second per-dose stage m = 2 for each of the doses, that is, α1 > α2, α3 > α4,
etc.
In order to confirm if the derived sets of stopping boundaries in Table 3.3 are able to
control the family-wise type I error under one-sided α < 0.05, we conducted simulation
with 50,000 simulated trials. Table 3.4 displays the simulated type I error under the global
null hypothesis. It can be seen that these boundary sets are able preserve the family-wise
type I error.
Table 3.4: Simulated type I error rates for the derived stopping boundary sets under the
selected eight alpha spending plans in Table 3.3
Constant boundary Pocock O’Brien-Fleming ρ = 0.3
Simulated type I error 0.0496 0.0482 0.04856 0.0481
ρ = 0.5 ρ = 1.0 ρ = 2.0 ρ = 3.0
Simulated type I error 0.0501 0.0488 0.0490 0.0481
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3.4.3 Cohort Sizes and Planned Trial Sample Sizes
Table 3.5 displays the cohort sizes, expected stages, expected sample sizes, and dose selection
probabilities under this proposed adaptive procedure to obtain statistical power of 0.8. Table
3.6 displays the same characteristics under this proposed adaptive procedure to obtain
statistical power of 0.9. The following summary and discussion focus on Table 3.6, but
similar, parallel interpretation can be drawn for Table 3.5. For all dose response models
except the flat model, the required cohort size is smaller when a trial uses informative
ordering and error spending schemes that favor earlier stages, namely Pocock, Rho with
ρ = 0.3 and 0.5 than a trial that uses other orderings and error spending schemes that
favor later stages. Considerable saving in patient resources in terms of sample size and
time can be achieved under these optimistic scenarios. When the prior knowledge of the
dose-response relationship is strong, we can plan the trial by putting presumably efficacious
doses first and applying an optimistic error spending function that favors earlier stages. On
the other hand, if we couple an informative ordering with an error spending plan that favors
later stages and doses, such as O’Brien & Fleming, Rho with ρ = 2 and 3, we will have to
increase the cohort size to maintain the same statistical power. O’Brien & Fleming error
spending performs the worst in this case due to its strong favoritism on the later stages.
In this case, this type of error spending plan is not complementary to the informative dose
ordering.
For these same dose response models except the flat model, the constant efficacy boundary
and Rho with ρ = 1 have similar results with the latter showing only a small advantage.
It can be seen that for these two error spending plans, informative ordering does not offer
additional advantage over dose escalation ordering. It is apparent that the flat dose response
model is immune to dose ordering and all error spending plans perform similarly under this
model.
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3.4.4 Expected Stages and Expected Trial Sample Sizes
Table 3.6 also tabulates the expected number of global stages out of K = 8 stages for
statistical power of 0.9. For all of the dose response models except the flat model, informative
dose ordering results in substantial reduction in the number of stages a trial goes through
for efficacy, regardless of which error spending function is used. This reduction in stages is
particularly greater, E(K) < 4, under Pocock, Rho with ρ = 0.3, 0.5, and 1 error spendings.
We can only achieve E(K) < 6 if we use O’Brien & Fleming, Rho with ρ = 2 and 3 under
informative ordering. Again, constant efficacy boundary and Rho ρ = 1 perform similarly.
As expected, the flat model does not depend on dose ordering, but Pocock, Rho with ρ = 0.3
and 0.5 error spendings can offer an advantage to stop the trial early for efficacy better than
the other error spending plans can.
We can also see from Table 3.6 that dose escalation ordering does not perform well in
reducing the expected number of stages a trial goes through before stopping for efficacy. It
is because the better doses are placed at the later stages, so trials that use dose escalation
ordering and error spending plans which favor later stages will tend to proceed through the
later stages. Table 3.6 combines the results of cohort sizes and expected number of stages
to obtain the expected trial sample sizes under statistical power of 0.9. This expected trial
sample sizes are expected to be substantially smaller than the planned trial sample sizes.
3.4.5 Probability of Selecting the Best Dose
Table 3.6 also shows the probabilities of dose selection. Under dose escalation ordering, the
best dose is usually located last except for flat and umbrella dose response models. Error
spending functions that favor later stages such as O’Brien & Fleming, Rho with ρ = 2 and 3
tend to push the trial to these later stages and therefore increase the probability of selecting
the best dose. On the other hand, error spending functions that favor earlier stages are
unlikely to move a trial to later stages, and thus they decrease the probabilities that these
44
better doses are selected. For example, under the linear model and dose escalation ordering,
if Rho error spending with ρ = 0.3 is used, the probability that d4 = 8 with µ4 = 0.35 is
selected is 0.31, but this probability increases to 0.43 if ρ = 3 is used. Under informative
ordering, the best dose is located first and when it is coupled with a complementary error
spending function like Pocock, Rho with ρ = 0.3 or 0.5 that favor earlier dose selection, the
probability that this best dose is selected is much higher. Using the same example of linear
model but using informative ordering, the probability of selecting d4 = 8 with µ4 = 0.35 is
0.9 for ρ = 0.3 or 0.88 for ρ = 0.5.
However, under the flat model, the later doses, although having similar mean effect, are not
likely selected. If one insists on fully exploring all of the experimental doses, a Rho error
spending plan with ρ = 3 or higher can help a trial goes through all the stages, allowing
doses under the flat dose response model to have comparable probabilities of being selected.
It is important to note that the probability of selecting the best dose not only depends on
the mean responses of the doses but also on the ordering of the doses and the error spending
plan chosen for the trial. Generally, error spending plans that favor the later stages tend
to push the trials all the way through the stages, and therefore most of the doses will be
studied. This will increase the probability of selecting the later doses.
3.4.6 Comparison of Statistical Power
Table 3.7 displays the statistical powers of the parallel group fixed dose design, the drop-the-
losers design, and the seamless two-stage dose response informed design. We can compare
these simulated powers to the 0.9 level. This table also displays the probabilities of dose
selection for the last two comparator designs. For parallel group design using traditional
Dunnett’s adjustment, its statistical power is generally lower than that of the adaptive
staggered dose procedure except under the following three error spending plans - O’Brien &
Fleming, Rho with ρ = 2 and 3. As we have seen earlier, these are the error spending plans
that favor later stages and therefore they need more expected number of global stages for
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the trial to stop for efficacy. As a result, they also tend to require larger expected sample
sizes under the proposed adaptive design and hence we will lose efficiency if we use these
types of error spending functions.
When compared to the drop-the-losers and the two-stage dose response informed designs,
the proposed adaptive procedure can outperform in statistical power only when certain
conditions are met. Figures 3.2, 3.3, 3.4, and 3.5 graphically compare the statistical powers
of the designs. Their powers are plotted against the cohort size that gives the same expected
trial sample size under the adaptive staggered dose design. It can be noted that the power
curves for the proposed design rise more steeply as cohort size increases than those of the
other designs.
Under the flat, emax or umbrella dose response models, the adaptive procedure performs
better than both the parallel group and drop-the-losers designs when using an error spending
that favors earlier doses such as Pocock or Rho with ρ 6 1. This can be confirmed from
Table 3.6. Under the linear dose response model, this adaptive design performs worse than
all three comparator designs, except under informative ordering coupled with Pocock or
Rho with ρ 6 1, but seamless two-stage design outperforms the proposed design when dose
response model is informative and cohort size is smaller. Generally, the adaptive design
performs better than the parallel group and drop-the-losers designs when using informative
ordering and optimistic error spending functions such as Pocock or Rho with ρ 6 1. If one
has to use the dose escalation ordering, then the cohort size must be increased substantially
to achieve comparable statistical power.
As for selecting the best dose, using the example of the linear dose response model discussed
earlier, the drop-the-loser design has a probability of selecting d4 = 8 (µ4 = 0.35) equal
to 0.72, comparing to 0.90 when we use Rho with ρ = 0.3 and informative dose ordering.
However, the two-stage dose-response informed design always selects the best dose under
the informative monotonic dose response model when the estimated dose response is sig-
nificant at interim. The probability of selecting the best dose can be higher only if we use
46
an optimistic error spending function and when knowledge of the dose response model is
strong for the proposed design. If dose safety is not of great concern, assuming a monoton-
ically increasing dose response curve, dose de-escalation ordering is considered as the best
informative ordering and can result in a higher probability of selecting the best dose.
Figure 3.2: Comparison of statistical power under flat dose response model (3,000 simulated
trials)
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Figure 3.3: Comparison of statistical power under linear dose response model (3,000 simu-
lated trials)
! 3 
 
 
 
                                                     Dose Response: Linear (Max ! = 0.35, ! ! !) 
 Rho Error Spending Function 
 ! !0.3 ! !1.0 ! !3.0 
D
os
e 
Es
ca
la
tio
n 
 
 
In
fo
rm
at
iv
e 
 
Un
in
fo
rm
at
iv
e 
 
   o Adaptive staggered dose    ∆ Drop-the-losers      + Dunnett        ! Seamless 
 
 
!
!
!
!
!
60 80 100 120 140
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
Cohort Size
 
!
!
!
!
!
60 80 100 120 140
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
Cohort Size
 
!
!
!
!
!
60 80 100 120 140
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
Cohort Size
 
!
!
!
!
!
60 80 100 120 140
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
Cohort Size
 
!
!
!
!
!
60 80 100 120 140
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
Cohort Size
 
!
!
!
!
!
60 80 100 120 140
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
Cohort Size
 
!
!
!
!
!
60 80 100 120 140
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
Cohort Size
 
!
!
!
!
!
60 80 100 120 140
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
Cohort Size
 
!
!
!
!
!
60 80 100 120 140
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
Cohort Size
 
49
Figure 3.4: Comparison of statistical power under Emax dose response model (3,000 simu-
lated trials)
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Figure 3.5: Comparison of statistical power under umbrella dose response model (3,000
simulated trials)
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3.5 Summary and Discussion
Reflecting on the simulation results from the previous section, we can learn some important
lessons about this adaptive staggered dose procedure. In order to achieve additional gain in
trial efficiency, several conditions must be met. First, it is assumed that the doses chosen
for the study are from a dose range of acceptable safety. Second, an informative ordering of
the doses necessitates, at a minimum, some prior qualitative knowledge of the dose response
relationship such as monotonicity from previous pre-clinical or clinical studies on a similar
class of drugs. However, an assumed parametric model for dose response is not necessary.
Third, an application of an optimistic error spending functions such as Pocock or Rho with
ρ 6 1 allows early efficacious doses to be selected.
By randomizing patients in an adaptive staggered dose fashion instead of randomizing to
all of the doses at the same time, we can learn about efficacy more quickly from one dose to
another. If a dose shows evidence of futility, we can drop it and move onto the next dose,
but if it shows evidence of efficacy, we do not need to expose patients to the remaining and
potentially inferior doses. As a result, we may be able to save patient resources earlier by
stopping for efficacy earlier. For example, in some oncology trials, where the recruitment
period is extended and patients enter a trial at a staggered rate, we can learn and make
decisions quickly by focusing patient resources on fewer but potentially more efficacious
doses first rather than allocating them to many doses, some of which may be potentially
inefficacious.
As we have seen from the earlier plots, the power curves for the adaptive procedure are
steeper as cohort size increases. Even under unfavorable ordering such as dose escalation
ordering, we may be able to use an error spending scheme that favors later stages such as
O’Brien & Fleming or Rho with ρ > 1 and a larger cohort size to offset the loss of statistical
power due to the use of dose escalation ordering. However, this may risk selecting a sub-
optimal dose too early and failing to explore other doses.
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This adaptive procedure, therefore, may have its limitations. First, information on dose-
response relationship may not be available before Phase 2B or 3 studies. This design,
unlike the other three comparator designs, may not be able to adequately estimate the dose
response, as this is not one of the objectives. Therefore, this proposed design may also be
suitable to situations when a parametric dose response is not relevant such as in the case
when we are comparing and selecting from a set of treatment regimes or schedules, rather
than dose levels, of the same agent. For example, a Phase 3 trial is planned to select and
confirm a regime out of several for a new biological product administered subcutaneously to
treat rheumatoid arthritis (RA). The regimes differ by the dosage, frequency of injections,
and the inclusion of Methotrexate (MTX), an immunosuppressant, or not. In this case, the
regimes are ordered in such a way that the assumed better treatment regimes are placed
earlier in the ordering.
Second, we have assumed that the J a priori doses are within range of acceptable safety and
the selection of best dose is based on efficacy alone. In practice, safety issues take a longer
time to assess and may happen even after regulatory approval. It can be suggested that,
during the conduct of this trial, safety can be qualitatively evaluated through an independent
data safety monitoring committee (DSMB) which can provide input on the safety of the
selected dose. Further work will be needed if the criterion of selecting the optimal dose is
explicitly based on joint assessment of efficacy and toxicity or risk-to-benefit ratio.
Third, it is also likely to randomize more patients to the control arm than to the new test
treatment. This is particularly undesirable if the trial continues to later stages due to un-
successful earlier doses. One way to overcome this undesirable condition, while maintaining
a blinded randomization, is to change the randomization ratio using a higher R such as 1 : 3
or 1 : 4. These ratios may reduce the overall power. Therefore, a trade-off may exist in
reducing the number of patients allocated to the control and maximizing statistical power.
In addition, if one insists on using the dose escalation ordering because of safety issues, this
adaptive staggered dose procedure may not be efficient compared to other designs. There-
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fore, this adaptive design may take longer time to complete as doses are studied one after
the other, especially if earlier doses do not show evidence of efficacy.
In section 3.3.3, we have mentioned the use of separate alpha spending functions for each of
the doses instead of using one single alpha spending function. We can have better control
over how the alpha is spent on each of the doses. As a result, the application of this adaptive
staggered dose procedure can be flexibly modified depending on the objectives of a specific
trial. Therefore, if a drug trial is to use this adaptive staggered dose procedure for dose
selection, it is strongly suggested that simulations are performed to understand its operating
characteristics under all plausible dose response models. Since the operating characteristics
depend on the chosen design parameters, by trying different sets of these design parameters
we can better understand their relative performance in dose selection. Investigators can
choose the trial among the ones studied that can optimize the trial efficiency under the
most probable scenario. Using simulations, the team can also determine the cohort sizes
and plan the trial sample sizes to achieve their target statistical power accordingly.
As we have discussed, this adaptive procedure has demonstrated some desirable features
in increasing trial efficiency. To further improve this design and to overcome some of
the potential drawbacks identified earlier, several possible solutions can be proposed. For
example, by increasing R, we can randomize fewer patients to the control arm and more
to the experimental doses. This will further reduce the overall expected sample size but
may affect the statistical power to some extent. Another solution is to use D = 2, that is,
to use a design that looks at two concurrent experimental doses at the same time. In this
case, if J = 4, we can conduct the experiment by randomizing patients to the control and
the first two experimental doses given the dose ordering. When either one or both of these
two doses do not show evidence of efficacy, the next dose or the remaining two doses can
be added to the experiment for randomization in order to maintain two concurrent doses.
In this case, we randomize fewer patients to the control dose. Another modification in the
trial design is to use different number of maximum per-dose stages M . However, higher M
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means additional interim analyses which can be costly. Therefore, the investigators should
carefully consider the availability of resources when choosing the design parameters.
3.6 Appendix
3.6.1 Stage-wise Type I Error ψj,k for D = 1,M = 2
In this section, we want to show the result in equation (3.3.2).
Proof. We represent the probability of rejecting the null hypothesis Hj0 for dose dj at the
kth interim given that it is true as ψj,k for j = 1, 2, .., J and k = 1, 2, ...,K. We let ak be
the futility boundary and bk the efficacy boundary for the kth interim. Under condition of
no futility analysis, ak = −∞, the probability that dose dj will be dropped due to futility
when m = 1 is P (Zjm 6 ak) = 0. As a result, dose dj is added to the trial only if the
previous doses d1, d2, ..., dj−1 do not show evidence of efficacy and dose dj will always go
through all M = 2 per-dose stages. Therefore, for j = 2, ..., J and when m = 1,
ψj,k =

k−1
2∏
i=1
P (Z1 6 b2i−1, Z2 6 b2i)
P (Z > bk),
and when m = 2,
ψj,k =

k−2
2∏
i=1
P (Z1 6 b2i−1, Z2 6 b2i)
P (Z1 6 bk−1, Z2 > bk)
where Z and (Z1, Z2) follow the distribution in 3.3.1. We can see that ψj,k can be similarly
generalized to any M with D = 1.
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3.6.2 Stage-wise Statistical Power ξj,k for D = 1,M = 2
This section will derive the analytical form of the stage-wise statistical power, which is also
know as boundary crossing probability. Based on the distributions of the standardized test
statistics in (3.2.4), we can derive the stage-wise statistical power, denoted as ξj,k, for dose
dj at the kth global stage. Under the alternative hypothesis of a dose response model,
µj = f(dj), the stage-wise statistical power can be shown as
ξj,k =

Φ (−ωj,k) if j = 1, k = 1∫∞
ωj,k
Φ
(√
2ωj,k−1 − t
)
φ(t)dt if j = 1, k = 2{∏ k−12
i=1
(∫ ωi,2i
−∞ Φ
(√
2ωi,2i−1 − t
)
φ(t)dt
)}
Φ (−ωj,k) if j > 1, k = 2j − 1{∏ k−22
i=1
(∫ ωi,2i
−∞ Φ
(√
2ωi,2i−1 − t
)
φ(t)dt
)}
(∫∞
ωj,k
Φ
(√
2ωj,k−1 − t
)
φ(t)dt
)
if j > 1, k = 2j
where
ωj,k = bk − f(dj)− µ0√
R+1
c
when k = 2j − 1,
ωj,k = bk − f(dj)− µ0√
R+1
2c
when k = 2j,
and Φ and φ are the cumulative density and the probability density functions of the standard
normal distribution.
Proof. When j = 1 and k = 1, we need P (Z11 > b1),
P (Z11 > b1) = P
Z11 − f(d1)− µ0√
R+1
c
> b1 − f(d1)− µ0√
R+1
c

= P
Z > b1 − f(d1)− µ0√
R+1
c

= 1− Φ (ω1,1)
= Φ (−ω1,1)
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When j = 1 and k = 2, we need P (Z11 6 b1, Z12 > b2). In general, since the joint
distribution P (Zj1, Zj2) for the jth dose can also be written as P (Zj1|Zj2)P (Zj2). It is
known that the conditional distribution of Zj1|Zj2 follows
Zj1|Zj2 = zj2 ∼ N
f(dj)− µ0√
R+1
c
+ 1√
2
zj2 − f(dj)− µ0√
R+1
2c
 , 12
 .
Therefore,
P (Zj1 6 bk−1|Zj2 = zj2) = Φ
√2
bk−1 − f(dj)− µ0√
R+1
c
−
zj2 − f(dj)− µ0√
R+1
2c

= Φ
√2ωj,k−1 −
zj2 − f(dj)− µ0√
R+1
2c

Suppose we want the probability P (Zj1 6 bk−1, Zj2 > bk), and it can be re-written as
P (Zj1 6 bk−1, Zj2 > bk)
=
∫ ∞
bk
Φ
√2ωj,k−1 −
zj2 − f(dj)− µ0√
R+1
2c
P (Zj2 = zj2) dzj2
=
∫ ∞
ωj,k
Φ
(√
2ωj,k−1 − t
)
φ(t) dt
where the last equality follows from a transformation of t = zj2 − f(dj)−µ0√R+1
2c
.
The remaining boundary crossing probabilities can be derived by inserting the correct limits
into the integral. For a given set of stopping boundaries and cohort size c, the stage-wise
power can be evaluated using these probabilities. It can be verified that ξ = ∑Kk=1 ξj,k is
monotonically increasing in c.
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3.6.3 Expected Stages E(K)
In this section, we want to show the result in equation (3.3.6). We denote the boundary
crossing probability under the alternative hypothesis for the jth dose at the kth stage as
ξj,k.
Proof. For M = 2, the sample space for the stopping stage, K, is (1, 2, ...,K = 2J), therefore
its expectation is given by
E(K)
= ξ1,1 + 2ξ1,2 + 3ξ2,3 + ...+ (2J − 1)ξJ,2J−1 + 2J
1− J−1∑
j=1
(ξj,2j−1 + ξj,2j)− ξJ,2J−1

= 2J −
J−1∑
j=1
((2J − 2j + 1)ξj,2j−1 + (2J − 2j)ξj,2j)
− ξJ,2J−1.
We can see that E(K) < 2J under alternative hypothesis.
3.6.4 Strong Control of Type I Error
Proposition 1. Given an adaptive staggered dose procedure with the following parameters:
D = 1, M = 2, and without stopping for futility, the α-level efficacy stopping boundaries
under global null hypothesis are sufficient to provide control of family-wise type I error rate
(FWER) under α in the strong sense.
Proof. Suppose we have the stopping boundaries b = (b1, b2, ..., bk, .., bK) calculated under
the global null hypothesis
HG0 =
J⋂
j=1
Hj0
using the null distributions in (3.3.1), the forms of ψj,k in (3.3.2) and alpha spending as in
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(3.3.4) that preserves the family-wise type I error under α. We need to show that this set
of boundary values b can also keep the type I error rate under α for any other intersection
hypotheses which contain any subsets of all null hypotheses. In other words, if we let J ⊂
{1, 2, ..., J} be any subset of doses with true null hypotheses J = {j : Hj0 : µj 6 µ0 is true},
we want to show that this set of boundary values b can also control the type I error for the
following intersection hypothesis
H0J =
⋂
j∈J
H0j .
When only a subset of doses J have true null hypotheses, we can let J ′ be the set of
the remaining doses whose alternative hypotheses are true, such that J ′⋂J = φ and
J ′⋃J = {1, 2, ..., J}. Therefore, we have J ′ = {j : Hja : µj > µ0 is true}. We can see
that for j′ ∈ J ′,
P (Zj′1 < bk, Zj′2 < bk+1) < P (Z1 < bk, Z2 < bk+1)
where (Zj′1, Zj′2) follows the alternative distributions in (3.2.4) while (Z1, Z2) follows the
null distributions in (3.3.1). It follows from the fact that µj′ − µ0 > 0, and therefore given
the same stopping boundaries (bk, bk+1), the probability on the left hand side is smaller than
the one on the right hand side. As a result, any dose j ∈ J that follows a dose j′ ∈ J ′ in the
pre-specified dose ordering will have smaller type I error ψj,k as in (3.3.2) as it depends on
the outcomes of the previous doses. Therefore, the probability of rejecting the intersection
null hypothesis stated above is smaller than α given this set of stopping boundary values.
Since the probability of rejecting any intersection null hypothesis, when it is true, is always
controlled at α, therefore for any dose dj with true null hypothesis Hj0, all intersection null
hypotheses containing it are tested at α. We can claim that this boundary set computed
under this staggered dose testing procedure has strong control of family-wise type I error
according to the closed testing principle (Marcus, Peritz, and Gabriel, 1976).
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3.7 R Codes
3.7.1 Function Codes
pocockesf <- function(alpha, t) {
if (t < 1) {at <- alpha*log(1+(exp(1)-1)*t)} else {at <- alpha}
return(at)
}
obfesf <- function(alpha, t) {
if (t < 1) {at <- 2*(1-pnorm((qnorm(1-alpha/2))/sqrt(t)))} else {at <- alpha}
return(at)
}
rhoesf <- function(alpha, rho, t) {
if (t < 1) {at <- alpha*(tˆrho)} else {at <- alpha}
return(at)
}
alphasegments <- function(type, alpha, K, rho=1) {
alphaseg <- rep(NA,K)
if (type==1) {
for (i in 1:K) {
alphaseg[i] <- pocockesf(alpha=alpha, t=(i/K))
}
} else if (type==2) {
for (i in 1:K) {
alphaseg[i] <- obfesf(alpha=alpha, t=(i/K))
}
} else if (type==3) {
for (i in 1:K) {
alphaseg[i] <- rhoesf(alpha=alpha, rho=rho, t=(i/K))
}
}
alphaseg2 <- alphaseg-c(0, alphaseg[1:(K-1)])
return(alphaseg2)
}
library(mvtnorm)
# p1 = P(Z < x)
p1 <- function(x) {pnorm(x)}
# p2 = P(Z > x)
p2 <- function(x) {pnorm(x, lower.tail=F)}
# p3 = P(x1 < Z1 < x2, Z2 < x3)
p3 <- function(x1, x2, x3) {prob <- pmvnorm(lower=c(x1,-Inf), upper=c(x2,x3), mean=rep(0,2),
corr=matrix(c(1,1/sqrt(2),1/sqrt(2),1), c(2,2))); return(prob)}
# p4 = P(x1 < Z1 < x2, Z2 > x3)
p4 <- function(x1, x2, x3) {prob <- pmvnorm(lower=c(x1,x3), upper=c(x2,Inf), mean=rep(0,2),
corr=matrix(c(1,1/sqrt(2),1/sqrt(2),1), c(2,2))); return(prob)}
effboundaryJ4D1M2 <- function(alphaseg, a, limits=c(1,3)) {
result <- list()
K <- length(alphaseg)
b <- rep(NA, K)
accuracy <- rep(NA, K)
tryb <- seq(limits[1], limits[2], by=0.001)
n <- length(tryb)
trypsi <- rep(NA, n)
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w <- 1
# find b[1]
if (w > K) {stop} else {
for (i in 1:n) {
trypsi[i] <- p2(tryb[i])
}
accuracy[1] <- min(abs(trypsi-alphaseg[1]))
b[1] <- tryb[which(abs(trypsi-alphaseg[1])==min(abs(trypsi-alphaseg[1])))]; w <- w+1}
# find b[2]
if (w > K) {stop} else {
for (i in 1:n) {
trypsi[i] <- p4(a[1],b[1],tryb[i])+p1(a[1])*p2(tryb[i])
}
accuracy[2] <- min(abs(trypsi-alphaseg[2]))
b[2] <- tryb[which(abs(trypsi-alphaseg[2])==min(abs(trypsi-alphaseg[2])))]; w<- w+1}
# find b[3]
if (w > K) {stop} else {
for (i in 1:n) {
trypsi[i] <- p3(a[1],b[1],b[2])*p2(tryb[i])+p1(a[1])*p4(a[2],b[2],tryb[i])+p1(a[1])*p1(a[2])
*p2(tryb[i])
}
accuracy[3] <- min(abs(trypsi-alphaseg[3]))
b[3] <- tryb[which(abs(trypsi-alphaseg[3])==min(abs(trypsi-alphaseg[3])))]; w <- w+1}
# find b[4]
if (w > K) {stop} else {
for (i in 1:n) {
trypsi[i] <- p3(a[1],b[1],b[2])*p4(a[3],b[3],tryb[i])+p3(a[1],b[1],b[2])*p1(a[3])
*p2(tryb[i])+p1(a[1])*p3(a[2],b[2],b[3])*p2(tryb[i])+p1(a[1])*p1(a[2])*p4(a[3],b[3],tryb[i])+
p1(a[1])*p1(a[2])*p1(a[3])*p2(tryb[i])
}
accuracy[4] <- min(abs(trypsi-alphaseg[4]))
b[4] <- tryb[which(abs(trypsi-alphaseg[4])==min(abs(trypsi-alphaseg[4])))]; w <- w+1}
# find b[5]
if (w > K) {stop} else {
for (i in 1:n) {
trypsi[i] <- p3(a[1],b[1],b[2])*p3(a[3],b[3],b[4])*p2(tryb[i])+p3(a[1],b[1],b[2])*p1(a[3])
*p4(a[4],b[4],tryb[i])+p1(a[1])*p3(a[2],b[2],b[3])*p4(a[4],b[4],tryb[i])+p3(a[1],b[1],b[2])
*p1(a[3])*p1(a[4])*p2(tryb[i])+p1(a[1])*p3(a[2],b[2],b[3])*p1(a[4])*p2(tryb[i])+p1(a[1])
*p1(a[2])*p3(a[3],b[3],b[4])*p2(tryb[i])+p1(a[1])*p1(a[2])*p1(a[3])*p4(a[4],b[4],tryb[i])
}
accuracy[5] <- min(abs(trypsi-alphaseg[5]))
b[5] <- tryb[which(abs(trypsi-alphaseg[5])==min(abs(trypsi-alphaseg[5])))]; w <- w+1}
# find b[6]
if (w > K) {stop} else {
for (i in 1:n) {
trypsi[i] <- p3(a[1],b[1],b[2])*p3(a[3],b[3],b[4])*p4(a[5],b[5],tryb[i])+p3(a[1],b[1],b[2])
*p3(a[3],b[3],b[4])*p1(a[5])*p2(tryb[i])+p3(a[1],b[1],b[2])*p1(a[3])*p3(a[4],b[4],b[5])
*p2(tryb[i])+p3(a[1],b[1],b[2])*p1(a[3])*p1(a[4])*p4(a[5],b[5],tryb[i])+p1(a[1])*
p3(a[2],b[2],b[3])*p3(a[4],b[4],b[5])*p2(tryb[i])+p1(a[1])*p3(a[2],b[2],b[3])*p1(a[4])
*p4(a[5],b[5],tryb[i])+p1(a[1])*p1(a[2])*p3(a[3],b[3],b[4])*p4(a[5],b[5],tryb[i])
}
accuracy[6] <- min(abs(trypsi-alphaseg[6]))
b[6] <- tryb[which(abs(trypsi-alphaseg[6])==min(abs(trypsi-alphaseg[6])))]; w <- w+1}
# find b[7]
if (w > K) {stop} else {
for (i in 1:n) {
trypsi[i] <- p3(a[1],b[1],b[2])*p3(a[3],b[3],b[4])*p3(a[5],b[5],b[6])*p2(tryb[i])+
p3(a[1],b[1],b[2])*p3(a[3],b[3],b[4])*p1(a[5])*p4(a[6],b[6],tryb[i])+p3(a[1],b[1],b[2])
*p1(a[3])*p3(a[4],b[4],b[5])*p4(a[6],b[6],tryb[i])+p1(a[1])*p3(a[2],b[2],b[3])
*p3(a[4],b[4],b[5])*p4(a[6],b[6],tryb[i])
}
accuracy[7] <- min(abs(trypsi-alphaseg[7]))
b[7] <- tryb[which(abs(trypsi-alphaseg[7])==min(abs(trypsi-alphaseg[7])))]; w <- w+1}
# find b[8]
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if (w > K) {stop} else {
for (i in 1:n) {
trypsi[i] <- p3(a[1],b[1],b[2])*p3(a[3],b[3],b[4])*p3(a[5],b[5],b[6])*p4(a[7],b[7],tryb[i])
}
accuracy[8] <- min(abs(trypsi-alphaseg[8]))
b[8] <- tryb[which(abs(trypsi-alphaseg[8])==min(abs(trypsi-alphaseg[8])))]; w <- w+1}
result$accuracy <- accuracy
result$effboundary <- b
return(result)
}
dose <- c(0,2,4,6,8)
maxmu <- 0.35
maxd <- dose[5]
ed50 <- dose[2]
maxumb <- dose[4]
midd <- dose[3]; alog <- -0.015
flat <- function(x) {y <- (x!=0)*maxmu; return(y)}
linear <- function(x) {y <- (maxmu/maxd)*x; return(y)}
emax <- function(x) {y <- (maxmu*(maxd+ed50)/maxd)*(x/(ed50+x)); return(y)}
umbrella <- function(x) {y <- (2*maxmu/maxumb)*x-(maxmu/(maxumb)ˆ2)*xˆ2
return(y)}
logistic <- function(x) {b <- (((maxmu/2)-alog)*2); c <- (log(-1-(b/alog)))/4
y <- alog+b/(1+exp(c*(midd-x))) ; return(y)}
drcurve <- function(model, dose) {
ndoses <- length(dose);
if (model==0) {
return(rep(0,ndoses))
} else if (model==1) {
return(flat(dose))
} else if (model==2) {
return(linear(dose))
} else if (model==3) {
return(emax(dose))
} else if (model==4) {
return(logistic(dose))
} else if (model==5) {return(umbrella(dose))}
}
onetrialD1 <- function(J=4, m=2, R, K, c, model, dose, ordering, stdev, delta=0, a, b) {
result <- list()
Nmax <- m*c
result$ordering <- ordering
result$dosereordered <- c(dose[1], dose[2:(J+1)][ordering])
mu <- drcurve(model=model, dose=dose)
result$muoriginal <- mu
mu <- c(mu[1],mu[2:(J+1)][ordering])
result$mureordered <- mu
x <- matrix(rnorm(J*Nmax, mean=mu[2:(J+1)], sd=stdev), c(J, Nmax), byrow=F)
result$simulatedmeans <- c(apply(x, 1, mean))
k <- 1
i <- 1
j <- 1
w <- 0
Nj <- 0
success <- 0
result$success <- success
ztrace <- rep(NA,K)
mtrace <- rep(NA,K)
atrace <- rep(NA,K)
jtrace <- rep(NA,K)
ktrace <- rep(NA,K)
while (j < (J+1) & k < (K+1)) {
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if (w==0) {x0 <- rnorm(Nmax/R, mean=mu[1], sd=stdev)}
w <- w+1
Nj <- Nj+c
jtrace[i] <- j
ktrace[i] <- k
z <- (mean(x[j,1:(w*c)])-mean(x0[1:(w*(c/R))])-delta)/(stdev*sqrt((R+1)/(w*c)))
ztrace[i] <- z
mtrace[i] <- mean(x[j,1:(w*c)])
a_k <- a[k]; b_k <- b[k]
if (z > b_k) {ind <- 1 # reject null
} else if (z < a_k) {ind <- 2 # accept null
} else if (a_k <= z & z <= b_k ) {ind <- 3} # continue to next cohort
atrace[i] <- ind
if (ind==1) { success <- 1; result$success <- success; result$selecteddose <- j
result$lastinterim <- k
result$summary <- paste("success=", success, ", current dose=", j, ",
current stage=", k, sep=""); break
} else if (ind==2) {j <- j+1; k <- k+1; w <- 0; Nj <- 0
} else if (ind==3 & Nj < Nmax) {j <- j; k <- k+1
} else if (ind==3 & Nj >= Nmax) {j <- j+1; k <- k+1; w <- 0; Nj <- 0}
i <- i+1
}
# note that the selecteddose is the j corresponding to the new order
if (result$success==0) { result$selecteddose <- NA; result$lastinterim <- k-1
result$summary <- "unsuccessful trial" }
trace <- cbind(ktrace, jtrace, mtrace, ztrace, atrace)
colnames(trace) <- c("interim","dose","samplemean","zstat","decision")
result$trace <- trace
return(result)
}
rejectnullprD1 <- function(J=4, m=2, R, K, c, model, dose, ordering, stdev,
delta=0, a, b, Nsim) {
sim <- list()
type1 <- rep(NA, Nsim); stage <- rep(NA, Nsim); selected <- rep(NA, Nsim)
for (g in 1:Nsim) {
result <- onetrialD1(J=4, m=2, R=R, K=K, c=c, model=model, dose=dose,
ordering=ordering, stdev=stdev, delta=delta, a=a, b=b)
type1[g] <- result$success
stage[g] <- result$lastinterim
if (result$success==1) {
selected[g] <- result$selecteddose
} else if (result$success==0) { selected[g] <- NA }
}
sim$avgtype1 <- mean(type1)
analyse <- cbind(type1,stage)
analyse <- analyse[analyse[,1]==1,]
counts <- rep(NA,K)
for (w in 1:K) {counts[w] <- sum(analyse[,2]==w)}
sim$type1bystage <- counts/Nsim
selected2 <- selected[complete.cases(selected)]
n <- length(selected2)
counts <- rep(NA,J)
for (w in 1:J) { counts[w] <- sum(selected2==w) }
# note the doseprop refers to the doses in new order, not original order
sim$doseprop <- counts/n
sim$avgk <- mean(stage)
sim$summary <- paste("probability of rejecting null =", sim$avgtype1, ",",
"average interim stage =", sim$avgk, sep=" ")
return(sim)
}
findcohortc3 <- function(targetpower, possiblec, J=4, m=2, R, K=8, model, dose,
ordering, stdev=1, delta=0, b) {
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meandose <- drcurve(model=model,dose=dose)
reordereddose <- meandose[2:5][ordering]
posspower <- rep(NA,length(possiblec))
findpower <- function(ccc) {
w1 <- b[1]-((reordereddose[1]-0)/(sqrt((R+1)/(ccc))))
w2 <- b[2]-((reordereddose[1]-0)/(sqrt((R+1)/(2*ccc))))
w3 <- b[3]-((reordereddose[2]-0)/(sqrt((R+1)/(ccc))))
w4 <- b[4]-((reordereddose[2]-0)/(sqrt((R+1)/(2*ccc))))
w5 <- b[5]-((reordereddose[3]-0)/(sqrt((R+1)/(ccc))))
w6 <- b[6]-((reordereddose[3]-0)/(sqrt((R+1)/(2*ccc))))
w7 <- b[7]-((reordereddose[4]-0)/(sqrt((R+1)/(ccc))))
w8 <- b[8]-((reordereddose[4]-0)/(sqrt((R+1)/(2*ccc))))
power1 <- p2(w1)
power2 <- p4(-Inf,w1,w2)
power3 <- p3(-Inf,w1,w2)*p2(w3)
power4 <- p3(-Inf,w1,w2)*p4(-Inf,w3,w4)
power5 <- p3(-Inf,w1,w2)*p3(-Inf,w3,w4)*p2(w5)
power6 <- p3(-Inf,w1,w2)*p3(-Inf,w3,w4)*p4(-Inf,w5,w6)
power7 <- p3(-Inf,w1,w2)*p3(-Inf,w3,w4)*p3(-Inf,w5,w6)*p2(w7)
power8 <- p3(-Inf,w1,w2)*p3(-Inf,w3,w4)*p3(-Inf,w5,w6)*p4(-Inf,w7,w8)
stagewise <- list()
stagewise$foundpower <- power1+power2+power3+power4+power5+power6+
power7+power8
stagewise$stagewisepower <- c(power1, power2, power3, power4, power5,
power6, power7, power8)
return(stagewise)
}
for (i in 1:length(possiblec)) {
ccc <- findpower(possiblec[i])
posspower[i] <- ccc$foundpower
}
result <- list()
result$possiblepower <- posspower
position <- which(posspower > targetpower)
position <- min(position)
result$position <- position
targetc <- possiblec[position]
result$targetc <- targetc
final <- findpower(targetc)
result$stagewisepower <- final$stagewisepower
check <- final$stagewisepower
result$expectedstage <- 8-(7*check[1]+6*check[2])-(5*check[3]+4*check[4])-
(3*check[5]+2*check[6])-check[7]
originalorder <- c(which(ordering==1),which(ordering==2),which(ordering==3),
which(ordering==4))
doseprob <- c(check[1]+check[2],check[3]+check[4],check[5]+check[6],check[7]+
check[8])/sum(check)
result$doseprob_originorder <- doseprob[originalorder]
# return the dose selection probabilities in original order
return(result)
}
library(multcomp)
onetrialdunnett <- function(J=4, ss, model, dose, stdev, delta=0, alternative="greater",
alpha=0.05) {
output <- list()
if ((J+1)!=length(dose)) {print("The length of dose do not match (J+1).", quote=F)}
outcome <- NULL
factor <- NULL
mu <- drcurve(model=model,dose=dose)
for (i in 1:(J+1)) {
outcome <- c(outcome, rnorm(ss, mu[i], sd=stdev));
factor <- c(factor, rep((i-1),ss))
}
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trial <- cbind(outcome,factor)
colnames(trial) <- c("outcome","treatment")
trial <- data.frame(trial)
trial$treatment <- as.factor(trial$treatment)
modelmc <- aov(outcome˜treatment, data=trial)
result1 <- glht(model=modelmc, linfct = mcp(treatment = "Dunnett"),
alternative=alternative)
ci95 <- confint(result1, level=(1-alpha))
confidence <- ci95[[10]]
output$success <- (sum(confidence[,2]>0)>0)*1
output$means <- confidence[,1]
output$significantdoses <- which(confidence[,2]>0)
return(output)
}
rejectnullprdunnett <- function(J=4, ss, model, dose, stdev, delta=0, alternative="greater",
alpha=0.05, Nsim) {
sim <- list()
type1 <- rep(NA, Nsim)
for (m in 1:Nsim) {
result <- onetrialdunnett(J=4, ss=ss, model=model, dose=dose, stdev=stdev, delta=0,
alternative="greater", alpha=0.05)
type1[m] <- result$success
}
sim$avgtype1 <- mean(type1)
sim$summary <- paste("probability of rejecting null =", sim$avgtype1, sep=" ")
return(sim)
}
onetrialdroploser2 <- function(J=4, c, model, dose, stdev=1, delta=0, a, b) {
result <- list()
mu <- drcurve(model=model, dose=dose)
x0 <- rnorm(2*c, mean=mu[1], sd=stdev)
x <- NULL
for (j in 1:J) {
x <- rbind(x, rnorm(2*c, mean=mu[j+1], sd=stdev))
}
result$simulatedmeans <- c(mean(x0),apply(x,1,mean))
# first stage
result$success <- 0
mean1 <- apply(x[,1:c],1,mean)
whichj <- which(mean1==max(mean1))
result$selecteddose <- whichj
# second stage
z <- (mean(x[whichj,1:(2*c)])-mean(x0[1:(2*c)])-delta)/(stdev*sqrt(2/(2*c)))
result$z <- z
if (z > b) { result$success <- 1;
result$summary <- paste("success=", result$success, ", selected dose=",
whichj, sep="")
} else if (z <= b) {result$summary <- "Unsuccessful trial"}
return(result)
}
rejectnullprdroploser <- function(J=4, c, model, dose, stdev=1, delta=0, a, b, Nsim=1000) {
sim <- list()
type1 <- rep(NA, Nsim); selected <- rep(NA, Nsim)
for (g in 1:Nsim) {
result <- onetrialdroploser2(J=4, c=c, model=model, dose=dose, stdev=stdev,
delta=delta, a=a, b=b)
type1[g] <- result$success
if (result$success==1) {
selected[g] <- result$selecteddose
} else if (result$success==0) { selected[g] <- NA }
}
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sim$avgtype1 <- mean(type1)
selected2 <- selected[complete.cases(selected)]
n <- length(selected2)
counts <- rep(NA,J)
for (w in 1:J) { counts[w] <- sum(selected2==w) }
sim$doseprop <- counts/n
sim$summary <- paste("probability of rejecting null =", sim$avgtype1, sep=" ")
return(sim)
}
effbounddroploser <- function(J=4, m=2, c, model, dose, stdev=1, delta=0, a=0,
Nsim=1000, decimal=2, limits=c(1.5,2.5), alpha=0.05) {
tryb <- seq(limits[1], limits[2], by=10ˆ(-decimal))
n <- length(tryb)
type1error <- rep(NA, n)
for (i in 1:n) {
temp <- rejectnullprdroploser(J=4, c=c, model=model, dose=dose, stdev=stdev,
delta=delta, a=a, b=tryb[i], Nsim=Nsim)
type1error[i] <- temp$avgtype1
}
smooth <- lowess(tryb, type1error)
posit <- which(smooth$y < alpha)
posit <- min(posit)
oneb <- smooth$x[posit]
return(oneb)
}
# For J=4, under null, boundary is 2.0588
bretzfinddose <- function(model, datain) {
if (model==2) {
nlsmodel <- nls(response ˜ beta*dose,
data=datain,
start=list(beta=0.1))
coef(nlsmodel)
nlslinear <- function(x) {y <- (coef(nlsmodel))*x; return(y)}
estmu <- nlslinear(dose[c(2,3,4,5)])
whichj <- which(estmu==max(estmu))
return(whichj)
} else if (model==3) {
nlsmodel <- nls(response ˜ beta*(dose/(2+dose)),
data=datain,
start=list(beta=0.1))
coef(nlsmodel)
nlsemax <- function(x) {y <- coef(nlsmodel)*(x/(2+x)); return(y)}
estmu <- nlsemax(dose[c(2,3,4,5)])
whichj <- which(estmu==max(estmu))
return(whichj)
} else if (model==5) {
nlsmodel <- nls(response ˜ beta1*dose + beta2*(doseˆ2),
data=datain,
start=list(beta1=0.1, beta2=0.1))
coef(nlsmodel)
nlsumbrella <- function(x) {y <- (coef(nlsmodel)[1])*x+(coef(nlsmodel)[2])*xˆ2; return(y)}
estmu <- nlsumbrella(dose[c(2,3,4,5)])
whichj <- which(estmu==max(estmu))
return(whichj)
}
}
onetrialbretz <- function(J=4, c, model, dose, stdev, delta=0, b) {
result <- list()
result$model <- model
result$success <- 0
mu <- drcurve(model=model, dose=dose)
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datafinal <- NULL
for (i in 1:(J+1)) {
data <- NULL
data <- rnorm(c, mean=mu[i], sd=stdev)
dim(data) <- c(c,1)
data <- cbind(data, rep(dose[i], c), rep((i-1), c))
datafinal <- rbind(datafinal, data) }
datafinal2 <- data.frame(datafinal)
names(datafinal2) <- c("response", "dose", "which")
# first stage
whichj <- bretzfinddose(model=model, datain=datafinal2)
result$selecteddose <- whichj
# second stage
z <- ( mean(c(datafinal[datafinal[,3]==whichj,1], rnorm(c, mu[whichj+1], sd=stdev)))
- mean(c(datafinal[datafinal[,3]==0,1], rnorm(c, mu[1], sd=stdev)))
- delta)/(stdev*sqrt(2/(2*c)))
result$z <- z
if (z > b) { result$success <- 1;
result$summary <- paste("success=", result$success, ", selected dose=",
whichj, sep="")
} else if (z <= b) {result$summary <- "Unsuccessful trial"}
return(result)
}
rejectnullprbretz <- function(J, c, model, dose, stdev, delta=0, b, Nsim) {
sim <- list()
type1 <- rep(NA, Nsim); selected <- rep(NA, Nsim)
for (g in 1:Nsim) {
result <- onetrialbretz(J=J, c=c, model=model, dose=dose, stdev=stdev,
delta=delta, b=b)
type1[g] <- result[[2]]
if (result[[2]]==1) {
selected[g] <- result[[3]]
} else if (result[[2]]==0) { selected[g] <- NA }
}
sim$avgtype1 <- mean(type1)
selected2 <- selected[complete.cases(selected)]
n <- length(selected2)
counts <- rep(NA,J)
for (w in 1:J) { counts[w] <- sum(selected2==w) }
sim$doseprop <- counts/n
sim$summary <- paste("probability of rejecting null =", sim$avgtype1, sep=" ")
return(sim)
}
3.7.2 Analysis Codes
D <- 1
J <- 4
m <- 2
K <- 8
R <- 2
dose <- c(0,2,4,6,8)
maxmu <- 0.35
rho <- c(0.3, 0.5, 1, 2, 3)
drc <- c("flat","linear","emax","logistic","umbrella")
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numericalb <- rep(2.4422,K)
pocockb <- c(2.337, 2.291, 2.451, 2.399, 2.534, 2.480, 2.599, 2.544)
obfb <- c(5.421, 3.750, 3.015, 2.600, 2.426, 2.220, 2.232, 2.078)
rho0.3b <- c(1.930, 2.277, 2.619, 2.613, 2.755, 2.728, 2.837, 2.802)
rho0.5b <- c(2.104, 2.273, 2.526, 2.493, 2.625, 2.577, 2.685, 2.632)
rho1.0b <- c(2.498, 2.407, 2.493, 2.402, 2.489, 2.397, 2.484, 2.392)
rho2.0b <- c(3.163, 2.797, 2.659, 2.474, 2.451, 2.289, 2.310, 2.151)
rho3.0b <- c(3.725, 3.190, 2.901, 2.638, 2.512, 2.289, 2.236, 2.016)
effbounds <- rbind(numericalb, pocockb, obfb, rho0.3b, rho0.5b, rho1.0b, rho2.0b, rho3.0b)
droploser <- 2.0588
ordering1 <- 1:4
orderingflat <- 1:4
orderinglinear <- 4:1
orderingemax <- 4:1
orderinglogistic <- 4:1
orderingumbrella <- c(3,2,4,1)
informordering <- rbind(orderingflat, orderinglinear, orderingemax,
orderinglogistic, orderingumbrella)
informordering
permute <- cbind(rep(1:4,each=6), c(2,2,3,3,4,4,1,1,3,3,4,4,1,1,2,2,4,4,1,1,2,2,3,3),
c(3,4,2,4,2,3,3,4,1,4,1,3,2,4,1,4,1,2,2,3,1,3,1,2),
c(4,3,4,2,3,2,4,3,4,1,3,1,4,2,4,1,2,1,3,2,3,1,2,1))
permute
# dose escalation ordering
check <- NULL; p <- 1
cohort8 <- NULL; cohort9 <- NULL
simpower8 <- NULL; simpower9 <- NULL
expstages8 <- NULL; expstages9 <- NULL
proportions8 <- NULL; proportions9 <- NULL
for (i in 1:8) {
for (j in 1:5) {
usethis1 <- findcohortc3(targetpower=0.8, possiblec=seq(30,130), J=4, m=2,
R=2, K=8, model=j, dose=c(0,2,4,6,8), ordering=ordering1, stdev=1, delta=0, b=effbounds[i,])
usethis2 <- findcohortc3(targetpower=0.9, possiblec=seq(50,160), J=4, m=2,
R=2, K=8, model=j, dose=c(0,2,4,6,8), ordering=ordering1, stdev=1, delta=0, b=effbounds[i,])
for (k in 1:4) {
if (k==1) { cohort8 <- rbind(cohort8, usethis1[[3]])
cohort9 <- rbind(cohort9, usethis2[[3]])
} else if (k==2) { simpower8 <- rbind(simpower8, usethis1[[1]][usethis1[[2]]])
simpower9 <- rbind(simpower9, usethis2[[1]][usethis2[[2]]])
} else if (k==3) { proportions8 <- rbind(proportions8, matrix(usethis1[[6]],c(1,J)))
proportions9 <- rbind(proportions9, matrix(usethis2[[6]],c(1,J)))
} else if (k==4) { expstages8 <- rbind(expstages8, usethis1[[5]])
expstages9 <- rbind(expstages9, usethis2[[5]])}
}
check <- matrix(c(i,j,p),c(1,3))
write.table(check, "check1.txt", append=T, quote=F, row.names=F, col.names=F)
}
}
dim(cohort8) <- c(5,8); cohort8; write.table(cohort8, "8cohortorderesca.txt",
append=T, quote=F, row.names=F, col.names=F)
dim(cohort9) <- c(5,8); cohort9; write.table(cohort9, "9cohortorderesca.txt",
append=T, quote=F, row.names=F, col.names=F)
plannedss8 <- cohort8*K*((1/R)+1); plannedss8; write.table(plannedss8,
"8plannedssorderesca.txt", append=T, quote=F, row.names=F, col.names=F)
plannedss9 <- cohort9*K*((1/R)+1); plannedss9; write.table(plannedss9,
"9plannedssorderesca.txt", append=T, quote=F, row.names=F, col.names=F)
dim(simpower8) <- c(5,8); simpower8; write.table(simpower8,
"8simpowerorderesca.txt", append=T, quote=F, row.names=F, col.names=F)
dim(simpower9) <- c(5,8); simpower9; write.table(simpower9,
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"9simpowerorderesca.txt", append=T, quote=F, row.names=F, col.names=F)
dim(expstages8) <- c(5,8); expstages8; write.table(expstages8,
"8expstageorderesca.txt", append=T, quote=F, row.names=F, col.names=F)
dim(expstages9) <- c(5,8); expstages9; write.table(expstages9,
"9expstageorderesca.txt", append=T, quote=F, row.names=F, col.names=F)
expectedss8 <- cohort8*expstages8*((1/R)+1); expectedss8; write.table(expectedss8,
"8expssorderesca.txt", append=T, quote=F, row.names=F, col.names=F)
expectedss9 <- cohort9*expstages9*((1/R)+1); expectedss9; write.table(expectedss9,
"9expssorderesca.txt", append=T, quote=F, row.names=F, col.names=F)
proportions8; write.table(proportions8, "8proporderesca.txt", append=T, quote=F,
row.names=F, col.names=F)
proportions9; write.table(proportions9, "9proporderesca.txt", append=T, quote=F,
row.names=F, col.names=F)
# informative ordering
check <- NULL; p <- 2
cohort8 <- NULL; cohort9 <- NULL
simpower8 <- NULL; simpower9 <- NULL
expstages8 <- NULL; expstages9 <- NULL
proportions8 <- NULL; proportions9 <- NULL
for (i in 1:8) {
for (j in 1:5) {
usethis1 <- findcohortc3(targetpower=0.8, possiblec=seq(30,150), J=4, m=2,
R=2, K=8, model=j, dose=c(0,2,4,6,8), ordering=informordering[j,], stdev=1, delta=0,
b=effbounds[i,])
usethis2 <- findcohortc3(targetpower=0.9, possiblec=seq(50,180), J=4, m=2,
R=2, K=8, model=j, dose=c(0,2,4,6,8), ordering=informordering[j,], stdev=1, delta=0,
b=effbounds[i,])
for (k in 1:4) {
if (k==1) { cohort8 <- rbind(cohort8, usethis1[[3]])
cohort9 <- rbind(cohort9, usethis2[[3]])
} else if (k==2) { simpower8 <- rbind(simpower8, usethis1[[1]][usethis1[[2]]])
simpower9 <- rbind(simpower9, usethis2[[1]][usethis2[[2]]])
} else if (k==3) { proportions8 <- rbind(proportions8, matrix(usethis1[[6]],c(1,J)))
proportions9 <- rbind(proportions9, matrix(usethis2[[6]],c(1,J)))
} else if (k==4) { expstages8 <- rbind(expstages8, usethis1[[5]])
expstages9 <- rbind(expstages9, usethis2[[5]])}
}
check <- matrix(c(i,j,p),c(1,3))
write.table(check, "check2.txt", append=T, quote=F, row.names=F, col.names=F)
}
}
dim(cohort8) <- c(5,8); cohort8; write.table(cohort8, "8cohortorderinform.txt", append=T,
quote=F, row.names=F, col.names=F)
dim(cohort9) <- c(5,8); cohort9; write.table(cohort9, "9cohortorderinform.txt", append=T,
quote=F, row.names=F, col.names=F)
plannedss8 <- cohort8*K*((1/R)+1); plannedss8; write.table(plannedss8,
"8plannedssorderinform.txt", append=T, quote=F, row.names=F, col.names=F)
plannedss9 <- cohort9*K*((1/R)+1); plannedss9; write.table(plannedss9,
"9plannedssorderinform.txt", append=T, quote=F, row.names=F, col.names=F)
dim(simpower8) <- c(5,8); simpower8; write.table(simpower8, "8simpowerorderinform.txt",
append=T, quote=F, row.names=F, col.names=F)
dim(simpower9) <- c(5,8); simpower9; write.table(simpower9, "9simpowerorderinform.txt",
append=T, quote=F, row.names=F, col.names=F)
dim(expstages8) <- c(5,8); expstages8; write.table(expstages8, "8expstageorderinform.txt",
append=T, quote=F, row.names=F, col.names=F)
dim(expstages9) <- c(5,8); expstages9; write.table(expstages9, "9expstageorderinform.txt",
append=T, quote=F, row.names=F, col.names=F)
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expectedss8 <- cohort8*expstages8*((1/R)+1); expectedss8; write.table(expectedss8,
"8expssorderinform.txt", append=T, quote=F, row.names=F, col.names=F)
expectedss9 <- cohort9*expstages9*((1/R)+1); expectedss9; write.table(expectedss9,
"9expssorderinform.txt", append=T, quote=F, row.names=F, col.names=F)
proportions8; write.table(proportions8, "8proporderinform.txt", append=T, quote=F,
row.names=F, col.names=F)
proportions9; write.table(proportions9, "9proporderinform.txt", append=T, quote=F,
row.names=F, col.names=F)
# uninformative ordering
check <- NULL
cohort8 <- NULL; cohort9 <- NULL
cohort8.2 <- NULL; cohort9.2 <- NULL
simpower8 <- NULL; simpower9 <- NULL
simpower8.2 <- NULL; simpower9.2 <- NULL
expstages8 <- NULL; expstages9 <- NULL
expstages8.2 <- NULL; expstages9.2 <- NULL
proportions8 <- NULL; proportions9 <- NULL
proportions8.2 <- matrix(rep(0,5*8*J),c(5*8,J))
proportions9.2 <- matrix(rep(0,5*8*J),c(5*8,J))
for (p in 1:24) { # ordering
for (i in 1:8) { # error spending
for (j in 1:5) { # dose response model
usethis1 <- findcohortc3(targetpower=0.8, possiblec=seq(30,300), J=4, m=2, R=2,
K=8, model=j, dose=c(0,2,4,6,8), ordering=permute[p,], stdev=1, delta=0,
b=effbounds[i,])
usethis2 <- findcohortc3(targetpower=0.9, possiblec=seq(30,300), J=4, m=2, R=2,
K=8, model=j, dose=c(0,2,4,6,8), ordering=permute[p,], stdev=1, delta=0,
b=effbounds[i,])
for (k in 1:4) {
if (k==1) { cohort8 <- rbind(cohort8, usethis1[[3]])
cohort9 <- rbind(cohort9, usethis2[[3]])
} else if (k==2) { simpower8 <- rbind(simpower8, usethis1[[1]][usethis1[[2]]])
simpower9 <- rbind(simpower9, usethis2[[1]][usethis2[[2]]])
} else if (k==3) { proportions8 <- rbind(proportions8, matrix(usethis1[[6]],c(1,J)))
proportions9 <- rbind(proportions9, matrix(usethis2[[6]],c(1,J)))
} else if (k==4) { expstages8 <- rbind(expstages8, usethis1[[5]])
expstages9 <- rbind(expstages9, usethis2[[5]])}
}
check <- matrix(c(i,j,p),c(1,3))
write.table(check, "check3.txt", append=T, quote=F, row.names=F, col.names=F)
}
}
dim(cohort8) <- c(1,40); dim(cohort9) <- c(1,40)
write.table(cohort8, "cohort8.txt", append=T, quote=F, row.names=F, col.names=F)
write.table(cohort9, "cohort9.txt", append=T, quote=F, row.names=F, col.names=F)
cohort8.2 <- rbind(cohort8.2, cohort8)
cohort9.2 <- rbind(cohort9.2, cohort9)
cohort8 <- NULL; cohort9 <- NULL
dim(simpower8) <- c(1,40); dim(simpower9) <- c(1,40)
write.table(simpower8, "simpower8.txt", append=T, quote=F, row.names=F, col.names=F)
write.table(simpower9, "simpower9.txt", append=T, quote=F, row.names=F, col.names=F)
simpower8.2 <- rbind(simpower8.2, simpower8)
simpower9.2 <- rbind(simpower9.2, simpower9)
simpower8 <- NULL; simpower9 <- NULL
dim(expstages8) <- c(1,40); dim(expstages9) <- c(1,40)
write.table(expstages8, "expstages8.txt", append=T, quote=F, row.names=F, col.names=F)
write.table(expstages9, "expstages9.txt", append=T, quote=F, row.names=F, col.names=F)
expstages8.2 <- rbind(expstages8.2, expstages8)
expstages9.2 <- rbind(expstages9.2, expstages9)
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expstages8 <- NULL; expstages9 <- NULL
write.table(proportions8, "proportions8.txt", append=T, quote=F, row.names=F, col.names=F)
write.table(proportions9, "proportions9.txt", append=T, quote=F, row.names=F, col.names=F)
proportions8.2 <- proportions8.2+proportions8
proportions9.2 <- proportions9.2+proportions9
proportions8 <- NULL; proportions9 <- NULL
}
cohort8.2
cohort8.3 <- apply(cohort8.2, 2, mean)
write.table(matrix(cohort8.3,c(5,8)), "8cohortorderuninf.txt", append=T, quote=F,
row.names=F, col.names=F)
dim(cohort8.3) <- c(5,8)
cohort8.3
cohort9.2
cohort9.3 <- apply(cohort9.2, 2, mean)
write.table(matrix(cohort9.3,c(5,8)), "9cohortorderuninf.txt", append=T, quote=F,
row.names=F, col.names=F)
dim(cohort9.3) <- c(5,8)
cohort9.3
plannedss8 <- cohort8.3*K*((1/R)+1); plannedss8; write.table(plannedss8,
"8plannedssorderuninf.txt", append=T, quote=F, row.names=F, col.names=F)
plannedss9 <- cohort9.3*K*((1/R)+1); plannedss9; write.table(plannedss9,
"9plannedssorderuninf.txt", append=T, quote=F, row.names=F, col.names=F)
simpower8.2
simpower8.3 <- apply(simpower8.2, 2, mean)
write.table(matrix(simpower8.3,c(5,8)), "8simpowerorderuninf.txt", append=T, quote=F,
row.names=F, col.names=F)
dim(simpower8.3) <- c(5,8)
simpower8.3
simpower9.2
simpower9.3 <- apply(simpower9.2, 2, mean)
write.table(matrix(simpower9.3,c(5,8)), "9simpowerorderuninf.txt", append=T, quote=F,
row.names=F, col.names=F)
dim(simpower9.3) <- c(5,8)
simpower9.3
expstages8.2
expstages8.3 <- apply(expstages8.2, 2, mean)
write.table(matrix(expstages8.3,c(5,8)), "8expstageorderuninf.txt", append=T, quote=F,
row.names=F, col.names=F)
dim(expstages8.3) <- c(5,8)
expstages8.3
expstages9.2
expstages9.3 <- apply(expstages9.2, 2, mean)
write.table(matrix(expstages9.3,c(5,8)), "9expstageorderuninf.txt", append=T, quote=F,
row.names=F, col.names=F)
dim(expstages9.3) <- c(5,8)
expstages9.3
expectedss8 <- cohort8.3*expstages8.3*((1/R)+1); expectedss8; write.table(expectedss8,
"8expssorderuninf.txt", quote=F, row.names=F, col.names=F)
expectedss9 <- cohort9.3*expstages9.3*((1/R)+1); expectedss9; write.table(expectedss9,
"9expssorderuninf.txt", quote=F, row.names=F, col.names=F)
proportions8.3 <- proportions8.2/factorial(4); proportions8.3
proportions9.3 <- proportions9.2/factorial(4); proportions9.3
write.table(proportions8.3, "8proporderuninf.txt", append=T, quote=F, row.names=F, col.names=F)
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write.table(proportions9.3, "9proporderuninf.txt", append=T, quote=F, row.names=F, col.names=F)
# set number of simulated trials
Nsim4power <- 10000
# parallel group design with dunnett’s adjustment
powerdunnett8 <- matrix(rep(NA,5*8), c(5,8))
powerdunnett9 <- matrix(rep(NA,5*8), c(5,8))
p <- 8
for (i in 1:8) {
for (j in 1:5) {
usethis <- rejectnullprdunnett(J=4, ss=ceiling(expectedss8[j,i]/(J+1)), model=j,
dose=c(0,2,4,6,8), stdev=1, delta=0, alternative="greater", alpha=0.05, Nsim=Nsim4power)
powerdunnett8[j,i] <- usethis[[1]]
check <- matrix(c(i,j,p),c(1,3))
write.table(check, "check4.txt", append=T, quote=F, row.names=F, col.names=F)
}
}
powerdunnett8; write.table(powerdunnett8, "powerdunnett8.txt", quote=F, col.names=F,
row.names=F)
p <- 9
for (i in 1:8) {
for (j in 1:5) {
usethis <- rejectnullprdunnett(J=4, ss=ceiling(expectedss9[j,i]/(J+1)), model=j,
dose=c(0,2,4,6,8), stdev=1, delta=0, alternative="greater", alpha=0.05, Nsim=Nsim4power)
powerdunnett9[j,i] <- usethis[[1]]
check <- matrix(c(i,j,p),c(1,3))
write.table(check, "check4.txt", append=T, quote=F, row.names=F, col.names=F)
}
}
powerdunnett9; write.table(powerdunnett9, "powerdunnett9.txt", quote=F, col.names=F,
row.names=F)
# drop-the-losers design
droploser <- rep(NA, 10)
for (i in 1:10) {
droploser[i] <- effbounddroploser(J=4, m=2, c=20, model=0, dose=c(0,2,4,6,8), stdev=1,
delta=0, a=0, Nsim=5000, decimal=3, limits=c(1.8,2.2), alpha=0.05)
}
droploser
droploser <- mean(droploser) # 2.0588
droploser
write.table(droploser, "dtleffbound.txt", quote=F, col.names=F, row.names=F)
powerdroploser8 <- matrix(rep(NA,5*8), c(5,8))
powerdroploser9 <- matrix(rep(NA,5*8), c(5,8))
proportions8 <- NULL
proportions9 <- NULL
p <- 8
for (i in 1:8) {
for (j in 1:5) {
usethis <- rejectnullprdroploser(J=4, c=ceiling(expectedss8[j,i]/(4+3)), model=j,
dose=c(0,2,4,6,8), stdev=1, delta=0, a=0, b=droploser, Nsim=Nsim4power)
powerdroploser8[j,i] <- usethis[[1]]
proportions8 <- rbind(proportions8, usethis[[2]])
check <- matrix(c(i,j,p),c(1,3))
write.table(check, "check5.txt", append=T, quote=F, row.names=F, col.names=F)
}
}
powerdroploser8; write.table(powerdroploser8, "powerdroploser8.txt", quote=F, col.names=F,
row.names=F)
proportions8; write.table(proportions8, "droplosersprop8.txt", quote=F, col.names=F, row.names=F)
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p <- 9
for (i in 1:8) {
for (j in 1:5) {
usethis <- rejectnullprdroploser(J=4, c=ceiling(expectedss9[j,i]/(4+3)), model=j,
dose=c(0,2,4,6,8), stdev=1, delta=0, a=0, b=droploser, Nsim=Nsim4power)
powerdroploser9[j,i] <- usethis[[1]]
proportions9 <- rbind(proportions9, usethis[[2]])
check <- matrix(c(i,j,p),c(1,3))
write.table(check, "check5.txt", append=T, quote=F, row.names=F, col.names=F)
}
}
powerdroploser9; write.table(powerdroploser9, "powerdroploser9.txt", quote=F, col.names=F,
row.names=F)
proportions9; write.table(proportions9, "droplosersprop9.txt", quote=F, col.names=F, row.names=F)
# dose-response informed seamless design
forbretz8 <- read.table("8expssorderinform.txt")
forbretz8 <- forbretz8[c(-1,-4),] # remove flat and logistic expected sample sizes
forbretz9 <- read.table("9expssorderinform.txt")
forbretz9 <- forbretz8[c(-1,-4),] # remove flat and logistic expected sample sizes
modelno <- c(2,3,5)
powerbretz8 <- matrix(rep(NA,3*8), c(3,8))
powerbretz9 <- matrix(rep(NA,3*8), c(3,8))
propbretz8 <- NULL
propbretz9 <- NULL
p <- 10
for (i in 1:8) {
for (j in 1:3) {
usethis <- rejectnullprbretz(J=4, c=ceiling(forbretz8[j,i]/(4+3)), model=modelno[j],
dose=dose, stdev=1, delta=0, b=1.645, Nsim=Nsim4power)
powerbretz8[j,i] <- usethis[[1]]
propbretz8 <- rbind(propbretz8, usethis[[2]])
check <- matrix(c(i,j,p),c(1,3))
write.table(check, "check6.txt", append=T, quote=F, row.names=F, col.names=F)
}
}
powerbretz8; write.table(powerbretz8, "powerbretz8.txt", quote=F, col.names=F, row.names=F)
propbretz8; write.table(propbretz8, "bretzprop8.txt", quote=F, col.names=F, row.names=F)
p <- 10
for (i in 1:8) {
for (j in 1:3) {
usethis <- rejectnullprbretz(J=4, c=ceiling(forbretz9[j,i]/(4+3)), model=modelno[j],
dose=dose, stdev=1, delta=0, b=1.645, Nsim=Nsim4power)
powerbretz9[j,i] <- usethis[[1]]
propbretz9 <- rbind(propbretz9, usethis[[2]])
check <- matrix(c(i,j,p),c(1,3))
write.table(check, "check6.txt", append=T, quote=F, row.names=F, col.names=F)
}
}
powerbretz9; write.table(powerbretz9, "powerbretz9.txt", quote=F, col.names=F, row.names=F)
propbretz9; write.table(propbretz9, "bretzprop9.txt", quote=F, col.names=F, row.names=F)
# end of chapter code
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Chapter 4
Variants of Adaptive Staggered Dose Design
4.1 Introduction
In Chapter 3, we have proposed an adaptive staggered dose design for a normal endpoint and
have fully investigated its operating characteristics via simulation and numerical studies.
We have also discussed its strengths as well as limitations. In this chapter, we are mainly
interested in varying four of the design parameters as in Table 3.1 to further characterize its
performance in treatment selection and confirmation. In the current context, the objective
of the clinical trial remains the same: selecting one or two efficacious doses and confirming
the efficacy and safety of these selected doses. As we know, a clinical development is a very
costly process and requires scrupulous attention to its design and conduct. Therefore, the
number of interim monitoring stages in a sequential trial should be carefully planned. The
more interim analyses are planned in a trial, the more costly it may become and the more
likely operational bias may be unintentionally introduced into the trial. Therefore, a trial
with fewer interim stages may be desirable. As for randomization ratio, Peto (1978) has
advocated the use of unequal allocation such as 2:1 of intervention to control. The rationale
for such allocation is that the study may gain more information about subjects responses to
the new treatment, especially if adverse event rate is low. Also, as the risk-to-benefit profile
for the control treatment has been established in the past, more subjects may be able to
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benefit from a potentially more effective new intervention. However, unequal allocation has
been known to decrease overall statistical power, and so a delicate balance exists between
unequal allocation and ethical considerations (Peto et al., 1976). Finally, alpha spending
function has been used to monitor group sequential clinical trials. When multiple arms are
involved, Chen, DeMets, and Lan (2010) suggested using marginal monitoring with each
dose-to-control comparison monitored separately by its own alpha spending function with a
pre-specified nominal alpha level αj(j = 1, 2, ..., J) where J is the number of experimental
doses. In this case, they suggested applying a Bonferroni adjustment such that αj = α/J .
Many of these proposals can be used for improving the efficiency of multi-arm clinical trials.
In the following sections, we will look at several variations of the adaptive staggered dose
designs. Just like the specific version discussed in Chapter 3, the following setting will
apply to all of these variants, (1) J doses or arms of the experimental treatment and one
control dose, (2) dose ordering denoted by {d1, d2, ..., dJ} and control dose denoted by d0,
(3) normal model for the endpoint as in (3.2.1), (4) one-sided hypotheses as in (3.2.2),
(5) c as the cohort size per dose and stage for the experimental dose, (6) 1 : R as the
randomization ratio between the control and experimental dose, (7) D as the number of
doses being studied per stage, (8) M per-dose stages and K global stages of the trial, (9)
standardized test statistics as in (3.2.3), (10) no futility analysis, (11) four dose response
curves µj = f(dj) as in Table 3.2, and (12) α(t) as the alpha spending function where t is
the information fraction. The distributions of the test statistics under the null hypotheses
are given in (3.3.1) while those under the alternative hypotheses are given in (3.2.4).
We consider four variations of the design and compare them with the specific version in
Chapter 3 (D = 1,M = 2, R = 2, global α(t)) in their operating characteristics. In Section
4.2, we look at a design that studies two concurrent doses at each stage (D = 2). In Section
4.3, we investigate a design that allows only one stage per dose (M = 1). In Section 4.4, we
explore a design with each dose assigned its own marginal alpha spending function (αj(t)).
In Section 4.5, we vary the randomization ratio to R = 3. We want to assess the impact of
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these design parameters on the overall performance of the staggered dose design. Finally,
in Section 4.7, we will discuss how this adaptive staggered dose design can be extended to
binary and time-to-event endpoints.
4.2 Two Concurrent Doses D = 2
In this section, we want to consider a variant of the adaptive staggered dose design that tests
the hypotheses of two concurrent doses with the control dose at each interim stage. That
means, we are interested in D = 2 (see Table 3.1), while keeping other design parameters
constant at M = 2 and R = 2. When we allow each dose to have a maximum of M = 2
per-dose stages, the total number of global stages will be K = J stages if J is even, but
K = J + 1 if J is odd. The decision rule is that if at least one of the two null hypotheses
of the two doses is rejected, then the trial will stop to declare efficacy. Therefore, if at
the kth (k = 1, ...,K) interim stage, we are testing two doses, dj1 and dj2 , we can denote
the probability of rejecting either of the null hypotheses, {Hj10, Hj20} or both of them by
ψ(j1,j2),k when they are both true, where (j1, j2) ∈ {(1, 2), (3, 4), ...}. Using the distributions
of the test statistics Z and (Z1, Z2) in (3.3.1) under the global null hypothesis, and when
no futility analysis is performed, the probability of rejecting either Hj10, or Hj20, or both
can be given by
ψ(j1,j2),k
=

(P (Z > bk))2 + 2P (Z 6 bk)P (Z > bk) k = 1
(P (Z1 6 bk−1, Z2 > bk))2 + 2P (Z1 6 bk−1, Z2 6 bk)P (Z1 6 bk−1, Z2 > bk) k = 2[∏ k−1
2
i=1 (P (Z1 6 b2i−1, Z2 6 b2i))
2
] [
(P (Z > bk))2 + 2P (Z 6 bk)P (Z > bk)
]
k = j1[∏ k−2
2
i=1 (P (Z1 6 b2i−1, Z2 6 b2i))
2
]
×[
(P (Z1 6 bk−1, Z2 > bk))2 + 2P (Z1 6 bk−1, Z2 6 bk)P (Z1 6 bk−1, Z2 > bk)
]
k = j2.
We have assumed conservatively here that the test statistics of the two concurrent doses
against the control dose are independent and we have also applied the Sˇida´k’s adjustment
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in (4.2.1). Stopping boundary values bk’s can be evaluated accordingly when an alpha
spending function is specified. If one assumes that these two test statistics are not inde-
pendent due to the use of the same control in the test statistics, one can use Dunnett’s
adjustment to calculate the stopping boundary values. In this case, the test statistics can
be re-parameterized in terms of independent stochastic increments and stopping boundaries
values can be evaluated on this re-parameterized scale. The overall type I error under the
global null hypothesis for this trial is given by
ψ =
J/2∑
i=1
(ψ(2i−1,2i),2i−1 + ψ(2i−1,2i),2i)
if J is even. This overall type I error may be smaller than the overall type I error when
independence of test statistics is not assumed. The goal is to keep this overall type I error
under a target level of α. Based on this setting, we can also obtain the form of the stage-
wise statistical power or boundary crossing probabilities, ξ(j1,j2),k under the alternative
hypotheses as follows:
ξ(j1,j2),k
=

Φ(−ωj1,k)Φ(−ωj2,k) + Φ(−ωj1,k)Φ(ωj2,k) + Φ(−ωj2,k)Φ(ωj1,k) k = 1
(∫∞
ωj1,k
Φ
(√
2ωj1,k−1 − t
)
φ(t)dt
)(∫∞
ωj2,k
Φ
(√
2ωj2,k−1 − t
)
φ(t)dt
)
+
(∫∞
ωj1,k
Φ
(√
2ωj1,k−1 − t
)
φ(t)dt
)(∫ ωj2,k
−∞ Φ
(√
2ωj2,k−1 − t
)
φ(t)dt
)
+
(∫∞
ωj2,k
Φ
(√
2ωj2,k−1 − t
)
φ(t)dt
)(∫ ωj1,k
−∞ Φ
(√
2ωj1,k−1 − t
)
φ(t)dt
)
k = 2
[∏ k−1
2
i=1
(∫ ωi,i+1
−∞ Φ
(√
2ωi,i − t
)
φ(t)dt
)(∫ ωi+1,i+1
−∞ Φ
(√
2ωi+1,i − t
)
φ(t)dt
)]
× [Φ(−ωj1,k)Φ(−ωj2,k) + Φ(−ωj1,k)Φ(ωj2,k) + Φ(−ωj2,k)Φ(ωj1,k)] k = j1
[∏ k−2
2
i=1
(∫ ωi,i+1
−∞ Φ
(√
2ωi,i − t
)
φ(t)dt
)(∫ ωi+1,i+1
−∞ Φ
(√
2ωi+1,i − t
)
φ(t)dt
)]
×
[(∫∞
ωj1,k
Φ
(√
2ωj1,k−1 − t
)
φ(t)dt
)(∫∞
ωj2,k
Φ
(√
2ωj2,k−1 − t
)
φ(t)dt
)
+
(∫∞
ωj1,k
Φ
(√
2ωj1,k−1 − t
)
φ(t)dt
)(∫ ωj2,k
−∞ Φ
(√
2ωj2,k−1 − t
)
φ(t)dt
)
+
(∫∞
ωj2,k
Φ
(√
2ωj2,k−1 − t
)
φ(t)dt
)(∫ ωj1,k
−∞ Φ
(√
2ωj1,k−1 − t
)
φ(t)dt
)]
k = j2
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since doses (dj1 , dj2) are explored at interim stages k = j1 and k = j2 = j1 + 1 and
ωj1,k = bk −
f(dj1)− µ0√
R+1
c
, ωj2,k = bk −
f(dj2)− µ0√
R+1
c
when k = j1,
ωj1,k = bk −
f(dj1)− µ0√
R+1
2c
, ωj2,k = bk −
f(dj2)− µ0√
R+1
2c
when k = j2 = j1 + 1.
In addition, the expected stage for stopping for efficacy, if J is even and therefore J = K,
is given by
E(K) = ξ(1,2),1 + 2ξ(1,2),2 + 3ξ(3,4),3 + ...+ J
(
1− ξ(1,2),1 − ...− ξ(J−1,J),J−1
)
= J − (J − 1)ξ(1,2),1 − (J − 2)ξ(1,2),2 − ...− ξ(J−1,J),J−1
= J −
J/2−1∑
i=1
(J − 2i+ 1) ξ(2i−1,2i),2i−1 + (J − 2i)ξ(2i−1,2i),2i
− ξ(J−1,J),J−1
and the expected trial sample size is given by
E(S) = c
( 1
R
+ 2
)
E(K).
It can be seen that E(K) < J if stopping probabilities are large. Also, for the case when J
is odd, the expected stage and sample size can also be similarly derived.
In this simulation, we want to compare the cohort sizes, expected stages, and expected
sample sizes between designs with D = 1 and D = 2 under the four dose response models:
flat, linear, emax, and umbrella models, given dose escalation and informative and uninfor-
mative orderings with the alpha spending plans of Pocock, O’Brien-Fleming, ρ = 0.3, 1, 3 to
attain statistical power of 90%. In addition, we also want to characterize the relationship
between statistical power and expected sample size for these two designs. For these designs,
we assume J = 4, R = 2, M = 2, and K = J = 4 since J is even.
Table 4.1 gives the stopping boundary values that keep the type I error under one-sided
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α-level of 0.05. We can see that Pocock-type boundary and Rho with ρ = 0.3 tend to favor
earlier stages and hence the earlier doses. For Rho function with ρ = 1.0, error spending is
similar across stages. Table 4.2 displays the cohort sizes, expected stages, expected sample
sizes under this variant design while Figures 4.1, 4.2, 4.3, and 4.4 plot the statistical power
of the designs across expected trial sample size. As expected, we can see the variant design
with D = 2 achieves better power than the original design with D = 1 given the same
expected sample size. This is observed almost unanimously under different dose response
curves, alpha spending plans, and dose orderings. This variant design, again like the original
design, performs best when informative dose ordering is used.
However, under the linear dose response model with informative ordering and especially
Rho function with ρ = 0.3, the variant design appears to perform slightly worse than the
original design when expected sample size increases. As observed, the expected sample size
is not monotonic with the overall statistical power, due to the fact that expected sample
size depends on (1) the cohort size and (2) expected stopping stage, as in (3.3.7). It can
be verified that statistical power is monotonic with cohort size (see Section 3.6.2), but as c
increases, under informative ordering where doses with better effects are placed earlier, the
expected stage in stopping the trial E(K) can decrease substantially. Therefore, the increase
in c can be offset by greater decrease in E(K), resulting in decreased expected sample size
E(S) even when power increases. This explains the curved plot and the non-monotonicity.
The operating characteristics of this variant design using D = 2 is presented, and the
expected sample size given the same power is lower than that of the original design with
D = 1. It is possible that since we have two concurrent doses in each interim stage, this
may increase the probability of at least one dose is declared efficacious at each interim stage.
In addition, fewer subjects are needed for the control dose as the number of global stages
decreases. This variant design also shortens the duration of the trial. However, in case
when two doses are selected simultaneously due to joint statistical significance, it is still
unsure which dose of the two should be used for the indication.
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Table 4.1: Five alpha spending schemes and their corresponding stage-wise efficacy stopping
boundaries (bk) and errors (αk) for J = 4, D = 2,M = 2, R = 2, and K = J = 4. Family-
wise type I error is controlled at one-sided α = 0.05. No futility is adopted, ak = −∞ for
all k.
Error Spending Scheme k 1 2 3 4
1. Pocock-type boundary bk 2.37 2.37 2.56 2.53
αk 0.0179 0.0131 0.010 0.0086
2. O’Brien & Fleming-type boundary bk 3.92 2.78 2.37 2.13
αk 0.0001 0.0055 0.0180 0.0264
3. Rho error spending ρ = 0.3 bk 2.13 2.48 2.78 2.78
αk 0.0330 0.0076 0.0052 0.0041
4. Rho error spending ρ = 1.0 bk 2.50 2.41 2.49 2.40
αk 0.0125 0.0125 0.0125 0.0125
5. Rho error spending ρ = 3.0 bk 3.36 2.76 2.44 2.11
αk 0.0008 0.0055 0.0148 0.0289
Figure 4.1: Comparison of statistical power under flat dose response model for variant
design D = 2.
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Figure 4.2: Comparison of statistical power under linear dose response model for variant
design D = 2.
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Figure 4.3: Comparison of statistical power under emax dose response model for variant
design D = 2.
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Figure 4.4: Comparison of statistical power under umbrella dose response model for variant
design D = 2.
! 5 
                                                                   Dose Response: Umbrella (Max ! = 0.35, ! ! !) 
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4.3 One Stage Per Dose M = 1
In this section, we want to explore another variant of the adaptive staggered dose design that
only allows one stage per dose (M = 1) rather than two stages (M = 2) as in the original
design. This variant design continues to stagger the doses according to their presumed
effects and keeps other design parameters constant at D = 1 and R = 2. Therefore, in this
84
design, the total number of global stages is equal to the number of doses (K = J). At the
kth interim stage, we are testing the dose dj(j = k) against the control dose, and we can
represent the probability of rejecting the null hypothesis of this dose, Hj0 when it is true,
by ψj where j = 1, 2, ..., J = K. The stage-wise type I error can simply be given by
ψj =
 P (Z > bj) if j = 1[∏j−1
i=1 P (Z 6 bi)
]
P (Z > bj) if j > 1.
Therefore, the family-wise type I error for this trial is simply the sum of all dose-wise type
I errors as in
ψ =
J∑
i=1
ψi
and we are interested in preserving it under target α level. The corresponding boundary
crossing probabilities ξj can be given by
ξj =
 Φ(−ωj) if j = 1[∏j−1
i=1 Φ(ωi)
]
Φ(−ωj). if j > 1
where
ωj = bj − f(dj)− µ0√
R+1
c
.
Under this setting, the expected stage for stopping early for efficacy is
E(K) = ξ1 + 2ξ2 + ...+ (J − 1)ξJ−1 + J (1− ξ1 − ...− ξJ−1)
= J −
J−1∑
j=1
(J − j)ξj

and it can be noted that E(K) < J . The expected trial sample size is thus equal to
c (1/R+ 1)E(K).
Given an alpha spending plan, we can calculate the stopping boundary values bj ’s under
this variant design. Our objective is to compare the cohort sizes, expected stages, and
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expected sample sizes between the designs where M = 1 and M = 2, under different dose
response models, dose orderings, and error spending plans such as Pocock, O’Brien-Fleming,
Rho with ρ = 0.3, 1, 3 for the power of 90%. In addition, we also want to characterize the
relationship between statistical power and expected sample size for these two designs. Like
before, for these two designs, we assume J = 4, R = 2, D = 1, and K = J = 4 except for
M .
Table 4.3 gives the stopping boundary values. As before, we find that the Pocock-type and
Rho with ρ = 0.3 spending plans provide an opportunity to stop the trial at earlier stages
if an informative dose ordering is applied, while the O’Brien-Fleming-type and Rho with
ρ = 3.0 favor later stages and doses. Rho with ρ = 1.0 offers almost equal error spending
across the staggered doses with similar stopping boundary values. Table 4.4 displays the
results of the simulation. Figures 4.5, 4.6, 4.7, and 4.8 show the plots of statistical power
of the designs across expected trial sample size.
We have presented another variant design that sets M = 1 and allows one stage for each
dose, but doses are still entering the trial sequentially if the previous ones fail to show
efficacy. This design however performs better than the original design with M = 2 only
when (1) informative ordering is used, or (2) escalation ordering with ρ 6 1.0 is adopted.
A practical advantage of this variant design is that it reduces the number of interim anal-
yses performed and hence the administration cost. If the dose ordering is favoring early
efficacious doses, and the cost of performing monitoring analyses and meetings is high, this
design is preferred to the design with M = 2.
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Table 4.3: Five alpha spending schemes and their corresponding stage-wise efficacy stopping
boundaries (bj) and errors (αj) for J = 4, D = 1,M = 1, R = 2, and K = J = 4. Family-
wise type I error is controlled at one-sided α = 0.05. No futility is adopted, ak = −∞ for
all k.
Error Spending Scheme k 1 2 3 4
1. Pocock-type boundary bj 2.10 2.22 2.30 2.37
αj 0.0179 0.0131 0.010 0.0086
2. O’Brien & Fleming-type boundary bj 3.75 2.54 2.09 1.93
αj 0.0001 0.0055 0.0180 0.0264
3. Rho error spending ρ = 0.3 bj 1.84 2.41 2.54 2.62
αj 0.0330 0.0076 0.0052 0.0041
4. Rho error spending ρ = 1.0 bj 2.24 2.24 2.23 2.22
αj 0.0125 0.0125 0.0125 0.0125
5. Rho error spending ρ = 3.0 bj 3.16 2.54 2.17 1.89
αj 0.0008 0.0055 0.0148 0.0289
Figure 4.5: Comparison of statistical power under flat dose response model for variant
design M = 1.
! 1 
Comparison of Statistical Power by Trial Design 
 
                                                      Dose Response: Flat (Max ! = 0.35, ! ! !) 
 Rho Error Spending Function 
 ! !0.3 ! !1.0 ! !3.0 
No
 O
rd
er
in
g 
 
 
 ! Adaptive staggered dose M=1    " Adaptive staggered dose M=2 
 
 
  
!
!
!
!
!
!
!
!
!
!
180 220 260 300
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
Expected Sample Size
 
!
!
!
!
!
!
!
!
!
!
200 250 300 350
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
Expected Sample Size
 
!
!
!
!
!
!
!
!
!
!
250 300 350 400 450 500
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
Expected Sample Size
 
!
!
!
!
!
!
!
!
!
!
180 220 260 300
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
Expected Sample Size
 
!
!
!
!
!
!
!
!
!
!
200 250 300 350
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
Expected Sample Size
 
!
!
!
!
!
!
!
!
!
!
250 300 350 400 450 500
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
Expected Sample Size
 
!
!
!
!
!
!
!
!
!
!
180 220 260 300
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
Expected Sample Size
 
!
!
!
!
!
!
!
!
!
!
200 250 300 350
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
Expected Sample Size
 
!
!
!
!
!
!
!
!
!
!
250 300 350 400 450 500
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
Expected Sample Size
 
87
Ta
bl
e
4.
4:
C
oh
or
t
siz
e
pe
r
st
ag
e
(c
),
ex
pe
ct
ed
gl
ob
al
st
ag
e
to
st
op
fo
r
effi
ca
cy
(E
(K
))
,e
xp
ec
te
d
tr
ia
ls
am
pl
e
siz
e
( c(1+
R
)
R
E
(K
)) ,
an
d
pr
ob
ab
ili
tie
s
of
do
se
se
le
ct
io
n
fo
r
at
ta
in
in
g
st
at
ist
ic
al
po
we
r
of
90
%
fo
r
va
ria
nt
de
sig
n
w
ith
M
=
1.
D
os
e
Po
co
ck
-ty
pe
bo
un
da
ry
O
’B
rie
n
&
Fl
em
in
g
bo
un
da
ry
—
R
es
po
ns
e
Es
ca
la
tio
n
In
fo
rm
at
iv
e
U
ni
nf
or
m
at
iv
e
Es
ca
la
tio
n
In
fo
rm
at
iv
e
U
ni
nf
or
m
at
iv
e
-
-
-
1.
Fl
at
co
ho
rt
siz
e
10
5
10
5
10
5
12
9
12
9
12
9
-
-
-
ex
pe
ct
ed
st
ag
e
1.
96
1.
97
1.
96
2.
71
2.
71
2.
71
-
-
-
ex
pe
ct
ed
sa
m
pl
e
siz
e
31
0
31
0
31
0
52
6
52
6
52
6
-
-
-
do
se
se
le
ct
io
n
pr
ob
(0
.5
42
,0
.2
51
,
(0
.5
42
,0
.2
51
,
(0
.2
50
,0
.2
50
,
(0
.0
81
,0
.4
13
,
(0
.0
81
,0
.4
13
,
(0
.2
50
,0
.2
50
,
-
-
-
0.
13
0,
0.
07
7)
0.
13
0,
0.
07
6)
0.
25
0,
0.
25
0)
0.
35
6,
0.
15
0)
0.
35
6,
0.
15
0)
0.
25
0,
0.
25
0)
-
-
-
2.
Li
ne
ar
co
ho
rt
siz
e
28
4
18
4
22
5
26
8
31
1
30
3
-
-
-
ex
pe
ct
ed
st
ag
e
2.
76
1.
53
2.
06
3.
09
2.
00
2.
52
-
-
-
ex
pe
ct
ed
sa
m
pl
e
siz
e
11
78
42
1
69
6
12
43
92
8
11
44
-
-
-
do
se
se
le
ct
io
n
pr
ob
(0
.1
18
,0
.3
02
,
(0
.0
24
,0
.0
29
,
(0
.0
56
,0
.1
45
,
(0
.0
02
,0
.2
07
,
(0
.0
67
,0
.1
08
,
(0
.0
50
,0
.1
16
,
-
-
-
0.
41
5,
0.
16
6)
0.
12
6,
0.
82
1)
0.
31
7,
0.
48
2)
0.
58
6,
0.
20
5)
0.
35
1,
0.
47
3)
0.
31
2,
0.
52
2)
-
-
-
3.
Em
ax
co
ho
rt
siz
e
14
9
12
7
14
2
15
7
16
9
17
7
-
-
-
ex
pe
ct
ed
st
ag
e
2.
31
1.
81
1.
98
2.
90
2.
55
2.
68
-
-
-
ex
pe
ct
ed
sa
m
pl
e
siz
e
51
6
34
5
42
1
68
3
64
6
71
0
-
-
-
do
se
se
le
ct
io
n
pr
ob
(0
.3
20
,0
.3
45
,
(0
.0
57
,0
.0
87
,
(0
.1
37
,0
.2
36
,
(0
.0
17
,0
.3
64
,
(0
.1
27
,0
.2
76
,
(0
.1
25
,0
.2
30
,
-
-
-
0.
22
5,
0.
11
1)
0.
22
3,
0.
63
3)
0.
29
5,
0.
33
1)
0.
44
6,
0.
17
4)
0.
45
1,
0.
14
5)
0.
30
0,
0.
34
5)
-
-
-
4.
U
m
br
el
la
co
ho
rt
siz
e
13
6
12
4
14
5
13
9
16
0
18
3
-
-
-
ex
pe
ct
ed
st
ag
e
2.
42
1.
86
1.
99
2.
91
2.
65
2.
67
-
-
-
ex
pe
ct
ed
sa
m
pl
e
siz
e
49
4
34
6
43
2
60
7
63
7
72
9
-
-
-
do
se
se
le
ct
io
n
pr
ob
(0
.2
38
,0
.3
94
,
(0
.0
67
,0
.2
03
,
(0
.1
15
,0
.2
73
,
(0
.0
08
,0
.3
69
,
(0
.1
46
,0
.3
85
,
(0
.1
03
,0
.2
72
,
-
-
-
0.
24
9,
0.
11
9)
0.
62
1,
0.
10
9)
0.
33
8,
0.
27
3)
0.
44
9,
0.
17
3)
0.
12
9,
0.
34
0)
0.
35
3,
0.
27
2)
-
-
-
D
os
e
R
ho
er
ro
r
sp
en
di
ng
ρ
=
0.
3
R
ho
er
ro
r
sp
en
di
ng
ρ
=
1.
0
R
ho
er
ro
r
sp
en
di
ng
ρ
=
3.
0
R
es
po
ns
e
Es
ca
la
tio
n
In
fo
rm
at
iv
e
U
ni
nf
or
m
at
iv
e
Es
ca
la
tio
n
In
fo
rm
at
iv
e
U
ni
nf
or
m
at
iv
e
Es
ca
la
tio
n
In
fo
rm
at
iv
e
U
ni
nf
or
m
at
iv
e
1.
Fl
at
co
ho
rt
siz
e
11
3
11
3
11
3
10
6
10
6
10
6
12
9
12
9
12
9
ex
pe
ct
ed
st
ag
e
1.
76
1.
76
1.
76
2.
06
2.
06
2.
06
2.
51
2.
51
2.
51
ex
pe
ct
ed
sa
m
pl
e
siz
e
29
8
29
8
29
8
32
8
32
8
32
8
48
6
48
6
48
6
do
se
se
le
ct
io
n
pr
ob
(0
.6
89
,0
.1
66
,
(0
.6
89
,0
.1
66
,
(0
.2
50
,0
.2
50
,
(0
.4
84
,0
.2
74
,
(0
.4
84
,0
.2
74
,
(0
.2
50
,0
.2
50
,
(0
.2
14
,0
.3
59
,
(0
.2
13
,0
.3
59
,
(0
.2
50
,0
.2
50
,
0.
08
8,
0.
05
7)
0.
08
8,
0.
05
7)
0.
25
0,
0.
25
0)
0.
15
4,
0.
08
7)
0.
15
5,
0.
08
7)
0.
25
0,
0.
25
0)
0.
29
4,
0.
13
3)
0.
29
4,
0.
13
3)
0.
25
0,
0.
25
0)
2.
Li
ne
ar
co
ho
rt
siz
e
33
3
17
8
23
8
27
5
19
4
22
9
28
2
27
9
28
8
ex
pe
ct
ed
st
ag
e
2.
65
1.
44
1.
93
2.
83
1.
56
2.
12
3.
06
1.
77
2.
39
ex
pe
ct
ed
sa
m
pl
e
siz
e
13
24
38
4
68
6
11
68
45
5
72
8
12
97
74
1
10
31
do
se
se
le
ct
io
n
pr
ob
(0
.2
00
,0
.2
59
,
(0
.0
15
,0
.0
16
,
(0
.0
65
,0
.1
63
,
(0
.0
89
,0
.2
93
,
(0
.0
28
,0
.0
35
,
(0
.0
52
,0
.1
38
,
(0
.0
11
,0
.2
18
,
(0
.0
50
,0
.0
73
,
(0
.0
45
,0
.1
10
,
0.
38
3,
0.
15
8)
0.
07
6,
0.
89
4)
0.
31
6,
0.
45
6)
0.
44
5,
0.
17
3)
0.
14
1,
0.
79
5)
0.
31
7,
0.
49
3)
0.
56
9,
0.
20
2)
0.
22
8,
0.
64
8)
0.
31
2,
0.
53
3)
3.
Em
ax
co
ho
rt
siz
e
16
8
13
2
15
1
14
7
12
9
14
3
16
3
16
5
17
5
ex
pe
ct
ed
st
ag
e
2.
11
1.
64
1.
79
2.
41
1.
89
2.
07
2.
80
2.
30
2.
48
ex
pe
ct
ed
sa
m
pl
e
siz
e
53
0
32
5
40
7
53
2
36
7
44
4
68
5
57
0
65
1
do
se
se
le
ct
io
n
pr
ob
(0
.4
66
,0
.2
63
,
(0
.0
41
,0
.0
56
,
(0
.1
52
,0
.2
41
,
(0
.2
65
,0
.3
57
,
(0
.0
67
,0
.1
06
,
(0
.0
36
,0
.1
26
,
(0
.0
67
,0
.3
62
,
(0
.1
08
,0
.2
14
,
(0
.1
16
,0
.2
25
,
0.
17
7,
0.
09
5)
0.
14
2,
0.
76
1)
0.
28
9,
0.
31
8)
0.
25
6,
0.
12
2)
0.
24
8,
0.
57
9)
0.
37
2,
0.
46
6)
0.
40
7,
0.
16
4)
0.
36
1,
0.
31
7)
0.
30
4,
0.
35
4)
4.
U
m
br
el
la
co
ho
rt
siz
e
15
6
13
0
15
5
13
3
12
6
14
7
14
5
15
7
18
0
ex
pe
ct
ed
st
ag
e
2.
24
1.
67
1.
81
2.
51
1.
94
2.
07
2.
84
2.
40
2.
47
ex
pe
ct
ed
sa
m
pl
e
siz
e
52
5
32
6
41
8
50
2
36
8
45
6
61
8
56
7
66
7
do
se
se
le
ct
io
n
pr
ob
(0
.3
67
,0
.3
20
,
(0
.0
49
,0
.1
27
,
(0
.1
30
,0
.2
72
,
(0
.1
91
,0
.4
00
,
(0
.0
77
,0
.2
24
,
(0
.1
09
,0
.2
73
,
(0
.0
39
,0
.3
76
,
(0
.1
25
,0
.3
14
,
(0
.0
94
,0
.2
71
,
0.
20
7,
0.
10
5)
0.
75
3,
0.
07
1)
0.
32
5,
0.
27
2)
0.
28
0,
0.
12
9)
0.
56
6,
0.
13
2)
0.
34
4,
0.
27
3)
0.
41
8,
0.
16
6)
0.
29
3,
0.
26
7)
0.
36
2,
0.
27
2)
88
Figure 4.6: Comparison of statistical power under linear dose response model for variant
design M = 1.
! 3 
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Figure 4.7: Comparison of statistical power under emax dose response model for variant
design M = 1.
! 2 
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Figure 4.8: Comparison of statistical power under umbrella dose response model for variant
design M = 1.
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4.4 Use of Marginal Alpha Spending Functions
In Chapter 3, we have demonstrated the use of an alpha spending function to globally
monitor the type I error of a trial across the stages and doses. However, this adaptive
staggered dose can allow for additional flexibility in specifying marginal alpha spending
functions to the doses. Therefore, each dose or set of doses can have its or their own alpha
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spending functions, depending on how optimistic or conservative the investigators think
regarding the dose ordering. We will illustrate this concept using two different variant
designs that employ marginal alpha spending plans. These two variant designs have the
same design setting as in the original design in Chapter 3, that is, D = 1, M = 2, R = 2,
and K = 2J .
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Figure 4.9: Alpha spending plan when each dose has its own αj,ρj (t) for J = 4 and ρj = 0.3,
represented by red solid line. Global α(t) with ρ = 0.3 by blue dashed line.
In the first variant design, we specify for each dose its own marginal alpha spending function.
We can represent the function for dose dj (j = 1, 2, ..., J) by αj,ρj (t) = αjtρj where ρj refers
to the dose-specific parameter for Rho spending function. We also assign αj as the nominal
alpha level for dose dj such that
∑J
j=1 αj = α. We only use the Rho spending function
for illustration here because of its flexibility, but the spending function is not restricted to
Rho function. Under the scheme that M = 2 and if ρj = 0.3 for all j, then the sequence of
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stage-wise alphas α′k’s across the stages will be
α′1 = α1,ρ1=0.3(1/2)
α′2 = α1,ρ1=0.3(1)− α1,ρ1=0.3(1/2)
α′3 = α2,ρ2=0.3(1/2)
... =
...
α′K−1 = αJ,ρJ=0.3(1/2)
α′K = αJ,ρJ=0.3(1)− αJ,ρJ=0.3(1/2)
since the cohort size c is constant across stage. Based on this sequence of α′k’s where∑K
k=1 α
′
k =
∑J
j=1 αj = α, and given the null distribution of the test statistics as in (3.3.2),
we can evaluate the stopping boundary values bk’s using numerical technique. Figure 4.9
shows the an example of marginal alpha spending plan for J = 4.
0.0 0.2 0.4 0.6 0.8 1.0
0.
00
0.
01
0.
02
0.
03
0.
04
0.
05
Marginal alpha spending scheme
t
a
lp
ha
(t)
Figure 4.10: Alpha spending plan when each two adjacent doses have their own
α(j1,j2),ρ(j1,j2)
(t) for J = 4 and ρ(j1,j2) = 0.3, represented by red solid line. Global α(t)
with ρ = 0.3 by blue dashed line.
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The second variant design will have one alpha spending function specified for each set of two
adjacent doses. We can represent the function for doses dj1 and dj2 by α(j1,j2),ρ(j1,j2)(t) =
α(j1,j2)t
ρ(j1,j2) where (j1, j2) = {(1, 2), (3, 4), ...}. For example, if J = 4, then there will be
two alpha spending functions: α(1,2),ρ(1,2)(t) = α(1,2)t
ρ(1,2) and α(3,4),ρ(3,4)(t) = α(3,4)t
ρ(3,4) .
Under the scheme that M = 2, and ρ(j1,j2) = 0.3, the sequence of α′k’s spent across the
stages will be
α′1 = α(1,2),ρ(1,2)=0.3(1/4)
α′2 = α(1,2),ρ(1,2)=0.3(2/4)− α(1,2),ρ(1,2)=0.3(1/4)
... =
...
α′7 = α(3,4),ρ(3,4)=0.3(3/4)− α(3,4),ρ(3,4)=0.3(2/4)
α′8 = α(3,4),ρ(3,4)=0.3(4/4)− α(3,4),ρ(3,4)=0.3(3/4).
Again, the stopping boundary values can be computed as usual. Figure 4.10 shows an
example of this marginal alpha spending plan for J = 4. Our objective is to compare the
cohort sizes, expected stages, and expected sample sizes between these designs under the
specification of ρ = 0.3.
In this section, we will explore the use of marginal alpha spending plan and specifically, the
two examples in Figures 4.9 and 4.10. For the one with one function for each dose, we have
(α1, α2, α3, α4) = (0.040, 0.005, 0.003, 0.002) and for the one with one function for each two
adjacent doses, we have (α(1,2), α(3,4)) = (0.04, 0.01). We also want to compare these two
spending plans to the original one we used in Chapter 3, which is Rho with ρ = 0.3. Table
4.5 tabulates the stopping boundary values under the three alpha spending plans.
Figure 4.11 displays the plots of statistical power against the expected sample size for the
three alpha spending plans. As seen from the plots, the alpha spending plan using one
function for two adjacent doses appears to have slightly better or similar performance as
the one using a global alpha spending function in most of the scenarios. However, the plan
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using one function for each dose shows the worse performance, except under linear dose
response model and using informative dose ordering where it offers a small advantage over
the global alpha spending function.
Table 4.5: Three alpha spending schemes and their corresponding stage-wise efficacy stop-
ping boundaries (bk) and errors (αk) for J = 4, D = 1,M = 2, R = 2, and K = 2J = 8.
Family-wise type I error is controlled at one-sided α = 0.05. No futility is adopted, ak = −∞
for all k.
Error Spending Scheme k 1 2 3 4 5 6 7 8
1. Global α(t), ρ = 0.3 bk 1.930 2.277 2.619 2.613 2.755 2.728 2.837 2.802
αk 0.0268 0.0062 0.0043 0.0034 0.0028 0.0024 0.0022 0.0020
2. Marginal α(1,2) = 0.04, α(3,4) = 0.01 bk 1.937 2.284 2.624 2.619 2.464 2.811 3.000 3.000
ρ(1,2) = ρ(3,4) = 0.3 αk 0.0264 0.0061 0.0042 0.0033 0.0066 0.0015 0.0013 0.0010
3. Marginal α1 = 0.04, α2 = 0.005 bk 1.845 2.191 2.633 2.978 2.800 3.000 2.928 3.000
α3 = 0.003, α4 = 0.002, ρj = 0.3 αk 0.0325 0.0075 0.0041 0.0009 0.0024 0.0009 0.0016 0.0010
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Figure 4.11: Comparison of statistical power under different dose response models for
marginal alpha spending functions.  
 Dose Ordering 
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4.5 Randomization Ratio 1 : R
In this section, we want to assess the impact of changing the randomization ratio. Specifi-
cally, we want to investigate the impact of increasing R from 2 to 3 and randomizing more
subjects to the experimental doses on the statistical power given the same expected sample
size.
In this variant design, we keep J = 4, D = 1, M = 2, K = 8, but vary R = 2, 3 under the
usual four dose response models, three dose orderings, and alpha spending plans of Pocock,
O’Brien-Fleming, and Rho with ρ = 0.3, 1, 3 for power of 90%. Since the null distributions
in (3.3.1) do not depend on R, the same set of stopping boundaries as in Table 3.3 can
be used. When R increases, we can see that ωj,k will also increase, and therefore, ξj,k is
expected to decrease, and hence the overall statistical power. In other words, if we want
to keep the same power when increasing R, then the cohort size needs to increase to offset
the loss of power and therefore, the expected sample size will increase as well. This clear
impact can be verified in Table 4.6 and Figures 4.12, 4.13, 4.14, and 4.15.
Figure 4.12: Comparison of statistical power under flat dose response model for variant
design R = 3.
! 1 
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Figure 4.13: Comparison of statistical power under linear dose response model for variant
design R = 3.
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Figure 4.14: Comparison of statistical power under emax dose response model for variant
design R = 3.
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Figure 4.15: Comparison of statistical power under umbrella dose response model for variant
design R = 3.
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4.6 Summary and Discussion
We have presented four different variations of the staggered dose design and described their
operating characteristics comparing to the original design as the reference design in Chapter
3. In summary, the design that simultaneously explores two concurrent doses will shorten
the duration of the trial and likely select more than one dose. However, if the objective is
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to select one dose only, then uncertainty still remains at the end of the trial as to which one
of the two selected doses is better. The use of one stage per dose M = 1 is only desirable if
the dose ordering is based on informative dose response in order to obtain additional gain in
statistical power and reduction in expected sample size. However, marginal alpha spending
function will only reap small improvement if informative dose ordering is plausible. Lastly,
increasing R for the randomization ratio 1 : R is not recommended as it reduces overall
statistical power. Therefore, when investigators think that this staggered dose design is
applicable to their clinical development, simulation and numerical techniques should be
used to evaluate and compare the performance of the design under different variations.
4.7 Binary and Time-to-Event Endpoints
4.7.1 Binary Endpoint
In some clinical trials, the proof of efficacy or safety is based on a binary outcome. The
proposed staggered dose design can also be applied with a simple adjustment. An example
of a binary endpoint is whether a subject responds to a given treatment or if this subject
experiences a specific toxic side effect. This binary outcome is usually coded as Yji = 0 if a
clinical response fails to take place, but Yji = 1 if it is observed, where j represents the jth
treatment for the ith subject (i = 1, 2, ...) receiving this treatment. Therefore, the model is
Yji ∼ Bernoulli(pij) (4.7.1)
where pij is the probability of a clinical response. If there are J different experimental
treatments and a control treatment in the trial, then we can have the following set of
one-sided hypotheses:
Hj0 : pij 6 pi0, Hja : pij > pi0 (4.7.2)
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where pi0 is the probability of response in the control arm. Using the same approach as in
(3.2.3), we define the sample means as Y jm =
∑cm
i=1 Yji/(cm) and Y 0m =
∑(cm)/R
i=1 Y0i/( cmR )
for m = 1, 2 like before. Under the null hypothesis, Hj0, we assume a common probability
as pij = pi0 = p˜ij and asymptotic normality under large sample condition,
Y jm − Y 0m d−→ N
(
0, p˜ij(1− p˜ij)cm
R+1
)
(4.7.3)
and therefore, we define the test statistics as
Zjm =
Y jm − Y 0m√
p˜ij(1−p˜ij)(R+1)
cm
(4.7.4)
and Zjm d−→ N(0, 1). As a result, under the null hypotheses, the null distributions of
the above test statistics Zj1 and (Zj1, Zj2)′ also converge to the distributions in (3.3.1).
However, since we do not know the true value of p˜ij , we can estimate it using the combined
data ˆ˜pij = (
∑cm
i=1 Yji +
∑(cm)/R
i=1 Y0i)/(cm + cm/R). In this case, the stopping boundary
values bk’s can be computed using the usual method.
Under the alternative hypotheses, we can assume a dose response model such that pij = g(dj)
where g(d) is the dose response function and pi0 = g(d0) and 0 6 g(d) 6 1. Commonly, the
function g(d) is assumed to be monotonic increasing, but non-monotonicity is also observed
such as a downturn model discussed earlier. We can denote the probability difference as
θj = pij − pi0 = g(dj)− g(d0). Using this notation, we can see that
Y jm − Y 0m d−→ N
(
θj ,
(pi0 + θj)(1− pi0 − θj)
cm
+ Rpi0(1− pi0)
cm
)
= N
(
g(dj)− g(d0), g(dj)(1− g(dj))
cm
+ Rg(d0)(1− g(d0))
cm
)
(4.7.5)
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and thus
Zjm =
Y jm − Y 0m√
g(dj)(1−g(dj))
cm +
Rg(d0)(1−g(d0))
cm
d−→ N
 g(dj)− g(d0)√
g(dj)(1−g(dj))
cm +
Rg(d0)(1−g(d0))
cm
, 1
 (4.7.6)
and cov(Zj1, Zj2) can be shown to be 1/
√
2 like before. Therefore, the cohort size c used to
attain a specified statistical power for a given dose response model can be evaluated using
the same form in Section 3.6.2, but this time,
ωj,k = bk − g(dj)− g(d0)√
g(dj)(1−g(dj))
c +
Rg(d0)(1−g(d0))
c
when k = 2j − 1, and
ωj,k = bk − g(dj)− g(d0)√
g(dj)(1−g(dj))
2c +
Rg(d0)(1−g(d0))
2c
when k = 2j.
In some other instances, one can also model the comparison in term of odds ratio, ORj0
such that
ORj0 =
pij(1− pi0)
pi0(1− pij)
and that we are interested in testing if the logarithm of ORj0, is equal to 0 or greater
than 0. In this case, the logarithm of the Mantel-Haenszel estimator can be used with the
assumption of normality under large sample condition (Mantel and Haenszel, 1959). This
can be left for future work.
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4.7.2 Time-to-Event Endpoint
In some other clinical trials such as an oncology trial, the evidence of efficacy is based on
a survival endpoint such as overall survival (OS) or progression-free survival (PFS). This
type of outcome is also known as time-to-failure. The proposed staggered dose design can
also be applied with some adjustment. We can denote the time elapsed since the start of
treatment until the observation of failure before or at the calendar time of analysis (time-to-
failure) as Tji (Tji > 0) for the ith subject receiving the jth treatment where i = 1, 2, ... and
j = 1, 2, ..., J . If at the calendar time of analysis, the event of failure is already observed,
then Tji is considered uncensored with sji = 0, but right-censored with sji = 1; and if
the event of interest is not observed, then Tji is in fact the time elapsed since the start of
treatment until calendar time of analysis. We can assume a model like
Tji ∼ fj(Tji) (4.7.7)
where fj(Tji) is a probability density function with unknown parametric form. We can also
represent the survival function as Sj(Tji) =
∫∞
Tji
fj(u)du and therefore, the hazard function
as hj(Tji) = fj(Tji)/Sj(Tji). If we denote λj0 = hj(Tji)/h0(T0i) as the hazard ratio between
the dose dj and the control dose d0, then we are interested in the following set of one-sided
hypotheses:
Hj0 : λj0 > 1, Hja : λj0 < 1. (4.7.8)
In this case, under the proportional hazard assumption, the test of choice is the optimal
non-parametric log-rank test. First of all, we denote the calendar times of analysis as ljm for
dj at mth per-dose interim (m = 1, 2). It is sometimes more practical to pre-specify these
calendar times at the design of the trial. In the staggered dose design with D = 1, these
calendar times are in this order: l11, l12, l21, ..., lJ1, lJ2. We further let qjm be the number
of failures combined for both dose dj and control dose observed at calendar time ljm with
corresponding times to failures as τ1(ljm) < τ2(ljm) < ... < τi(ljm) < ... < τqjm(ljm) for
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m = 1, 2. At each of these qjm distinct times, we can count the number of failures and
number of subjects at risk by treatment dose as below:
ej(τi(ljm)) = no. of failures for dj at τi(ljm) for calendar time ljm
rj(τi(ljm)) = no. of subjects at risk for failure for dj at τi(ljm) for calendar time ljm
e0(τi(ljm)) = no. of failures for d0 at τi(ljm) for calendar time ljm
r0(τi(ljm)) = no. of subjects at risk for failure for d0 at τi(ljm) for calendar time ljm
for i = 1, 2, ..., qjm. For example, if there are no ties at failure time τi(ljm), then if this
failure happens for dj , then ej(τi(ljm)) = 1 and correspondingly, e0(τi(ljm)) = 0; else if it
happens for the control dose d0, then the numbers are reversed. The log-rank score statistic
for dose dj at mth per dose stage is given by
Sjm = −
qjm∑
i=1
{
ej(τi(ljm))− rj(τi(ljm))
(
e0(τi(ljm)) + ej(τi(ljm))
r0(τi(ljm)) + rj(τi(ljm))
)}
. (4.7.9)
If the distributions are the same (fj = f0) or, in other words, under the null hypothesis of
λj0 = 1, then the following convergence in distribution holds
Sjm
d−→ N(0, var(Sjm)). (4.7.10)
If we make a further assumption of proportional hazard, that is, the ratio λj0 is constant
over time. In this case,
Sjm
d−→ N
(
− ln(λj0)D(ljm)R(R+ 1)2 ,
D(ljm)R
(R+ 1)2
)
(4.7.11)
where D(ljm) =
∑qjm
i=1(e0(τi(ljm)) + ej(τi(ljm))) is the total combined number of failures
observed by calendar time ljm and R is our usual definition of randomization ratio (see
Table 3.1). Under the null hypothesis, Sjm d−→ N
(
0, D(ljm)R(R+1)2
)
. Tsiatis (1981) proved that
Sj1, Sj2 have independent increments, and so cov(Sj1, Sj2) = var(Sj1). For the special case
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when R = 1 in balanced allocation, under the null hypothesis, Sjm is sometimes known to
follow N(0, D(ljm)/4).
For our staggered dose design, we can standardize it as
Zjm =
Sjm√
D(ljm)R
(R+1)2
so that Zjm ∼ N(0, 1) under the null hypothesis and cov(Zj1, Zj2) =
√
D(lj1)
D(lj2) . It is impor-
tant to notice that instead of cohort size, the Fisher Information is the number of failures
which depends on the calendar times, ljm, and if the calendar times of analysis are equally
spaced, then approximately, cov(Zj1, Zj2) = 1/
√
2. We can then resort to using the distri-
butions in (3.3.1) to calculate the stopping boundaries. If we assume a dose response model
q such that λj0 = q(dj , d0), we can calculate, instead of cohort size c, the number of failures
D for a specified statistical power. We will also compute the expected stages, expected trial
number of failures, and hence the calendar time required to observe these failures. This can
be left for future work.
4.8 R Codes
4.8.1 Function Codes
# Only the variant design with D=2 is presented here
# Codes for other designs can be available on request
findboundsJ4D2 <- function(J=4, alphaseg) {
b <- NULL
# b1
bseq <- seq(2,4, by=0.01)
alphaseq <- rep(NA, length(bseq))
for (i in 1:length(bseq)) {
alphaseq[i] <- ((1-pnorm(bseq[i]))ˆ2) + 2*(pnorm(bseq[i])*(1-pnorm(bseq[i])))
}
minposition <- min(which(alphaseq < alphaseg[1]))
bound1 <- bseq[minposition]
b <- c(b, bound1)
# b2
alphaseq <- rep(NA, length(bseq))
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for (i in 1:length(bseq)) {
alphaseq[i] <- ((p4(-Inf, bound1, bseq[i]))ˆ2) + 2*(p3(-Inf, bound1, bseq[i]))
*(p4(-Inf, bound1, bseq[i]))
}
minposition <- min(which(alphaseq < alphaseg[2]))
bound2 <- bseq[minposition]
b <- c(b, bound2)
# b3
alphaseq <- rep(NA, length(bseq))
for (i in 1:length(bseq)) {
alphaseq[i] <- (p3(-Inf, bound1, bound2)ˆ2)*(((1-pnorm(bseq[i]))ˆ2) +
2*(pnorm(bseq[i])*(1-pnorm(bseq[i]))))
}
minposition <- min(which(alphaseq < alphaseg[3]))
bound3 <- bseq[minposition]
b <- c(b, bound3)
# b4
alphaseq <- rep(NA, length(bseq))
for (i in 1:length(bseq)) {
alphaseq[i] <- (p3(-Inf, bound1, bound2)ˆ2)*(((p4(-Inf, bound3, bseq[i]))ˆ2) +
2*(p3(-Inf, bound3, bseq[i]))*(p4(-Inf, bound3, bseq[i])))
}
minposition <- min(which(alphaseq < alphaseg[4]))
bound4 <- bseq[minposition]
b <- c(b, bound4)
return(b)
}
findcohortcD2 <- function(targetpower, possiblec, J=4, m=2, R, K=4, model, dose,
ordering, stdev=1, delta=0, b) {
meandose <- drcurve(model=model,dose=dose)
reordereddose <- meandose[2:5][ordering]
posspower <- rep(NA,length(possiblec))
findpower <- function(ccc) {
w11 <- b[1]-((reordereddose[1]-0)/(sqrt((R+1)/(ccc))))
w21 <- b[1]-((reordereddose[2]-0)/(sqrt((R+1)/(ccc))))
w12 <- b[2]-((reordereddose[1]-0)/(sqrt((R+1)/(2*ccc))))
w22 <- b[2]-((reordereddose[2]-0)/(sqrt((R+1)/(2*ccc))))
w33 <- b[3]-((reordereddose[3]-0)/(sqrt((R+1)/(ccc))))
w43 <- b[3]-((reordereddose[4]-0)/(sqrt((R+1)/(ccc))))
w34 <- b[4]-((reordereddose[3]-0)/(sqrt((R+1)/(2*ccc))))
w44 <- b[4]-((reordereddose[4]-0)/(sqrt((R+1)/(2*ccc))))
power1 <- (1-pnorm(w11))*(1-pnorm(w21)) + (pnorm(w11)*(1-pnorm(w21))) +
(pnorm(w21)*(1-pnorm(w11)))
power2 <- (p4(-Inf, w11, w12))*(p4(-Inf, w21, w22)) + (p3(-Inf, w11, w12))
*(p4(-Inf, w21, w22)) + (p3(-Inf, w21, w22))*(p4(-Inf, w11, w12))
power3 <- p3(-Inf, w11, w12)*p3(-Inf, w21, w22)*((1-pnorm(w33))*(1-pnorm(w43)) +
(pnorm(w33)*(1-pnorm(w43))) + (pnorm(w43)*(1-pnorm(w33))))
power4 <- p3(-Inf, w11, w12)*p3(-Inf, w21, w22)*(p4(-Inf, w33, w34))
*(p4(-Inf, w43, w44)) + (p3(-Inf, w33, w34))*(p4(-Inf, w43, w44)) +
(p3(-Inf, w43, w44))*(p4(-Inf, w33, w34))
stagewise <- list()
stagewise$foundpower <- power1+power2+power3+power4
stagewise$stagewisepower <- c(power1, power2, power3, power4)
return(stagewise)
}
for (i in 1:length(possiblec)) {
ccc <- findpower(possiblec[i])
posspower[i] <- ccc$foundpower
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}
result <- list()
result$possiblepower <- posspower
position <- which(posspower > targetpower)
position <- min(position)
result$position <- position
targetc <- possiblec[position]
result$targetc <- targetc
final <- findpower(targetc)
result$stagewisepower <- final$stagewisepower
result$simpower <- sum(final$stagewisepower)
check <- final$stagewisepower
result$expectedstage <- 1*check[1]+2*check[2]+3*check[3]+4*(1-check[1]-
check[2]-check[3])
return(result)
}
4.8.2 Analysis Codes
# Only the variant design with D=2 is presented here
# Codes for other designs can be available on request
D <- 2
J <- 4
m <- 2
K <- 4
R <- 2
segpocock <- alphasegments(type=1, alpha=0.05, K=4)
segpocock
sum(segpocock)
boundpocock <- findboundsJ4D2(J=4, alphaseg=segpocock)
segobf <- alphasegments(type=2, alpha=0.05, K=4)
segobf
sum(segobf)
boundobf <- findboundsJ4D2(J=4, alphaseg=segobf)
segrho0.3 <- alphasegments(type=3, alpha=0.05, K=4, rho=0.3)
segrho0.3
sum(segrho0.3)
boundrho0.3 <- findboundsJ4D2(J=4, alphaseg=segrho0.3)
segrho1.0 <- alphasegments(type=3, alpha=0.05, K=4, rho=1.0)
segrho1.0
sum(segrho1.0)
boundrho1.0 <- findboundsJ4D2(J=4, alphaseg=segrho1.0)
segrho3.0 <- alphasegments(type=3, alpha=0.05, K=4, rho=3.0)
segrho3.0
sum(segrho3.0)
boundrho3.0 <- findboundsJ4D2(J=4, alphaseg=segrho3.0)
effbounds <- rbind(boundpocock,
boundobf,
boundrho0.3,
boundrho1.0,
boundrho3.0)
effbounds; write.table(effbounds, "effboundsD2.txt", append=F, quote=F, row.names=T,
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col.names=F)
ordering1 <- 1:4
orderingflat <- 1:4
orderinglinear <- 4:1
orderingemax <- 4:1
orderinglogistic <- 4:1
orderingumbrella <- c(3,2,4,1)
informordering <- rbind(orderingflat, orderinglinear, orderingemax, orderinglogistic,
orderingumbrella)
informordering
permute <- cbind(rep(1:4,each=6), c(2,2,3,3,4,4,1,1,3,3,4,4,1,1,2,2,4,4,1,1,2,2,3,3),
c(3,4,2,4,2,3,3,4,1,4,1,3,2,4,1,4,1,2,2,3,1,3,1,2),
c(4,3,4,2,3,2,4,3,4,1,3,1,4,2,4,1,2,1,3,2,3,1,2,1))
permute
# dose escalation ordering
check <- NULL; p <- 1
cohort9 <- NULL
simpower9 <- NULL
expstages9 <- NULL
proportions9 <- NULL
for (i in 1:5) { # 5 error spending plans
for (j in 1:5) { # 5 dose response models
usethis <- findcohortcD2(targetpower=0.9, possiblec=seq(20,250), J=4, m=2,
R=2, K=4, model=j, dose=c(0,2,4,6,8), ordering=ordering1, stdev=1, delta=0, b=effbounds[i,])
cohort9 <- rbind(cohort9, usethis[[3]])
simpower9 <- rbind(simpower9, usethis[[5]])
expstages9 <- rbind(expstages9, usethis[[6]])
check <- matrix(c(i,j,p),c(1,3))
write.table(check, "check1.txt", append=T, quote=F, row.names=F, col.names=F)
}
}
cohort9
simpower9
expstages9
dim(cohort9) <- c(5,5); cohort9; write.table(cohort9, "9cohortorderesca.txt", append=T,
quote=F, row.names=F, col.names=F)
plannedss9 <- cohort9*K*((1/R)+2); plannedss9; write.table(plannedss9,
"9plannedssorderesca.txt", append=T, quote=F, row.names=F, col.names=F)
dim(simpower9) <- c(5,5); simpower9; write.table(simpower9, "9simpowerorderesca.txt",
append=T, quote=F, row.names=F, col.names=F)
dim(expstages9) <- c(5,5); expstages9; write.table(expstages9, "9expstageorderesca.txt",
append=T, quote=F, row.names=F, col.names=F)
expectedss9 <- cohort9*expstages9*((1/R)+2); expectedss9; write.table(expectedss9,
"9expssorderesca.txt", append=T, quote=F, row.names=F, col.names=F)
# informative ordering
check <- NULL; p <- 2
cohort9 <- NULL
simpower9 <- NULL
expstages9 <- NULL
for (i in 1:5) {
for (j in 1:5) {
usethis <- findcohortcD2(targetpower=0.9, possiblec=seq(20,250), J=4, m=2, R=2, K=4,
model=j, dose=c(0,2,4,6,8), ordering=informordering[j,], stdev=1, delta=0, b=effbounds[i,])
cohort9 <- rbind(cohort9, usethis[[3]])
simpower9 <- rbind(simpower9, usethis[[5]])
expstages9 <- rbind(expstages9, usethis[[6]])
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check <- matrix(c(i,j,p),c(1,3))
write.table(check, "check2.txt", append=T, quote=F, row.names=F, col.names=F)
}
}
dim(cohort9) <- c(5,5); cohort9; write.table(cohort9, "9cohortorderinform.txt", append=T, quote=F,
row.names=F, col.names=F)
plannedss9 <- cohort9*K*((1/R)+2); plannedss9; write.table(plannedss9,
"9plannedssorderinform.txt", append=T, quote=F, row.names=F, col.names=F)
dim(simpower9) <- c(5,5); simpower9; write.table(simpower9, "9simpowerorderinform.txt",
append=T, quote=F, row.names=F, col.names=F)
dim(expstages9) <- c(5,5); expstages9; write.table(expstages9, "9expstageorderinform.txt",
append=T, quote=F, row.names=F, col.names=F)
expectedss9 <- cohort9*expstages9*((1/R)+2); expectedss9; write.table(expectedss9,
"9expssorderinform.txt", append=T, quote=F, row.names=F, col.names=F)
# uninformative ordering
check <- NULL
cohort9 <- NULL
cohort9.2 <- NULL
simpower9 <- NULL
simpower9.2 <- NULL
expstages9 <- NULL
expstages9.2 <- NULL
for (p in 1:24) { # ordering
for (i in 1:5) { # error spending
for (j in 1:5) { # dose response model
usethis <- findcohortcD2(targetpower=0.9, possiblec=seq(20,300), J=4, m=2, R=2, K=4,
model=j, dose=c(0,2,4,6,8), ordering=permute[p,], stdev=1, delta=0, b=effbounds[i,])
cohort9 <- rbind(cohort9, usethis[[3]])
simpower9 <- rbind(simpower9, usethis[[5]])
expstages9 <- rbind(expstages9, usethis[[6]])
check <- matrix(c(i,j,p),c(1,3))
write.table(check, "check3.txt", append=T, quote=F, row.names=F, col.names=F)
}
}
dim(cohort9) <- c(1,25)
write.table(cohort9, "cohort9.txt", append=T, quote=F, row.names=F, col.names=F)
cohort9.2 <- rbind(cohort9.2, cohort9)
cohort9 <- NULL
dim(simpower9) <- c(1,25)
write.table(simpower9, "simpower9.txt", append=T, quote=F, row.names=F, col.names=F)
simpower9.2 <- rbind(simpower9.2, simpower9)
simpower9 <- NULL
dim(expstages9) <- c(1,25)
write.table(expstages9, "expstages9.txt", append=T, quote=F, row.names=F,
col.names=F)
expstages9.2 <- rbind(expstages9.2, expstages9)
expstages9 <- NULL
}
cohort9.2
cohort9.3 <- apply(cohort9.2, 2, mean)
write.table(matrix(cohort9.3,c(5,5)), "9cohortorderuninf.txt", append=T, quote=F,
row.names=F,
col.names=F)
dim(cohort9.3) <- c(5,5)
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cohort9.3
plannedss9 <- cohort9.3*K*((1/R)+2); plannedss9; write.table(plannedss9,
"9plannedssorderuninf.txt", append=T, quote=F, row.names=F, col.names=F)
simpower9.2
simpower9.3 <- apply(simpower9.2, 2, mean)
write.table(matrix(simpower9.3,c(5,5)), "9simpowerorderuninf.txt", append=T, quote=F,
row.names=F, col.names=F)
dim(simpower9.3) <- c(5,5)
simpower9.3
expstages9.2
expstages9.3 <- apply(expstages9.2, 2, mean)
write.table(matrix(expstages9.3,c(5,5)), "9expstageorderuninf.txt", append=T, quote=F,
row.names=F, col.names=F)
dim(expstages9.3) <- c(5,5)
expstages9.3
expectedss9 <- cohort9.3*expstages9.3*((1/R)+2); expectedss9; write.table(expectedss9,
"9expssorderuninf.txt", quote=F, row.names=F, col.names=F)
# end of chapter code
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Chapter 5
Bayesian Hierarchical Bias Model for Establishing
Biosimilarity
5.1 Introduction
The concept of biosimilarity has received increasing popularity within the scientific com-
munity recently. One big motivation to explore biosimilar products is the unprecedented
opportunity gradually opened up by numerous soon-to-be expiring licenses of major biolog-
ical products. In 2010, the passage of the Biologics Price Competition and Innovation Act
(BPCI) created an abbreviated licensure pathway in section 351(k) of the Public Health
Service Act (PHS). This new law allows for an expeditious approval process for a generic
follow-on biological product shown to be biosimilar to a licensed reference biological prod-
uct. Section 351(i) of the PHS Act defines biosimilarity to mean “that the biological product
is highly similar to the reference product notwithstanding minor differences in clinically in-
active components” and that “there are no clinically meaningful differences between the
biological product and the reference product in terms of the safety, purity, and potency
of the product.” Due to their large and complex molecular structures, biological products
are fundamentally disparate from small synthetic drugs, and so are their mechanisms of
action (see Figure 5.1). Traditional statistical methods used to test for bioequivalence as
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in a generic drug development may not be the most efficient way to apply to biosimilarity
(Kang and Chow, 2012).
Figure 5.1: Structure of erythropoietin and aspirin, illustrating the larger and small complex
structure of biological products compared with traditional small molecule therapeutics.
(Reprint with permission from Springer. Calvo and Zun˜iga, 2012)
Many of the recently proposed methods to establish biosimilarity between an innovator
reference biological product and a generic follow-on biological product primarily borrowed
ideas from average bioequivalence (ABE) trials. An ABE trial using a 2 × 2 crossover design
is the standard approach suggested by the U.S. Food and Drug Administration (FDA) to
test for the equivalence between a reference drug and a new generic drug. Often before
the conduct of a bioequivalence trial, if the dissolution profiles of the reference and the
new generic drugs are proved to be similar, the need to conduct a clinical bioequivalence
trial will be waived (Saranadasa and Krishnamoorthy, 2005). This can save both time and
cost in conducting a clinical study. Therefore, statistical methodologies also exist to show
similarity between dissolution profiles. Before discussing their suitability to biosimilarity
studies, it is important to review and compare the current approaches to both average
bioequivalence and dissolution profile studies.
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When estimating a drug dissolution profile, the mean dissolution concentration is measured
across p specified time points. Testing for dissolution profile similarity requires a multi-
variate test of similarity. The current FDA standard approach is to assess if the similarity
factor f2 defined as
f2 = 50 log10
{
100
(
1 + µ
′µ
p
)}
falls within similarity margins, where µ = µT − µR is the p-dimensional vector of mean
differences between the generic test drug and the reference drug and p is the total number of
time points (Moore and Flanner, 1996). Saranadasa and Krishnamoorthy (2005) assumed
that µT − µR = δe where e is a unit vector and developed a test that shows the scalar
parameter δ is within equivalence margins ±δ0. The methods just described rely on reducing
a multivariate testing problem into a univariate testing problem. Other methods assuming a
profile model are also proposed. A common example in these model-dependent approaches
is the auto-regressive time series model (Tsong et al., 1997; Chow and Ki, 1997). When
directly approaching this multivariate problem, Berger and Hsu (1996) provided an α-level
test that rejects dissimilar dissolution profiles if
Max
|di|+ c
(
S2i
ν
) 1
2
 < δ0
among all time points where i = 1, 2, ..., p, |di| is the observed absolute mean difference, S2i
is the pooled variance at ith time point, ν = nT + nR − 2 is the degree of freedom, and c is
the (1− α)100% percentile of the Student’s t distribution.
For testing average bioequivalence, the standard approach is the two one-sided test (TOST)
developed by Schuirmann (1987) for the following equivalence hypotheses:
H0 : µT − µR > δ or µT − µR 6 −δ versus HA : −δ < µT − µR < δ
where µT and µR represent the mean bioavailability measures for the test and reference drugs
respectively on the logarithmic scale. The three major bioavailability measures are Tmax, the
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time until the maximum concentration of the drug in plasma is reached, Cmax, the maximum
concentration, and AUC, the area under the concentration curve from dose administration
to final observation time. The most accepted rule stated in the regulatory guideline is the
80%/125% margins which are ±δ = ±0.22314 on the logarithmic scale. Under normality
assumption, the two sets of one-sided hypotheses will be tested with ordinary one-sided
t-tests. It can be concluded that µR and µT are equivalent, for a balanced study (n = nR =
nT ), if
t1 =
(xT − xR)− δ
s
√
2/n
> t1−α(ν) and t2 =
δ − (xT − xR)
s
√
2/n
> t1−α(ν)
where ν is the degree of freedom. This is statistically equivalent to the confidence interval
approach developed by Westlake (1981). Recently, the concepts of population bioequiv-
alence (PBE) and individual bioequivalence (IBE) are proposed and they are related to
drug prescribability and switchability respectively. PBE refers to not only the equivalence
of population means in bioavailability between reference and generic drugs, but also the
equivalence of their population variances in bioavailability. When these two formulations
are equivalent in both means and variances, they are considered as equally prescribable to
a new patient. IBE refers to the equivalence of bioavailability when a patient switches from
the reference formulation to the generic formulation, or vice versa and so within-subject
variances for both formulations will be accounted for. Additional criteria were proposed
to test for these equivalence concepts. Dragalin et al. (2003) introduced the symmetric
Kullback-Leibler divergence (KLD), a distance metric, as a new criterion for both PBE and
IBE,
4(f, g) =
[∫ (
f(x)− g(x))log
(
f(x)
g(x)
))
dx
]1/2
where f and g are probability density functions of the outcome variables corresponding
to the two formulations, and 4(f, g) represents their difference. They derived the criteria
using KLD for the parametric exponential family distributions. The advantages of using
KLD are that it is invariant to monotonic transformation and that it can be easily extended
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to the multivariate cases. Chervoneva, Hyslop, and Hauck (2007) extended the univariate
population equivalence criterion to the multivariate case by looking into the trace of the
multivariate expected difference between reference and generic drugs.
Biological products are fundamentally different from drug compounds. They are large
polypeptide molecules with a much larger molecular weight than small-molecule synthetic
drugs. Therefore, they tend to have a longer half-life and require a longer wash-out period.
In this case, the standard crossover design normally used for bioequivalence trial may not
be efficient if applied to biosimilarity trials. A more appropriate design would be the
parallel group design. Various biosimilarity criteria have been suggested and they depend
on the study designs and objectives. For a parallel three-arm trial with two of the arms
for the reference product from two different manufacturing lots and the other one for the
follow-on biological product, Kang and Chow (2012) proposed the relative distance rd as a
biosimilarity criterion
rd =
∣∣∣∣ µT − µRµR1 − µR2
∣∣∣∣
where µT is the population mean of the efficacy outcome for test biosimilar product T , µR1
and µR2 are those of reference product R1 and R2 from two different manufacturing lots,
and finally µR = (µR1 + µR2)/2. The authors developed a test that assumes asymptotic
distribution of its maximum likelihood estimator (MLE). Lin et al. (2012) presented the
parallel line assay design that requires two dose-response trials for both the reference and
follow-on biological products. Under the assumption of the parallel line bioassay, they
assumed a linear relationship between the binary efficacy endpoint and the mean dose-
dependent product characteristic. The biosimilarity criterion in this case is the relative
potency defined as
4 = αT − αR
βc
where αT is the intercept term of the linear regression for new generic biologics, αR for
reference biologics and βc is the assumed common slope. Earlier, Chow and Liu (2010) also
presented the same criterion but the efficacy endpoint is normally distributed. In order
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to avert the distributional assumption of normality and developing a potentially insuffi-
cient aggregated criterion, Lei and Olson (2010) introduced the use of non-parametric tests
comparing the distributions of the efficacy endpoint between reference and follow-on bio-
logics. They performed a simulation study to compare the performance of the TSOT, the
Kolmogorov-Smimov (KS) test, and the overlap coefficient test. TSOT is sensitive to the
magnitude of the variance but the two non-parametric tests are not. However, the non-
parametric tests are sensitive to group differences in variance and centrality. When the two
distributions are the same, the KS test has a more stable probability of claiming equivalence
without requiring bigger sample size.
This chapter is motivated by the need to develop an innovative statistical method for prov-
ing biosimilarity. Here is the organization of the subsequent sections. Section 5.2 introduces
the composite endpoint of interest and describes the proposed clinical study for the demon-
stration of biosimilarity that uses this composite endpoint. This section also provides the
rationale for a non-inferiority testing framework and a Bayesian inferential approach to
achieve the study’s objectives. Section 5.3 describes the details of a simulation plan to
examine the operating characteristics of this proposed method and also summarizes the
simulation results with comparison to the frequentist approach. Section 5.3.4 discusses the
impact of different prior densities on the operating characteristics. Section 5.3.3 describes
an adaptive two-stage design that has an interim assessment based on predictive probability
and briefly studies its characteristics. Section 5.4 discusses the overall results and proposes
further work in this area.
5.2 Biosimilarity Using Composite Endpoint
Although in the past few years some statistical methods have been proposed for the case of
a single primary efficacy endpoint, some biological products are designed to treat medical
conditions with improvement measured by several endpoints. For example, rheumatoid
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arthritis (RA) is a disease of the immune system that leads to the inflammation in the
joints. It causes a myriad of symptoms such as pain, joint swelling, fatigue, weakness, and
stiffness. It also leads to loss of physical function and permanent joint damage. The exact
cause of RA is unknown, but it is believed that patients with RA have changing immune and
inflammatory system and an over-abundance of tumor necrosis factor (TNF). An increased
level of TNF is responsible for joint inflammation. Treatments of mild cases of RA include
disease-modifying anti-rheumatic drugs (DMARDs). However, for moderate to severe cases
of RA that do not respond well to DMARDs, intervention using biological products such
as TNF blockers may be helpful in slowing down RA progression.
In clinical trials studying RA, the current standard measure of efficacy is the ACR20 criteria
recommended by the American College of Rheumatology (ACR) Committee. For each
individual patient in a trial, it measures if this patient has experienced a clinical response
of overall improvement by evaluating the percentage of improvement in a core set of variables
during the trial. Generally speaking, if a patient experiences at least 20% improvement from
baseline in multiple variables simultaneously, this patient is defined as having satisfied the
definition of a clinical response. Therefore, ACR20 is a composite criterion and has served
as a working model to other disorders that currently require multiple primary endpoints
(Offen et al., 2007). The percent change in each of these variables is also measured at
different time points such as 3, 6 and 12 months and one of the time points is used to
establish primary efficacy. Table 5.1 summarizes the ACR20 improvement criteria (Felson
et al., 1993). Other more stringent measures such as ACR50 or ACR70 (i.e. > 50% or
> 70% improvement on the same set of endpoints) and other validated scales such as the
Disease Activity Score in 28 joints (DAS28) criteria are also adopted.
5.2.1 Study Design and Non-Inferiority Hypotheses
We can consider a clinical development program to show an experimental generic biological
product is biosimilar to a licensed reference biological product, and that these products
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Table 5.1: ACR20 Improvement Criteria
Quantitative criterion Endpoints
percent reduction 1. Tender joint count, and
> 20% improvement in 2. Swollen joint count, and
At least 3 of the following:
3. Physician global assessment of disease activity
4. Patient global assessment of disease activity
5. Patient assessment of pain (e.g. Visual Analog Scale)
6. Physical disability or functionality
7. Inflammatory marker: erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP)
are used to treat a medical condition with symptom improvement defined by a compos-
ite endpoint. Since biological products require a much longer washout period, a clinical
cross-over design may not be efficient, and therefore we suggest using a parallel two-arm
randomized clinical design. As implied in the FDA guidance document for the industry
titled “Scientific Considerations in Demonstrating Biosimilarity to a Reference Product”,
when accumulated evidence on biosimilarity is clear from previous molecular, functional,
and pre-clinical studies, a smaller clinical study can be convened to confirm biosimilarity.
Motivated by the need to decrease sample size for a clinical study, we propose a non-
inferiority framework to test for biosimilarity using the clinical data. This non-inferiority
trial design allows the current biosimilarity trial to meaningfully connect to any similarly
conducted historical trials that have evaluated the effect of the licensed reference biological
product. Since a standard treatment is already available for the medical condition, including
a placebo arm in the current trial will not be ethical. We can use k to index the biological
product with k = 1 representing the innovator reference product and k = 2 the proposed
follow-on biological product. In this case, we are interested in testing if, based on the
composite endpoint, the proposed biological product is not inferior to the licensed biological
product. This non-inferiority design may reduce the number of sample subjects needed.
In this two-arm design, patients are randomized to either the original reference or the follow-
on generic biological product. For each patient, outcomes on J multiple endpoints will be
measured at pre-specified follow-up times. These J endpoints can be generally considered as
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independent measures. We can use xkji to denote the jth endpoint (j = 1, 2, ..., J) observed
in the ith patient receiving the product k. In this case, we can assume that it is normally
distributed as
xkji ∼ N(µkj , σ2k) (5.2.1)
where k = 1 or 2, and i = 1, 2, ..., nk. The fixed randomization ratio is therefore equal to
R = n2/n1. µkj is the mean response for the jth endpoint and σ2k is the variance which is
assumed to be the same for all J endpoints but different between the products. In addition,
we want to consider combining these J endpoints into a single composite binary efficacy
endpoint yki which can be generally defined as
yki =
 1 xki > ω0 otherwise (5.2.2)
where xki = (xk1i, xk2i, ..., xkJi)′ is the random vector of outcomes for the ith patient and
ω = (ω1, ω2, ..., ωJ)′ is a J-dimensional vector of cutoff points for the endpoints common
to both biological products, assuming that higher values of xkji’s are desirable. If we
denote the probability of a response on the composite endpoint for product k as pk, then
pk = P (yki = 1) = P (xki > ω) , and our non-inferiority (NI) hypotheses of interest can be
constructed as
H0 : p2 − p1 6 −δ versus HA : p2 − p1 > −δ (5.2.3)
where δ(δ > 0) is the pre-specified non-inferiority margin for the difference between the two
probabilities.
5.2.2 Bayesian Approach
There are several advantages of approaching this biosimilarity hypothesis testing problem
from a Bayesian perspective. First, if the efficacy profile of the licensed reference biological
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product comparing to a placebo control has been established in a historical trial, and if
there are additional historical trials evaluating the effect of this product, then we can
incorporate these sources of information into the analysis of the current trial of biosimilarity.
These historical trials can be further assumed to be exchangeable. Also, since multiple
endpoints are considered in developing the composite endpoint, the Bayesian approach
allows for the borrowing of estimative strength between the J multiple endpoints on the
precision parameters in addition to the borrowing between historical trials. This also means
that fewer subjects may be needed for the reference product and more subjects can be
randomized to the new and potentially biosimilar product. This is a realization of the
FDA guidance regarding its suggestion to use smaller clinical studies and to convene them
based on results from previously conducted studies. Furthermore, the composite endpoint
can be defined by criteria on the multiple endpoints which provide clinically meaningful
interpretation. According to (5.2.2), pk will be defined as a function of the parameters such
that pk = f(µk1, µk2, ..., µkJ , σ2k) for k = 1 or 2.
5.2.3 Hierarchical Bias Model
In this proposed hierarchical bias model, we allow the inclusion of any number of historical
trials for the licensed reference product. For example, if there areH historical trials available
before the conduct of the current biosimilarity trial, we can let x1hji be the value of the jth
endpoint observed for the ith patient receiving the original reference product k = 1 in the
hth historical trial such that
x1hji ∼ N(µ1hj , σ21) (5.2.4)
where i = 1, 2, ..., n1h, h = 1, 2, ...,H, and j = 1, 2, ..., J . In the above model, we assume
that these H trials and the current biosimilarity trial share the same within-study variance
parameter σ21 and it is also assumed to be constant across all J endpoints. This assumption
allows borrowing between the historical trials and also between the J endpoints. In addition,
we can represent the jth sample mean as x1hj which is equal to (
∑n1h
i=1 x1hji)/n1h. Other
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sample means can be similarly defined.
Additionally, under exchangeability, we consider the mean parameters, µ1j of the current
biosimilarity trial and µ1hj of the hth historical trial, for the original reference product,
come from the same distribution as
µ1j , µ1hj ∼ N(µo1j , σ21b) (5.2.5)
where h = 1, 2, ...,H. µo1j is the overall mean and σ21b is the between-trial variance pa-
rameter, which is assumed to be the same across the J endpoints. Hierarchical modeling
is a logical way of combining historical data when exchangeability between parameters is
highly plausible, and as in the current problem, these historical trials used an efficacy re-
sponse defined by the same criterion. This hierarchical structure implies heterogeneity of
the mean endpoints. Modeling the mean endpoints hierarchically recognizes that these
historical trials, although using the same licensed reference product, may exhibit slightly
different mean endpoints due to possible but small differences in the conduct of the trials
or in the study populations they enrolled to these trials. This variation will be captured
by the between-trial variance parameter. This ensures that the current biosimilarity trial
is validly connected to the historical trials via the assumption of exchangeability.
For the new generic follow-on product in the current biosimilarity trial, we think of its mean
response on the j endpoint, µ2j , as having a bias term from that of the mean endpoint of
the original product, µ1j . Pocock (1976) discussed the parameterizing a bias term to model
the difference between mean of historical control and the same control but in the current
trial. Therefore, we propose this relationship
µ1j = µ2j + ξj (5.2.6)
where ξj represents the bias of µ2j from µ1j . If ξj is equal to 0, then µ2j = µ1j meaning
that the follow-on product has the same mean as the licensed reference product on the jth
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endpoint. If ξj < 0, then it means the follow-on product exhibits a better effect than the
reference product in the jth endpoint, and the opposite interpretation follows if ξj > 0.
Since we do not know the true value of ξj , we can assume a model for this bias parameter
as
ξj ∼ N(θ, σ2ξ ) (5.2.7)
where j = 1, 2, ..., J . We center the expectation of ξj skeptically at the null hypothesis, θ, to
allow the data to reflect and influence its true direction and magnitude away from the null
value. The null value θ is the margin on the scale of individual endpoints, such that when
this margin is uniformly subtracted from all of the mean responses, the probability of the
binary composite endpoint will decrease by exactly the amount of δ as in f(µk1 − θ, µk2 −
θ, ..., µkJ−θ, σ2k)−f(µk1, µk2, ..., µkJ , σ2k) = −δ. This relationship between δ and θ is one-on-
one. Therefore, centering the mean of ξj on θ also suggests that µ1j and µ2j are dissimilar
to begin with. We also assume that the variance parameter σ2ξ to be the same across all
J endpoints but a large σ2ξ will suggest that this distribution is only weakly informative.
Figure 5.2 displays the graphical representation of this model with each circle representing
a random node, a single-line arrow representing the dependent stochastic relationship and
a double-line arrow representing a logical relationship.
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Figure 5.2: Graphical representation of the proposed Bayesian hierarchical bias model,
j = 1, 2, ..., J .
Now that we have completely specified the hierarchical bias model, we can consider the fol-
lowing prior distributions for the parameters. For µo1j , we can assume a flat non-informative
prior as P (µo1j) ∝ 1 for j = 1, 2, ..., J since we have no prior information regarding these over-
all mean parameters. We can elicit Jeffrey’s prior distributions for the remaining variance
parameters such that P (σ21) ∝ 1/σ21, P (σ22) ∝ 1/σ22, P (σ21b) ∝ 1/σ21b, and P (σ2ξ ) ∝ 1/σ2ξ . As
a result, the joint posterior distribution of all parameters will be given by the product of
all likelihoods and specified densities of the parameters as
P (µ1,µ11, ...,µ1h, ...,µ1H ,µo1,µ2, ξ, σ21, σ21b, σ22, σ2ξ |x1j ,x11j , ...,x1Hj ,x2j , j = 1, ..., J)
∝
 J∏
j=1
{
L(µ1j , σ21|x1j)
(
H∏
h=1
L(µ1hj , σ21|x1hj)
)
L(µ2j = µ1j − ξj , σ22|x2j)P (µ1j |µo1j , σ21b)(
H∏
h=1
P (µ1hj |µo1j , σ21b)
)
P (ξj |θ, σ2ξ )
}
P (µo1j)
](
1
σ21σ
2
1bσ
2
2σ
2
ξ
)
(5.2.8)
where µ’s and ξ ∈ RJ , x1j representing the data on all n1 subjects, x1hj representing
the data on all n1h subjects, and x2j representing the data on all n2 subjects for the jth
endpoint with j = 1, 2, ..., J .
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Based on the joint density in (5.2.8), we can find the conditional posterior distributions for
the parameters. For the hth historical trial, the conditional posterior distribution for µ1hj
is given by
µ1hj |x1hj ∼ N
σ˜21h
(
n1hx1hj
σ21
+
µo1j
σ21b
)
, σ˜21h =
(
n1h
σ21
+ 1
σ21b
)−1 (5.2.9)
where h = 1, 2, ...,H and j = 1, 2, ..., J . The mean of the posterior distribution is a weighted
average of the sample mean x1hj and µo1j . As for the original reference product in the current
trial, the mean parameters will have conditional posterior distributions as
µ1j |x1j ,x2j ∼ N
σ˜21
(
n1x1j
σ21
+ n2(x2j + ξj)
σ22
+
µo1j
σ21b
)
, σ˜21 =
(
n1
σ21
+ n2
σ22
+ 1
σ21b
)−1 .(5.2.10)
The mean of the distribution is given by the weighted average of the sample mean x1j ,
µo1j , and (x2j + ξj). The derivation of this analytical form is given in Section 5.5.1 in
the Appendix. The overall mean parameter µo1j will therefore have conditional posterior
distribution given by
µo1j ∼ N
(
µ1j +
∑H
h=1 µ1hj
1 +H , σ˜
2
o =
σ21b
1 +H
)
. (5.2.11)
The bias parameters will take on the following conditional posterior distributions
ξj ∼ N
σ˜2ξ
(
n2(µ1j − x2j)
σ22
+ θ
σ2ξ
)
, σ˜2ξ =
(
n2
σ22
+ 1
σ2ξ
)−1 . (5.2.12)
However, the mean parameters for the generic follow-on product is completely specified by
both µ1j and ξj as in (5.2.6), therefore, its posterior distribution will be given by their
respective posterior distributions
µ2j |x1j ,x2j = µ1j |x1j ,x2j − ξj , j = 1, 2, ..., J. (5.2.13)
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As for the within-study variance parameter for the licensed reference product, using the Jef-
frey’s prior, we get the conditional posterior distribution as the inverse-gamma distribution
with shape and scale parameters given by
σ21 |x1j ,x11j , ...,x1Hj , j = 1, 2, ..., J
∼ IG
J(n1 +∑Hh=1 n1h)
2 ,
1
2
 J∑
j=1
n1∑
i=1
(x1ji − µ1j)2 +
H∑
h=1
J∑
j=1
n1h∑
i=1
(x1hji − µ1hj)2
 .(5.2.14)
The derivation of this analytical form is given in Section 5.5.2 in the Appendix. The
between-study variance parameter for the licensed reference product will also follow a con-
ditional posterior distribution as an inverse-gamma distribution given by
σ21b ∼ IG
J(1 +H)
2 ,
1
2
 J∑
j=1
(µ1j − µo1j)2 +
H∑
h=1
J∑
j=1
(µ1hj − µo1j)2
 . (5.2.15)
Additionally, the variance parameter for the follow-on product has conditional posterior
distribution as
σ22|x2j , j = 1, 2, ..., J ∼ IG
Jn2
2 ,
1
2
J∑
j=1
n2∑
i=1
(x2ji − (µ1j − ξj))2
 . (5.2.16)
Lastly, the variance parameter for the bias term σ2ξ can be shown to be an inverse-gamma
distribution
σ2ξ ∼ IG
J
2 ,
1
2
J∑
j=1
(ξj − θ)2
 . (5.2.17)
Using the conditional posterior distributions in (5.2.9), (5.2.10), (5.2.13), (5.2.12), (5.2.14),
(5.2.15), (5.2.16), and (5.2.17), we can find the marginal posterior distributions of µ1j ,
σ21, µ2j , and σ22, and hence those of pk = f(µk1, µk2, ..., µkJ , σ2k) for k = 1 or 2 and per-
form posterior inference based on the distribution of p2 − p1. There are two ways to find
the marginal posterior densities. One way is to integrate out the conditioning param-
eters using their conditional posterior densities, but this can be highly intractable. A
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more viable way is to use Markov chain Monte Carlo (MCMC) methods to simulate the
marginal posterior densities from the conditional posterior densities. In this case, since we
have close forms for the conditional posterior distributions, we can use Gibbs sampling,
one of the widely used MCMC techniques. Using the same Gibbs sampling, we can also
simulate the marginal posterior distribution of p2 − p1. We can directly estimate the pos-
terior probability P (p2 − p1 > −δ|x1j ,x11j , ...,x1Hj ,x2j , j = 1, 2, ..., J) = E[I(p2 − p1 >
−δ)|x1j ,x11j , ...,x1Hj ,x2j , j = 1, 2, ..., J ]. The decision rule is to reject the null hypoth-
esis when this posterior probability is greater than a critical probability pc which can be
pre-specified as high as 95% or 97.5% depending on the clinical significance.
5.2.4 Determination of Bayesian Non-Inferiority Margin
Another major challenge in a non-inferiority trial design is to determine the NI margin δ
and hence its corresponding θ for each of the individual endpoints. One way to specify δ
is to mirror the fixed margin method in the frequentist paradigm in the current Bayesian
paradigm (Gamalo, Wu, Tiwari, 2012; Gamalo, Tiwari, LaVange, 2013). In the frequentist
paradigm, the NI margin is set to be the lower bound of the 100%(1 − α) confidence
interval for the effect p1h′ − p0h′ in a selected historical placebo-controlled trial h′, where
0h′ represents the placebo arm and 1h′ represents the innovator reference product arm in
this trial. This historical placebo-controlled trial h′ was usually a trial that led to its first
FDA approval.
If we assume a similar model as in (5.2.4) for the placebo and treatment arms in this
placebo-controlled trial
xkh′ji ∼ N(µkh′j , σ2kh′)
where k = 0 or 1 and elicit a flat non-informative prior for µkh′j as in P (µkh′j) ∝ 1 and a
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Jeffery’s prior for the variance σ2kh′ as in P (σ2kh′) ∝ 1/σ2kh′ , then
µkh′j |xkh′j , j = 1, 2, ..., J ∼ N
(
xkh′j ,
σ2kh′
nkh′
)
σ2kh′ |xkh′j , j = 1, 2, ..., J ∼ IG
Jnkh′
2 ,
1
2
J∑
j=1
nkh′∑
i=1
(xkh′ji − µkh′j)2
 . (5.2.18)
We can use Gibbs sampling to simulate for p1h′ − p0h′ and solve for δ as the lower bound of
the 100%(1− α) credibility interval such that
P (p1h′ − p0h′ > δ|x0h′j ,x1h′j , j = 1, 2, ..., J) > 1− α2 . (5.2.19)
In addition, we want to explore a slightly more conservative margin δλ = (1 − λ)δ where
0 < λ < 1. This margin δλ can represent the clinically relevant effect that the follow-on
generic product should not be worse than the innovator reference product. Examples of λ
are 0% (full margin: δ0 = δ), 25%, or 50% (half of the margin: δ0.5 = δ/2).
5.3 Simulation Study
5.3.1 Simulation Objectives and Plan
In order to characterize the operating characteristics of this Bayesian non-inferiority design
for biosimilarity, we will conduct a simulation study that is motivated by our previous
example of rheumatoid arthritis (RA). The primary composite efficacy endpoint is the
ACR20 at 6 months (or 24 weeks) although ACR50, ACR70, or ACR20 at other time
points can be secondary endpoints for generating future hypotheses. There is no safety
endpoint in this study and it can be assumed that doses higher than the recommended dose
do not create safety concerns.
The ACR20 has seven components and they represent separate categories of symptoms as in
Table 5.1. These components are generally assumed to be independent measures. Therefore,
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J is equal to 7 such that µk1 and µk2 are at least 20% and at least 3 of {µk3, ..., µk7} are at
least 20% where k = 0h′, 1h′, 1h, 1, 2 and h = 1, 2, ...,H. The objectives of this simulation
study are (1) to assess the type I error in the Bayesian paradigm under the null hypothesis
and to compare it with that in the frequentist paradigm, (2) to evaluate the statistical
power in the Bayesian paradigm under the alternative hypothesis given overall sample size
n and randomization ratio R as well as to compare it with that in the frequentist paradigm,
and (3) to characterize the impact of different λ as in δλ and pc on the aforementioned
characteristics. The following delineate the simulation steps.
1. As a real-life motivating example, we conducted a literature search on historical trials
on Etanercept. Etanercept is a TNF receptor (p75) fusion protein, linked to the Fc
portion of human IgG1. We found five published studies: (1) Moreland et al. (1997),
(2) Moreland et al. (1999), (3) Weinblatt et al. (1999), (4) Bathon et al. (2000),
and (5) Klareskog et al. (2004). Among these studies, only one of them (More-
land et al., 1999) was a confirmatory placebo-controlled trial for the monotherapy
of Etanercept (25mg/mL) while the other trials studied either combined therapies
of Etanercept or lower doses of Etanercept. Etanercept (25mg/mL) was adminis-
tered subcutaneously twice a week and the primary efficacy endpoint is ACR20 at 6
months (or 24 weeks). This trial led to its FDA approval for RA in 1998. Therefore,
H = 1, and we will use this historical trial to determine the NI margin as well as
including it in the hierarchical bias model (h′ = h). Table 5.2 below summarizes
the partial result from this historical trial. A positive percent change is interpreted
as a reduction in the corresponding symptom component while a negative percent
change means an increase. Table 5.3 describes the simulation setting for the follow-
on biological product in the current proposed biosimilarity study. We can specify
µ0h′j , µ1h′j , µ1j , µ2j , σ
2
0h′ , σ
2
1h′ , σ
2
1, σ
2
2, n0h′ , n1h′ , n,R, λ, and pc for j = 1, 2, ..., 7 using
the results from this trial.
2. Since we do not have patient-level data on the chosen historical trial, except reported
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sample mean values on the endpoints in Table 5.2, we will use these reported sample
means as true values for the parameters. We simulate data on x0h′ji ∼ N(µ0h′j , σ20h′)
for i = 1, 2, ..., n0h′ and x1h′ji ∼ N(µ1h′j , σ21h′) for i = 1, 2, ..., n1h′ .
3. Use Gibbs sampling to generate posterior samples for µ0h′j , µ1h′j , σ20h′ , and σ21h′ using
conditional posterior distributions in (5.2.18). Using Gelman-Rubin-Brooks plots,
trace plots, and auto-correlation plots with five chains of sampling, determine the
number of MCMC iterations N sufficient for the convergence of the MCMC chains
after 10% burn-in (Gelman and Rubin, 1992; Plummer et al., 1992).
4. During each successive iteration of the same Gibbs sampling in step (3), compute p0h′
and p1h′ according to the definition of the composite endpoint ACR20 as follow:
pk = f(µk1, µk2, ..., µk7, σ2k)
=
2∏
j=1
Φ
(
−20− µkj
σk
)P ({S3}) + P ({S4}) + 7∏
j=3
Φ
(
−20− µkj
σk
)(5.3.1)
where k = 0h′ or 1h′. Φ is the cumulative density function of the standardized normal
distribution. S3 is the event that any three of the 3rd to 7th endpoints are equal to or
greater than 20% while the remaining two endpoints are less than 20% and similarly
S4 is the event that any four of them are equal to or greater than 20% while the
remaining one is less than 20%.
5. Using the posterior samples of p0h′ and p1h′ after 10% burn-in from step (4), estimate
δ, the lower bound of the credibility interval of p1h′ − p0h′ , as in (5.2.19) using an α
level of 0.05. For a given λ, we can specify the NI margin as δλ = (1− λ)δ. Find the
corresponding θλ such that µ2j−µ1j = −θλ(θλ > 0) for j = 1, 2, ..., J and p2−p1 = −δλ
according to (5.3.1). A strictly (one-on-one) increasing relationship exists between δλ
and θλ since there is a one-on-one relationship between θ and Φ(−(20− (µk− θ))/σk)
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and hence pk, therefore as
p2 − p1 = f(µ21, µ22, ..., µ27, σ22)− f(µ11, µ12, ..., µ17, σ21)
= f(µ11 − θλ, µ12 − θλ, ..., µ17 − θλ, σ22)− f(µ11, µ12, ..., µ17, σ21)
= −δλ,
then θλ and δλ are also one-on-one.
6. If there is more than one historical trial (H > 1), then we can simulate data on
x1hji ∼ N(µ1hj , σ21h) for h = 1, 2, ...,H using the reported sample means for µ1hj .
However, since we only have one historical trial (H = 1) and it is the same as the
placebo-controlled trial (h = h′), we will simply use the data simulated in step (2).
For the current trial of biosimilarity, we simulate data using µ1j = µ1h′j +4 where
4 represents the difference of the means of the reference product in the current and
historical trials, uniform across J endpoints. If 4 = 0, it means the effect is the
same, i.e. constancy assumption is met. If 4 > 0, it means the reference product
is performing better in the current trial than in the historical trial; and then the
opposite argument is true when 4 < 0. Then we simulate data on x1ji ∼ N(µ1j , σ21)
for i = 1, 2, ..., n1 and x2ji ∼ N(µ2j , σ22) for i = 1, 2, ..., n2 where n1 = n/(1 + R) and
n2 = nR/(1 +R).
7. Use Gibbs sampling to generate posterior samples of size N after 10% burn-in for the
following parameters: µ1hj , µ1j , µo1j , µ2j , ξj , σ21, σ21b, σ22 and σ2ξ using conditional pos-
terior distributions in (5.2.9), (5.2.10), (5.2.11), (5.2.13), (5.2.12), (5.2.14), (5.2.15),
(5.2.16), and (5.2.17).
8. During each successive iteration of the same Gibbs sampling, use the posterior samples
of these parameters, µ1j , σ21, µ2j , and σ22 in step (7) to compute p1 and p2 according
to the definition of the composite endpoint ACR20.
9. Using the posterior samples of p1 and p2 after 10% burn-in from step (8), estimate
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the posterior probability, P (p2 − p1 > −δλ|x1j ,x1h′j ,x2j , j = 1, 2, ..., J) and if this
posterior probability is greater than pc as the Bayesian criterion or decision rule, then
we can conclude that this non-inferiority biosimilarity trial is a success in term of its
efficacy in ACR20.
10. In order to assess the Bayesian type I error, 10,000 simulated trials will be used to
estimate the probability of rejecting the null hypothesis when µ2j−µ1j = −θλ (θλ > 0)
for j = 1, 2, ..., J such that p2 − p1 = −δλ according to (5.3.1).
11. In order to assess the Bayesian power given n, R, and µ2j − µ1j = −θa > −θλ for
j = 1, 2, ..., J , 10,000 simulated trials will also be used to estimate the probability of
rejecting the null hypothesis. This will estimate the Bayesian power.
12. In order to compare the Bayesian type I error with the frequentist type I error, use
the simulated data from steps (2) and (6) to estimate the probabilities pk = P (yki =
1), k = 0h′, 1h′, 1, 2. These estimators can be denoted as pˆk. We conclude that in
the current biosimilarity trial, the follow-on biologic is non-inferior to the reference
biologic if the following is true:
(pˆ2 − pˆ1)− Z1−α2
√
pˆ2(1− pˆ2)
n2
+ pˆ1(1− pˆ1)
n1
> −(1− λ)
(pˆ1h′ − pˆ0h′)− Z1−α2
√
pˆ1h′(1− pˆ1h′)
n1h′
+ pˆ0h
′(1− pˆ0h′)
n0h′
 (5.3.2)
where α/2 is set to be 0.025. Using the data from the same 10,000 trials in steps
(10) and (11), the probability of rejecting the null hypothesis is estimated and can be
compared to that from the Bayesian paradigm.
13. All of the statistical programming will be conducted in the open-source R software.
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Table 5.2: Historical trial on monotherapy of Etanercept (25mg/mL) at 6 months - Moreland
et al., 1999
k Treatment nk P (ACR20 = 1) or pˆk µˆk1 µˆk2 µˆk3 µˆk4 µˆk5 µˆk6 µˆk7 σ2k
0h′ Placebo 80 11% 6% -7% 2% -3% -22% 2% -207% 1600%
1h′ Etanercept (25mg/mL) 78 59% 56% 47% 44% 46% 53% 39% 31% 1600%
Note: For µˆk7, CRP is used instead of ESR. The variance was reported in Moreland et al., 1997 and was assumed to
be 1,600% for the calculation of sample size.
Table 5.3: Simulation setting for the current non-inferiority biosimilarity trial.
Parameter Values Description
λ 0, 0.25, 0.5 Sizing factor for non-inferiority margin
δλ = (1− λ)δ δ0 = δ, δ0.25 = 0.75δ, δ0.5 = 0.5δ Re-sized non-inferiority margin for δ
θλ θ0, θ0.25, θ0.5 Re-sized non-inferiority margin for θ
4 -2, 0, 2 Impact of constancy assumption
µ1j , σ21 µ1j = µ1h′j +4, σ21h′ Use historical trial on Etanercept (25mg/ML) arm in Table 5.2
µ2j , σ22 µ1j − θλ, σ21h′ For assessing Bayesian type I error
µ2j , σ22 µ1j − θa (θa = 0, θλ/2), σ21h′ For assessing Bayesian power
n 60, 120 Overall trial sample size
R 1, 2 Fixed randomization ratio
pc 95%, 97.5% Critical probability
N determined by simulation Number of posterior Gibbs samples after 10% burn-in
5.3.2 Simulation Results
Using the estimated means from Table 5.2 and the simulation setting laid out in Table
5.3, we simulated patient-level data for the selected historical trial. Using this hypothetical
patient-level data, we generated Gibbs samplings on the parameters, µ0h′j , µ1h′j , σ20h′ , and
σ21h′ . In order to determine the optimal number of iterations for posterior convergence,
Figures 5.3, 5.4, and 5.5 for k = 1h′ are used to assess if N = 3, 000 is sufficient for
convergence. As seen from the Gelman-Rubin-Brooks plots (Figure 5.3), the shrink factors
are well close to 1, suggesting convincing evidence of convergence. Therefore, before 10%
burn-in, N = 3, 000 can be a sufficient choice. This is also confirmed by the trace plots
(Figure 5.5) and auto-correlation plots (Figure 5.4) which indicate minimal lags between
simulations. Figure 5.6 shows the kernel plots of the posterior samples after 10% burn-
in. Using these chains of sampling, we derived the posterior samples of the probability of
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clinical response ACR20, p0h′ and p1h′ , and hence their difference, p1h′ − p0h′ . The kernel
distribution of the posterior probability difference is given in Figure 5.7. The lower bound
of the 95% credibility interval is estimated to be 0.4604. Therefore, under different pre-
specified sizing factors λ, we can state the different NI margins for subsequent simulation:
λ = 0 will give δ0 = 0.4604, λ = 0.25 will give δ0.25 = 0.3453, and finally λ = 0.5 will give
δ0.5 = 0.2302. Using the equation in (5.3.1), we can find their corresponding θ: θ0 = 34.7,
θ0.25 = 22.2, and θ0.5 = 14.0.
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Figure 5.3: Gelman-Rubin-Brooks plots of posterior simulations for mean and variance
parameters, µ1h′j (j = 1, 2, ..., 7) and σ21h′ .
Using the same patient-level data, we also calculated the probabilities of clinical response
ACR20: pˆ0h′ = 0 and pˆ1h′ = 0.5641 under the frequentist perspective. The estimate for the
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Figure 5.4: Autocorrelation plots of posterior simulations for mean and variance parameters,
µ1h′j (j = 1, 2, ..., 7) and σ21h′ .
treatment arm is not far from the one reported in this historical trial (59% in Table 5.2), but
the estimate for the placebo arm is under-estimated (11% in Table 5.2). The lower bound
of the 95% confidence interval is therefore estimated to be 0.4019. The corresponding re-
sized NI margins will be 0.4019, 0.3014, and 0.2009. These are somewhat smaller than the
corresponding ones estimated in the Bayesian method above. Based on the same simulation
plan as described in Table 5.3, we conducted subsequent simulation using 10,000 simulated
identical trials. The same simulated two-arm trial data will be used to determine if the
trial is a success separately for the proposed Bayesian method and the standard frequentist
method. Table 5.4 shows the result of the simulated type I error under both analytical
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Figure 5.5: Trace plots of posterior simulations for mean and variance parameters, µ1h′j (j =
1, 2, ..., 7) and σ21h′ .
paradigms and Table 5.5 displays the result of the simulated statistical power.
In Table 5.4, we observe general preservation of type I error under 0.025 when 4 = µ1j −
µ1hj = 0 or 2, but inflated type I error when 4 = −2. That is, when the reference product
is performing identically or better in the current biosimilarity trial than in the reference
historical trial, the type I error is controlled under the target size. However, if it performs
worse in the current trial than in the historical trial, the type I error is inflated, both for
the Bayesian and the frequentist methods. However, as λ increases to 0.5 when the NI
margin is smaller, the type I error inflation is only seen in the frequentist approach but not
the proposed Bayesian approach. In fact, the type I error under the Bayesian method is
well-controlled under 0.01 even when the reference product is doing worse in the current
trial. Figure 5.8 explores the relationship between the type I error rate and 4 = µ1j −µ1hj
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Figure 5.6: Kernel plots of posterior simulations for mean and variance parameters,
µ1h′j (j = 1, 2, ..., 7) and σ21h′ .
for n = 60, R = 1 and 0.95. As 4 falls below zero, indicating the reference product is doing
worse in the current trial than in the reference historical trial, type I error rate increases
in both Bayesian and frequentist approaches, with the Bayesian approach having a steeper
increase than the frequentist approach. Both methods are able to preserve the type I error
at 0.025 when 4 = 0, that is when the effect of the reference product is constant in both
trials. The inflation of type I error, when reference product is doing worse in the current
trial, is possibly due to the larger lower bound of 95% credibility interval in the historical
trial as related to the reduced effect size of the reference product comparing to the putative
placebo, which does not exist in the current trial. However, as λ increases, the re-sized NI
margin narrows, due to the influence of the skeptical prior for ξj , the proposed Bayesian
method is able to protect the inflation of type I error, even when 4 < 0 but the frequentist
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Figure 5.7: Kernel plot showing the posterior distribution of probability difference p1h′−p0h′
based on simulated hypothetical patient-level data.
approach cannot.
In Table 5.5, we can see that when λ = 0 and 4 = 0, 2, that is, when the full NI margin is
used, the statistical power of the Bayesian method is unanimously higher than that of the
frequentist method. As for λ = 0.25 and 4 = 0, 2, statistical power of the Bayesian method
is smaller than that of the frequentist method only when sample size is small as in n = 60
and when the alternative is at δa = δ0.25/2. Other than that, the power of the Bayesian
method is superior to the frequentist method. As λ decreases to 0.5 and when 4 = 0, 2,
the NI margin narrows down to δ0.5 = 0.2302, when n = 60 and the alternative is either
at δa = δ0.5/2 = 0.1151 or at δa = 0, statistical power is very low in both the Bayesian
and frequentist approaches with the Bayesian method suffering more loss of power due to
the strong influence of the skeptical prior on ξj within the smaller margin. However, an
increase in sample size to n = 120 seems to promise a much better improvement in statistical
power when δa = 0 than the improvement in frequentist power. This is mainly due to the
increasing influence of the data over the skeptical null prior, resulting in improved Bayesian
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Figure 5.8: Plot of type I error against value of 4 = µ1j − µ1hj for all j. Setting is n = 60,
R = 1, and pc = 0.95
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power.
5.3.3 Adaptive Two-Stage Bayesian Design
Additionally, we want to propose a design that is comprised of two stages, with an interim
assessment that is based on predictive probability to decide if the trial can be stopped
for early efficacy. Predictive distribution has been proposed as a criterion for clinical trial
monitoring (Spiegelhalter and Freedman, 1986; Dmitrienko and Wang, 2006) and has been
successfully applied to clinical trials (Lee and Liu, 2008). In this Bayesian adaptive design,
we can assign n(1) subjects to the first stage and n(2) subjects to the second stage so that
n(1)+n(2) = n. As a result, the innovator reference product will receive n(s)1 = n(s)R/(1+R)
subjects in the sth stage (s = 1, 2) such that n(1)1 + n(2)1 = n1 and generic follow-on
product will have n(s)2 = n(s)/(1 + R) subjects randomized in the sth stage such that
n(1)2 + n(2)2 = n2.
We also let x(s)kji be the outcome for the jth endpoint for products k = 1, 2, collected in
the sth stage where i = 1, 2, ..., n(s)k and that it follows the same model in (5.2.1). Interim
inference will use the predictive probability of rejecting the null hypothesis P ∗ based on
the interim data x(1)kji observed so far as well as future samples x∗(2)kji that is based on
their predictive distributions. In this problem, we have multiple parameters and therefore
the estimation of predictive distributions will rely on Gibbs sampling using their respective
conditional predictive distributions. For example, the conditional predictive distributions of
future sample means for the reference product for the second stage x∗(2)1j given the interim
143
data of the first stage collected so far can be shown to be
x∗(2)1j |x(1)1j ,x(1)2j ,x1hj
∼ N
(n(1)1
σ21
+
n(1)2
σ22
+ 1
σ21b
)−1(
n(1)1x(1)1j
σ21
+
n(1)2(x(1)2j + ξj)
σ22
+
µo1j
σ21b
)
,
σ˜2∗1 =
σ21
n(2)1
+
(
n(1)1
σ21
+
n(1)2
σ22
+ 1
σ21b
)−1 .
(5.3.3)
The close forms of the conditional predictive distributions of future sample means for the
follow-on product for the second stage x∗(2)2j are not shown here since they depend on those
of ξ∗j . If we denote all of the interim data as x(1)kj based on n(1)k and predictive future
data as x∗(2)kj based on n(2)k, the predictive probability of trial success at the end of the
first interim stage is defined as
P ∗ =
∫
I
{
P (p2 − p1 > −δ|x(1)kj ,x∗(2)kj , k = 1, 2; j = 1, 2, ..., J) > γ
}
P
(
x∗(2)kj
)
dx∗(2)kj
(5.3.4)
where I{.} is an indicator function, P
(
x∗(2)kj
)
is the joint predictive probability distribution
of the future samples x∗(2)kj , and γ can be set to as high as 0.90. P ∗ is essentially a
weighted average of the indicator functions conditioned on all possible predictive samples.
Additionally, we can set pc1 as the stopping boundary for the first stage such that we will
reject the null hypothesis if P ∗ > pc1 . However, obtaining exact form of P ∗ is intractable
and therefore, we will rely on the Gibbs sampling. If the trial fails to reject the null
hypothesis based on the interim data, the trial will continue by randomizing the remaining
planned n(2) samples and final inference will be based on the original posterior distribution
using the combined data. The stopping boundary is set at pc2. The additional simulation
steps for this two-stage design are listed as follows.
1. Use the same simulation setting as in Table 5.3, but this time we only focus on λ = 0.5,
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n = 120 with n(1) = 90 and n(2) = 30. γ is set at 0.90. Stopping probability for the
first stage is set at pc1 = 0.98 and for the second stage pc2 = 0.95.
2. When simulating data for a current trial of biosimilarity, we simulate only the first
stage data: x1ji(i = 1, 2, ..., n(1)1) and x2ji(i = 1, 2, ..., n(1)2).
3. Use Gibbs sampling to generate posterior samples of size N with 10% burn-in on the
parameters using the conditional posterior distributions.
4. During each iteration of the Gibbs sampling in the previous step, we also generate pre-
dictive samples of size n(2): x∗1ji(i = 1, 2, ..., n(2)1) and x∗2ji(i = 1, 2, ..., n(2)2) for both
arms using the Gibbs samples of parameters. Theoretically, these predictive samples
will converge to the predictive distributions as the posterior samples of the parameters
converge to their posteriors. These predictive future samples will be appended to the
interim data simulated in step (2). Generate 1,000 corresponding posterior samples
on the parameters now conditioning on the combined interim trial data and predicted
future data.
5. Use the 1,000 posterior samples of the parameters generated in the previous step
to calculate the corresponding posterior samples of pk, and hence determine if the
estimated posterior probability P (p2 − p1 > −δ|x(1)kj ,x∗(2)kj , k = 1, 2; j = 1, 2, ..., J)
is greater than γ or not. If yes, then for this Gibbs iteration, we assign an indicator
value of 1, otherwise 0. The predictive probability P ∗ will be empirically estimated
using the Gibbs sampler of size N after 10% burn-in of these indicator values. If
this empirical predictive probability is greater than pc1, then we stop the trial and
conclude it is a success based on the composite efficacy endpoint; otherwise, we will
continue to the second stage.
6. If interim analysis fails to reject the null hypothesis, additionally simulate trial data
on the remaining n(2) data. Follow the same previous steps and obtain the estimate
of posterior probability. If this posterior probability is greater than pc2, then the trial
145
is a success, otherwise, the trial cannot claim success.
7. Based on the above steps, we can simulate 10,000 identical trials and assess the type
I error, statistical power, and expected sample size based on this Bayesian two-stage
design. Additionally, we will also compute the type I error and statistical power based
on the original Bayesian fixed sample design and the frequentist approach.
Table 5.6 shows the result of this simulation on the Bayesian two-stage design. Generally,
we can see that type I error is preserved under the level of 0.025. The statistical power
using the two-stage design is comparable to the one using the fixed sample design in all
scenarios. However, there is a noticeable decrease in expected trial sample size to around
105 for cases where δa = 0, that is when the follow-on product has identical effect as the
reference product, indicating possible early trial termination based on interim evidence of
efficacy.
5.3.4 Sensitivity Analysis
In order to assess the robustness of the results we obtain in Tables 5.4 and 5.5, we want to
conduct sensitivity analysis to further investigate if these results are sensitive to alternative
specifications of the prior density. We have seen earlier that the operating characteristics of
this Bayesian design can be influenced by the informative yet skeptical prior density for the
bias term ξj(j = 1, 2, ..., J) as well as the prior density specified for its variance parameter,
σ2ξ . Equivalently, we can also view it as the precision parameter defined as τ2ξ = 1/σ2ξ . In
general, if we assume a gamma distribution such as G(a, b) as prior density for τ2ξ where a
is the shape parameter and b is the rate parameter, then the variance parameter will have
inverse-gamma density IG(a, b) as prior density where a is still the shape parameter, but b is
called the scale parameter. By changing the pre-specified hyper-parameters: decreasing the
shape parameter a or increasing the scale parameter b, one may adjust the influence of the
skeptical prior because the strength of the skeptical prior for the bias term is parameterized
by the variance parameter. If the variance parameter is distributed at higher values or
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precision parameter at lower values, this will weaken the skeptical prior. If the variability
or uncertainty of the variance or precision parameter is high, this may further weaken the
skeptical prior.
In the design, we have specified a Jeffrey’s prior for this variance parameter P (σ2ξ ) ∝ 1/σ2ξ
which is often thought of as having a = 0 and b = 0. Jeffrey’s prior densities have
been known to be non-informative and invariant to transformations of the parameter,
but they occasionally give improper posterior densities. In our case, the posterior den-
sity is a proper density given by (5.2.17). Other non-informative prior densities have
been suggested in the literature such as the “just proper” inverse-gamma prior density
of P (σ2ξ ) = IG(0.001, 0.001) or a Uniform prior density P (σ2ξ ) ∝ constant (Gelman et al.,
1995). When the IG(0.001, 0.001) is used as prior density, the posterior density will be
given by
σ2ξ ∼ IG
J
2 + 0.001,
1
2
J∑
j=1
(ξj − θ)2 + 0.001
 .
When the Uniform prior is used, it assumes a locally uniform distribution and therefore,
the posterior density will be given by
σ2ξ ∼ IG
J
2 − 1,
1
2
J∑
j=1
(ξj − θ)2
 .
In addition, we also want to consider another inverse-gamma prior IG(0.001, 1) which has a
larger prior variability or uncertainty and is distributed more at larger values for the variance
parameter than the Jeffery’s prior and IG(0.001, 0.001) prior do (see Figure 5.9). Figure
5.10 displays examples of posterior distributions of the variance parameter σ2ξ after the
likelihood of the data is combined with the four different prior densities. Jeffrey’s prior and
IG(0.001, 0.001) prior appear to result in similar posterior distributions. IG(0.001, 1) prior
gives a posterior distribution that allows slightly higher values of the variance parameter
than Jeffery’s and IG(0.001, 0.001), and finally Uniform prior results in much more variable
and higher values in the posterior distribution.
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Figure 5.9: Prior densities for the variance parameter σ2ξ for two IG.
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good control of type I error rate at 0.025 in all scenarios where 4 > 0.
Table 5.8 tabulates the simulated Bayesian powers based on different prior densities. Again,
Jeffery’s prior and IG(0.001, 0.001) perform similarly. For prior of IG(0.001, 1), there is an
increase in statistical power comparing to Jeffery’s and IG(0.001, 0.001) priors. However, for
scenarios where λ = 0.5, δλ = 0.2302, and alternative hypothesis at δa = 0.1151, all three
priors, Jeffery’s, IG(0.001, 0.001), and IG(0.001, 1) cannot surpass the frequentist power
except for Uniform prior. The design using the Uniform prior generally has the greatest
statistical power comparing to other priors as well as the frequentist approach in all the
scenarios under study. Given this result, we see that the operating characteristics display
some degree of sensitivity to the hyper-parameters of the inverse-gamma prior density of σ2ξ .
In fact, given a very small value of the shape hyper-parameter such as a = 0.001, one can
adjust the value of the scale hyper-parameter b to a suitable value while preserving the type
I error at 0.025. Increasing the value of b, has the effect of increasing the posterior mean
or median of σ2ξ as well as its variability, thus weakening the skeptical prior on ξj in the
direction to favor the alternative hypothesis. The control of type I error using the Bayesian
approach with different prior specifications is still better than the frequentist approach,
particularly when 4 = −2, that is, when the reference product is performing worse in the
current trial than in the historical trial. Therefore, it is strongly recommended to conduct
simulation to assess the influence of different candidate prior densities when deciding which
one to use with regulatory agencies.
5.4 Summary and Discussion
In this chapter, we have presented a Bayesian method to assess biosimilarity between a
licensed reference biological product and a generic follow-on (also known as a subsequent-
entry) biological product. This approach adopts a non-inferiority testing framework that
connects the current trial of biosimilarity to historical trials of the reference product. The
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proposed Bayesian analytical approach recognizes that the reference product was approved
for license in the past and that information in these historical trials can be meaningfully
incorporated in the analysis of the current trial. However, due to changing clinical prac-
tices and improvement in the overall delivery of care over time, the effect of a medicinal
product may not be always constant. This is, in the context of a non-inferiority clinical
trial, sometimes known as the constancy assumption, the historical difference between the
original product and placebo is assumed to hold in the current setting of the new trial if a
placebo is in place (D’Agostino, Massaro, and Sullivan, 2003). Therefore, we presented the
hierarchical model to incorporate historical trials while accounting for the potential lack
of biosimilarity via a bias parameter. In this model, non-informative priors are elicited
for most parameters except for the bias parameter which assumes a skeptical prior with
expectation centered on the null hypothesis. We also characterized the sensitivity of this
design to different prior specifications for the variance parameter for the bias term. As
most biological products are meant to treat illnesses with improvement in multiple end-
points, we illustrate the application of this method to studying rheumatoid arthritis that
uses a composite efficacy endpoint known as ACR20.
Simulation studies have demonstrated that the Bayesian method usually has type I error
preserved under the α-level of 0.025, comparable to a typical level assumed in a one-sided
non-inferiority trial. This is made possible with the placement of the skeptical prior on
the bias parameter, even when a more relaxed critical probability pc = 0.95 is used under
different prior specifications. When the reference product performs worse in the current
trial, due to potential violation of the constancy assumption, the NI margin that is based
on its historical trial appears to be wider, thus inflating its type I error. Both Bayesian
and frequentist methods have no immunity to this inflation, however, the Bayesian method
is able to cancel out this inflation by tapping into the influence of the skeptical null prior
as NI margin narrows, therefore offering some protection even when constancy assumption
is slightly violated in the negative direction. It is important to emphasize that this type
I error is an error rate conditional on the outcomes of the historical trial selected. Under
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this hierarchical model, we presume in (5.2.5) that both µ1j and µ1hj come from the same
underlying distribution, therefore the difference 4 = µ1j − µ1hj follows the normal distri-
bution, N(0, 2σ21b). Another way to look at the type I error is the average type I error rate
over all possible values of 4. Further simulation can be useful in characterizing this average
type I error over all possible trial performance for the reference product in historical and
current trials. It is important that, prior to the design of the biosimilarity trial, a thorough
literature search should be made to assess if the effect of the reference product is consistent
in the historical trials and if the design and conduct of these studies are not too dissimilar.
If such large variability in estimation is observed, sources of this inconsistency should be
investigated.
As for statistical power, it somewhat suffers when NI margin is small. However, as sample
size increases from n = 60 to 120 under smaller margins and as the follow-on product is
truly biosimilar to the reference product, Bayesian statistical power starts to outperform
the frequentist approach. Adopting an equal randomization ratio of R = 1 offers only a
slight advantage in the overall statistical power. In the Bayesian two-stage adaptive design
using predictive probability as an interim stopping criterion, reduced expected sample size is
observed especially in cases when a follow-on product is biosimilar to the reference product
without compromising its statistical power. In our example, as much as a 12.5% reduction
in expected sample size is observed.
Another possibility of using hierarchical modeling is that we may be able to include other
historical trials which perhaps studied different doses of the reference product or were
conducted under systematically different trial-specific circumstances. If such characteristics
can be assumed to be linearly related to the efficacy parameters, their inclusion into the
model may help increase the precision of the estimation, and hence the inference.
In this chapter, we have illustrated the method using a composite endpoint that has several
separate endpoints combined into a single one. When we directly model the component
endpoints, it is likely that instead of the global null hypothesis, some of the component
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endpoints may have inferior means such that for some j, µ2j 6 µ1j − θ but not the oth-
ers, and this trial can still claim success based on the predictive or posterior probability.
Composite endpoint may present different null configurations which may warrant further
study. In our example, we have only presented the global null configuration using θ as the
non-inferiority margin across all component endpoints. In other cases, a single endpoint
or multiple endpoints are used to establish efficacy. For example, for studying psoriasis, a
common chronic inflammatory skin disease characterized by thick red flaky patches called
scales, there are two major endpoints: proportion of subjects who achieved at least 75%
reduction in PASI score (PASI75) and treatment success on the Physician’s Global Assess-
ment (PGA). This Bayesian hierarchical bias approach can still be similarly applied and
final inference may be based on the joint posterior probabilities that these endpoints are
greater than their respective non-inferiority margins.
5.5 Appendix
5.5.1 Conditional Posterior Distribution of µ1j
In this section, we want to show how to obtain the conditional posterior distribution for µ1j
as in (5.2.10). A similar algebraic algorithm can be employed to obtain the other conditional
posterior densities for normal mean parameters.
Proof. Based on the complete likelihood function in (5.2.8), the parameter µ1j depends on
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the following components
µ1j |x1j ,x2j ∝ L(µ1j , σ21 |x1j)L(µ2j = µ1j − ξj , σ22 |x2jP (µ1j |µo1j , σ21b)
∝ exp
{
−1
2
(∑n1
i=1(µ1j − x1ji)2
σ21
+
∑n2
i=1(µ1j − (ξj + x2ji))2
σ22
+
(µ1j − µo1j)2
σ21b
)}
∝ exp
{
−1
2
(
n1µ21j − 2µ1j
∑n1
i=1 x1ji
σ21
+
n2µ21j − 2µ1j(n2ξj +
∑n2
i=1 x2ji)
σ22
+
µ21j − 2µ1jµo1j
σ21b
)}
∝ exp
−12
(
n1
σ21
+ n2
σ22
+ 1
σ21b
)µ21j − 2
(
n1x1j
σ21
+ n2(x2j+ξj)
σ22
+
µo1j
σ21b
)
(
n1
σ21
+ n2
σ22
+ 1
σ21b
) µ1j

∝ exp
−12
(
n1
σ21
+ n2
σ22
+ 1
σ21b
)µ1j −
(
n1x1j
σ21
+ n2(x2j+ξj)
σ22
+
µo1j
σ21b
)
(
n1
σ21
+ n2
σ22
+ 1
σ21b
)
2
 .
We can see that it belongs to a normal distribution with mean and variance given by
(5.2.10).
5.5.2 Conditional Posterior Distribution of σ21
In this section, we want to show how to obtain the conditional posterior distribution for
σ21 as in (5.2.14). A similar algebraic algorithm can be employed to obtain the posterior
densities for other variance parameters.
Proof. Based on the complete likelihood function in (5.2.8), the parameter σ21 depends on
the following components
σ21 |x1j ,x2j ∝
J∏
j=1
(
L(µ1j , σ21 |x1j)
(
H∏
h=1
L(µ1hj , σ21 |x1hj)
))
1
σ21
∝ 1
(σ21)
J
(
n1+
∑H
h=1
n1h
)
2 +1
exp
{
−1
2
J∑
j=1
(∑n1
i=1(µ1j − x1ji)2
σ21
+
H∑
h=1
(∑n1h
i=1 (µ1hj − x1hji)2
σ21
))}
∝ (σ21)−
J
(
n1+
∑H
h=1
n1h
)
2 −1exp
{
−
1
2
∑J
j=1
(∑n1
i=1(x1ji − µ1j)2 +
∑H
h=1
∑n1h
i=1 (x1hji − µ1hj)2
)
σ21
}
.
It can be seen that this posterior distribution takes on the form of an inverse-gamma dis-
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tribution. Simulation from this inverse-gamma distribution can be performed by simulating
from its corresponding gamma distribution with shape parameter given by J
(
n1+
∑H
h=1 n1h
)
2
and rate parameter given by 12
∑J
j=1
(∑n1
i=1(x1ji − µ1j)2 +
∑H
h=1
∑n1h
i=1(x1hji − µ1hj)2
)
and
then taking reciprocal of the simulated value.
5.6 R Codes
5.6.1 Function Codes
myvariance <- function(x){
sum((x-.Internal(mean(x)))ˆ2)/(length(x)-1)
}
plotconvgmatrix <- function(gibbssample, range, outfile) {
pdf(outfile)
par(mfrow=c(4,2), mex=0.7)
for (i in 1:ncol(gibbssample)) {
if (i < 8) { plot(range, gibbssample[range, i], type="l", col="red", ylab="value",
main=paste("Traceplot for mean of ", i, "th endpoint", sep=""))
} else if (i==8) { plot(range, gibbssample[range, i], type="l", col="red", ylab="value",
main=paste("Traceplot for variance")) }}
dev.off()
}
plotkernelmatrix <- function(gibbssample, range, outfile) {
pdf(outfile)
par(mfrow=c(4,2), mex=0.7)
for (i in 1:ncol(gibbssample)) {
if (i < 8) { plot(density(gibbssample[range, i]), col="blue", xlab="value",
main=paste("Kernel plot for mean of ", i, "th endpoint", sep=""))
} else if (i==8) { plot(density(gibbssample[range, i]), col="blue", xlab="value",
main=paste("Kernel plot for variance")) }}
dev.off()
}
gibbs <- function(xdata, nsim, outfile) {
inits <- c(rnorm(7, 0, 1000), runif(1, 0, 100000))
nn <- ncol(xdata)
writeinits <- inits
dim(writeinits) <- c(1,8)
file.con <- file(outfile,"w")
write.table(writeinits, file.con, append=T, row.names=F, col.names=F, quote=F)
lastsim <- inits
for (i in 1:nsim) {
newsim <- rnorm(7, rowMeans(xdata), sd=sqrt(lastsim[8]/nn))
newsim[8] <- 1/rgamma(1, shape=(7*nn/2), rate=((1/2)
*sum(apply((xdata - lastsim[1:7])ˆ2, 1, sum))))
writenewsim <- newsim
dim(writenewsim) <- c(1, 8)
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write.table(writenewsim, file.con, append=T, row.names=F, col.names=F, quote=F)
lastsim <- newsim
}
close(file.con)
}
calculatep <- function(meanandvar) {
probvecge <- pnorm(as.numeric(-(20-meanandvar[1:7])/(sqrt(meanandvar[8]))))
probvecst <- pnorm(as.numeric((20-meanandvar[1:7])/(sqrt(meanandvar[8]))))
pS3 <- prod(probvecge[c(3,4,5)])*prod(probvecst[c(6,7)])
+ prod(probvecge[c(3,4,6)])*prod(probvecst[c(5,7)])
+ prod(probvecge[c(3,4,7)])*prod(probvecst[c(5,6)])
+ prod(probvecge[c(3,5,6)])*prod(probvecst[c(4,7)])
+ prod(probvecge[c(3,5,7)])*prod(probvecst[c(4,6)])
+ prod(probvecge[c(4,5,6)])*prod(probvecst[c(3,7)])
+ prod(probvecge[c(4,5,7)])*prod(probvecst[c(3,6)])
+ prod(probvecge[c(5,6,7)])*prod(probvecst[c(3,4)])
+ prod(probvecge[c(3,6,7)])*prod(probvecst[c(4,5)])
+ prod(probvecge[c(4,6,7)])*prod(probvecst[c(3,5)])
pS4 <- prod(probvecge[c(4,5,6,7)])*prod(probvecst[3])
+ prod(probvecge[c(3,5,6,7)])*prod(probvecst[4])
+ prod(probvecge[c(3,4,6,7)])*prod(probvecst[5])
+ prod(probvecge[c(3,4,5,7)])*prod(probvecst[6])
+ prod(probvecge[c(3,4,5,6)])*prod(probvecst[7])
ptotal <- probvecge[1]*probvecge[2]*(pS3 + pS4 + prod(probvecge[3:7]))
return(ptotal)
}
findtheta <- function(delta, meanvec, vari) {
result <- list()
kk <- length(delta)
theta <- vector(mode="numeric",length=kk)
thetaerror <- vector(mode="numeric",length=kk)
theta_lambda <- seq(1, 60, by=0.1)
nn <- length(theta_lambda)
delta_lambda <- vector(mode="numeric",length=nn)
for (k in 1:nn) {
delta_lambda[k] <- calculatep(meanandvar=c(meanvec, vari)) -
calculatep(meanandvar=c(meanvec-theta_lambda[k], vari))
}
for (i in 1:kk) {
error <- abs(delta_lambda-delta[i])
theta[i] <- theta_lambda[which(error == min(error))]
thetaerror[i] <- min(error)
}
result$theta <- theta
result$thetaerror <- thetaerror
result$theta_lambda <- theta_lambda
result$delta_lambda <- delta_lambda
return(result)
}
acr20 <- function(vec) {
return(ifelse((vec[1]>20 & vec[2]>20 & ((vec[3]>20)+(vec[4]>20)+(vec[5]>20)
+(vec[6]>20)+(vec[7]>20))>=3), 1, 0))
}
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getpk <- function(xdata) {
txdata <- t(xdata)
return(mean(apply(txdata, 1, acr20)))
}
# for H=1 only
onetrialhier <- function(x1h, n, R, pc, triangle, lambdaf, deltaf, thetaf, p0h, p1h, n0h,
meanvec1h, thetafactual, var1, var2, nsim, plotconvg) {
result <- list()
result$true.x1h.means <- meanvec1h
meanfor1 <- meanvec1h + triangle
result$true.x1.means <- meanfor1
meanfor2 <- meanfor1 - thetafactual
result$true.x2.means <- meanfor2
result$delta <- deltaf
result$thetas <- c(thetaf, thetafactual)
n1 <- n/(1+R)
n2 <- n*R/(1+R)
n1h <- ncol(x1h)
range <- (ceiling(0.1*nsim)):nsim
result$no.iterations.used <- length(range)
x1 <- matrix(rnorm(7*n1, meanfor1, sqrt(var1)), c(7,n1), byrow=F)
result$observed.x1.means <- rowMeans(x1)
freqp1 <- getpk(x1)
result$observed.freq.p1 <- freqp1
x2 <- matrix(rnorm(7*n2, meanfor2, sqrt(var2)), c(7,n2), byrow=F)
result$observed.x2.means <- rowMeans(x2)
freqp2 <- getpk(x2)
result$observed.freq.p2 <- freqp2
mu1ogibbs <- matrix(data=NA, nrow=nsim+1, ncol=7)
mu1hgibbs <- matrix(data=NA, nrow=nsim+1, ncol=7)
mu1gibbs <- matrix(data=NA, nrow=nsim+1, ncol=7)
biasgibbs <- matrix(data=NA, nrow=nsim+1, ncol=7)
vargibbs <- matrix(data=NA, nrow=nsim+1, ncol=4)
lastmu1o <- rnorm(7, 0, 1000)
lastmu1h <- rnorm(7, 0, 1000)
lastmu1 <- rnorm(7, 0, 1000)
lastbias <- rnorm(7, 0, 1000)
lastvar <- runif(4, 0, 100000)
mu1ogibbs[1,] <- lastmu1o
mu1hgibbs[1,] <- lastmu1h
mu1gibbs[1,] <- lastmu1
biasgibbs[1,] <- lastbias
vargibbs[1,] <- lastvar
x1hmean <- rowMeans(x1h)
x1mean <- rowMeans(x1)
x2mean <- rowMeans(x2)
for (i in 1:nsim) {
newmu1o <- rnorm(7, mean=(lastmu1+lastmu1h)/2, sd=sqrt(lastvar[3]/2))
newmu1h <- rnorm(7, mean=(1/((n1h/lastvar[1])+(1/lastvar[3])))
*((n1h*x1hmean/lastvar[1])+(lastmu1o/lastvar[3])),
sd=sqrt(1/((n1h/lastvar[1])+(1/lastvar[3]))))
newmu1 <- rnorm(7, mean=(1/((n1/lastvar[1])+(n2/lastvar[2])+(1/lastvar[3])))
*((n1*x1mean/lastvar[1])+((n2*(x2mean+lastbias))/lastvar[2])
+(lastmu1o/lastvar[3])),
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sd=sqrt(1/((n1/lastvar[1])+(n2/lastvar[2])+(1/lastvar[3]))))
newbias <- rnorm(7, mean=(1/((n2/lastvar[2])+(1/lastvar[4])))
*(((n2*(lastmu1-x2mean))/lastvar[2])+(thetaf/lastvar[4])),
sd=sqrt(1/((n2/lastvar[2])+(1/lastvar[4]))))
shapes <- c(7*(n1+n1h)/2, 7*n2/2, 7*2/2, 7/2)
rates <- c(0.5*(sum(rowSums((x1h-lastmu1h)ˆ2))+sum(rowSums((x1-lastmu1)ˆ2))),
0.5*sum(rowSums((x2-(lastmu1-lastbias))ˆ2)),
0.5*(sum((lastmu1-lastmu1o)ˆ2)+sum((lastmu1h-lastmu1o)ˆ2)),
0.5*sum((lastbias-thetaf)ˆ2))
newvar <- 1/rgamma(4, shape=shapes, rate=rates)
mu1ogibbs[i+1,] <- newmu1o
mu1hgibbs[i+1,] <- newmu1h
mu1gibbs[i+1,] <- newmu1
biasgibbs[i+1,] <- newbias
vargibbs[i+1,] <- newvar
lastmu1o <- newmu1o
lastmu1h <- newmu1h
lastmu1 <- newmu1
lastbias <- newbias
lastvar <- newvar
}
mu2gibbs <- mu1gibbs - biasgibbs
forp1gibbs <- cbind(mu1gibbs, vargibbs[,1])
forp2gibbs <- cbind(mu2gibbs, vargibbs[,2])
result$gibbs.mu1o.means <- colMeans(mu1ogibbs[range,])
result$gibbs.var.1o <- apply(mu1ogibbs[range,], 2, myvariance)
result$gibbs.mu1.means <- colMeans(mu1gibbs[range,])
result$gibbs.mu2.means <- colMeans(mu2gibbs[range,])
result$gibbs.bias.means <- colMeans(biasgibbs[range,])
result$gibbs.var1.var2.var1b.varbias.means <- colMeans(vargibbs[range,])
# optional assessment of convergence for mu2gibbs, j=1
if (plotconvg==1) {
plot(range, mu2gibbs[range, 1], type="l")
plot(density(mu2gibbs[range, 1], na.rm=T)) }
p1 <- apply(forp1gibbs, 1, calculatep)
p2 <- apply(forp2gibbs, 1, calculatep)
Ip2.p1 <- ifelse(p2-p1 > -deltaf, 1, 0)
p1 <- p1[range]
p2 <- p2[range]
result$bay.p1.mean <- .Internal(mean(p1))
result$bay.p2.mean <- .Internal(mean(p2))
result$bay.p2.p1.diff.mean <- .Internal(mean(p2-p1))
obspc <- .Internal(mean(Ip2.p1[range]))
result$obs.prob.decision <- obspc
if (is.na(obspc)==0 & obspc > pc) {baysuccess <- 1
} else if (is.na(obspc)==0 & obspc <= pc) {baysuccess <- 0
} else if (is.na(obspc)==1) {baysuccess <- NA}
result$bay.success <- baysuccess
# only explore alpha/2 = 0.025 for one-sided test
if ((freqp2-freqp1-qnorm(0.975)*sqrt((freqp2*(1-freqp2)/n2)+(freqp1*(1-freqp1)/n1))) >
-(1-lambdaf)*(p1h-p0h-qnorm(0.975)*sqrt((p1h*(1-p1h)/n1h)+(p0h*(1-p0h)/n0h)))) {freqsuccess <- 1
} else {freqsuccess <- 0}
result$freq.success <- freqsuccess
return(result)
}
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probrejectnullhier <- function(x1h, n, R, pc, triangle, lambdaf, deltaf, thetaf, p0h, p1h, n0h,
meanvec1h, thetafactual, var1, var2, nsim, plotconvg, nsimtrial) {
result <- list()
obspc <- rep(NA, nsimtrial)
baytype1 <- rep(NA, nsimtrial)
freqtype1 <- rep(NA, nsimtrial)
for (k in 1:nsimtrial) {
onetrial <- onetrialhier(x1h=x1h, n=n, R=R, pc=pc, triangle=triangle,
lambdaf=lambdaf, deltaf=deltaf, thetaf=thetaf,
p0h=p0h, p1h=p1h, n0h=n0h,
meanvec1h=meanvec1h, thetafactual=thetafactual,
var1=var1, var2=var2, nsim=nsim, plotconvg=0)
obspc[k] <- onetrial$obs.prob.decision
baytype1[k] <- onetrial$bay.success
freqtype1[k] <- onetrial$freq.success
}
result$obspc <- obspc
result$baytype1 <- baytype1
result$freqtype1 <- freqtype1
result$baysuccesssum <- sum(baytype1, na.rm=T)
result$baytype1error <- mean(baytype1, na.rm=T)
result$freqtype1error <- mean(freqtype1, na.rm=T)
return(result)
}
# for H=1 only
onetrialhier2stage <- function(x1h, ns1, ns2, R, pc1, pc2, gammaf=0.9, triangle, lambdaf, deltaf,
thetaf, p0h, p1h, n0h, meanvec1h, thetafactual, var1, var2, nsim, plotconvg) {
result <- list()
result$true.x1h.means <- meanvec1h
meanfor1 <- meanvec1h + triangle
result$true.x1.means <- meanfor1
meanfor2 <- meanfor1 - thetafactual
result$true.x2.means <- meanfor2
result$delta <- deltaf
result$thetas <- c(thetaf, thetafactual)
ns11 <- ns1/(1+R)
ns12 <- ns1*R/(1+R)
ns21 <- ns2/(1+R)
ns22 <- ns2*R/(1+R)
n1h <- ncol(x1h)
range <- (ceiling(0.1*nsim)):nsim
result$no.iterations.used <- length(range)
x1 <- matrix(rnorm(7*(ns11+ns21), meanfor1, sqrt(var1)), c(7, (ns11+ns21)), byrow=F)
result$observed.x1.means <- rowMeans(x1)
freqp1 <- getpk(x1)
result$observed.freq.p1 <- freqp1
result$obs.freq.p1.stg1.stg2 <- c(getpk(x1[,1:ns11]), freqp1)
x2 <- matrix(rnorm(7*(ns12+ns22), meanfor2, sqrt(var2)), c(7, (ns12+ns22)), byrow=F)
result$observed.x2.means <- rowMeans(x2)
freqp2 <- getpk(x2)
result$observed.freq.p2 <- freqp2
result$obs.freq.p2.stg1.stg2 <- c(getpk(x2[,1:ns12]), freqp2)
lastmu1o <- rnorm(7, 0, 1000)
lastmu1h <- rnorm(7, 0, 1000)
lastmu1 <- rnorm(7, 0, 1000)
lastbias <- rnorm(7, 0, 1000)
lastvar <- runif(4, 0, 1000)
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YNpred <- rep(NA, nsim)
x1hmean <- rowMeans(x1h)
x1mean <- rowMeans(x1[,1:ns11])
x2mean <- rowMeans(x2[,1:ns12])
for (i in 1:nsim) {
newmu1o <- rnorm(7, mean=(lastmu1+lastmu1h)/2, sd=sqrt(lastvar[3]/2))
newmu1h <- rnorm(7, mean=(1/((n1h/lastvar[1])+(1/lastvar[3])))
*((n1h*x1hmean/lastvar[1])+(lastmu1o/lastvar[3])),
sd=sqrt(1/((n1h/lastvar[1])+(1/lastvar[3]))))
newmu1 <- rnorm(7, mean=(1/((ns11/lastvar[1])+(ns12/lastvar[2])+(1/lastvar[3])))
*((ns11*x1mean/lastvar[1])+((ns12*(x2mean+lastbias))/lastvar[2])
+(lastmu1o/lastvar[3])),
sd=sqrt(1/((ns11/lastvar[1])+(ns12/lastvar[2])+(1/lastvar[3]))))
newbias <- rnorm(7, mean=(1/((ns12/lastvar[2])+(1/lastvar[4])))
*(((ns12*(lastmu1-x2mean))/lastvar[2])+(thetaf/lastvar[4])),
sd=sqrt(1/((ns12/lastvar[2])+(1/lastvar[4]))))
newmu2 <- newmu1 - newbias
shapes <- c(7*(ns11+n1h)/2, 7*ns12/2, 7*2/2, 7/2)
rates <- c( 0.5*(sum(rowSums((x1h-lastmu1h)ˆ2))+sum(rowSums((x1[,1:ns11]-lastmu1)ˆ2))),
0.5*sum(rowSums((x2[,1:ns12]-(lastmu1-lastbias))ˆ2)),
0.5*(sum((lastmu1-lastmu1o)ˆ2)+sum((lastmu1h-lastmu1o)ˆ2)),
0.5*sum((lastbias-thetaf)ˆ2))
newvar <- 1/rgamma(4, shape=shapes, rate=rates)
newmu1vec <- sapply(newmu1, function(x) rep(x, ns21))
x1predict <- matrix(rnorm(7*ns21, newmu1vec, sqrt(newvar[1])), c(7, ns21), byrow=T)
x1comb <- cbind(x1[,1:ns11], x1predict)
newmu2vec <- sapply(newmu2, function(x) rep(x, ns22))
x2predict <- matrix(rnorm(7*ns22, newmu2vec, sqrt(newvar[2])), c(7, ns22), byrow=T)
x2comb <- cbind(x2[,1:ns12], x2predict)
pnewmu1vec <- (1/(((ns11+ns21)/newvar[1])+((ns12+ns22)/newvar[2])+(1/newvar[3])))
*(((ns11+ns21)*rowMeans(x1comb)/newvar[1])+(((ns12+ns22)
*(rowMeans(x2comb)+newbias))/newvar[2])+(newmu1o/newvar[3]))
pnewmu1 <- t(matrix(rnorm(7*1000, pnewmu1vec, sqrt(1/(((ns11+ns21)/newvar[1])
+((ns12+ns22)/newvar[2])+(1/newvar[3])))), c(7, 1000), byrow=F))
pnewbiasvec <- (1/(((ns12+ns22)/newvar[2])+(1/newvar[4])))
*((((ns12+ns22)*(newmu1-rowMeans(x2comb)))/newvar[2])+(thetaf/newvar[4]))
pnewbias <- t(matrix(rnorm(7*1000, pnewbiasvec, sqrt(1/(((ns12+ns22)/newvar[2])
+(1/newvar[4])))), c(7, 1000), byrow=F))
pnewmu2 <- pnewmu1 - pnewbias
pnewvar <- matrix(rep(NA, 2*1000), nrow=1000)
pnewvar[,1] <- 1/rgamma(1000, shape=(7*(ns11+ns21+n1h)/2),
rate=(1/2)*(sum(rowSums((x1h-newmu1h)ˆ2))+ sum(rowSums((x1comb-newmu1)ˆ2))))
pnewvar[,2] <- 1/rgamma(1000, shape=(7*(ns12+ns22)/2),
rate=(1/2)*(sum(rowSums((x2comb-(newmu1-newbias))ˆ2))))
lastmu1o <- newmu1o
lastmu1h <- newmu1h
lastmu1 <- newmu1
lastbias <- newbias
lastvar <- newvar
lastmu2 <- newmu2
predp1 <- apply(cbind(pnewmu1, pnewvar[,1]), 1, calculatep)
predp2 <- apply(cbind(pnewmu2, pnewvar[,2]), 1, calculatep)
predIp2.p1 <- ifelse(predp2-predp1 > -deltaf, 1, 0)
YNpred[i] <- mean(predIp2.p1, na.rm=T) > gammaf
}
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obspc1 <- mean(YNpred, na.rm=T)
result$pred.obs.prob.decision <- obspc1
if (is.na(obspc1)==0 & obspc1 > pc1) {baysuccess1 <- 1
} else if (is.na(obspc1)==0 & obspc1 <= pc1) {baysuccess1 <- 0
} else if (is.na(obspc1)==1) {baysuccess1 <- NA}
result$bay.success1 <- baysuccess1
mu1ogibbs <- matrix(data=NA, nrow=nsim+1, ncol=7)
mu1hgibbs <- matrix(data=NA, nrow=nsim+1, ncol=7)
mu1gibbs <- matrix(data=NA, nrow=nsim+1, ncol=7)
biasgibbs <- matrix(data=NA, nrow=nsim+1, ncol=7)
vargibbs <- matrix(data=NA, nrow=nsim+1, ncol=4)
lastmu1o <- rnorm(7, 0, 1000)
lastmu1h <- rnorm(7, 0, 1000)
lastmu1 <- rnorm(7, 0, 1000)
lastbias <- rnorm(7, 0, 1000)
lastvar <- runif(4, 0, 100000)
mu1ogibbs[1,] <- lastmu1o
mu1hgibbs[1,] <- lastmu1h
mu1gibbs[1,] <- lastmu1
biasgibbs[1,] <- lastbias
vargibbs[1,] <- lastvar
x1hmean <- rowMeans(x1h)
x1mean <- rowMeans(x1)
x2mean <- rowMeans(x2)
for (i in 1:nsim) {
newmu1o <- rnorm(7, mean=(lastmu1+lastmu1h)/2, sd=sqrt(lastvar[3]/2))
newmu1h <- rnorm(7, mean=(1/((n1h/lastvar[1])+(1/lastvar[3])))*((n1h*x1hmean/lastvar[1])
+(lastmu1o/lastvar[3])), sd=sqrt(1/((n1h/lastvar[1])+(1/lastvar[3]))))
newmu1 <- rnorm(7, mean=(1/(((ns11+ns21)/lastvar[1])+((ns12+ns22)/lastvar[2])+(1/lastvar[3])))
*(((ns11+ns21)*x1mean/lastvar[1])+(((ns12+ns22)*(x2mean+lastbias))/lastvar[2])
+(lastmu1o/lastvar[3])), sd=sqrt(1/(((ns11+ns21)/lastvar[1])
+((ns12+ns22)/lastvar[2])+(1/lastvar[3]))))
newbias <- rnorm(7, mean=(1/(((ns12+ns22)/lastvar[2])+(1/lastvar[4])))*((((ns12+ns22)
*(lastmu1-x2mean))/lastvar[2])+(thetaf/lastvar[4])),
sd=sqrt(1/(((ns12+ns22)/lastvar[2])+(1/lastvar[4]))))
shapes <- c(7*(ns11+ns21+n1h)/2, 7*(ns12+ns22)/2, 7*2/2, 7/2)
rates <- c( 0.5*(sum(rowSums((x1h-lastmu1h)ˆ2))+sum(rowSums((x1-lastmu1)ˆ2))),
0.5*sum(rowSums((x2-(lastmu1-lastbias))ˆ2)),
0.5*(sum((lastmu1-lastmu1o)ˆ2)+sum((lastmu1h-lastmu1o)ˆ2)),
0.5*sum((lastbias-thetaf)ˆ2))
newvar <- 1/rgamma(4, shape=shapes, rate=rates)
mu1ogibbs[i+1,] <- newmu1o
mu1hgibbs[i+1,] <- newmu1h
mu1gibbs[i+1,] <- newmu1
biasgibbs[i+1,] <- newbias
vargibbs[i+1,] <- newvar
lastmu1o <- newmu1o
lastmu1h <- newmu1h
lastmu1 <- newmu1
lastbias <- newbias
lastvar <- newvar
}
mu2gibbs <- mu1gibbs - biasgibbs
forp1gibbs <- cbind(mu1gibbs, vargibbs[,1])
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forp2gibbs <- cbind(mu2gibbs, vargibbs[,2])
result$gibbs.mu1o.means <- colMeans(mu1ogibbs[range,])
result$gibbs.var.1o <- apply(mu1ogibbs[range,], 2, myvariance)
result$gibbs.mu1.means <- colMeans(mu1gibbs[range,])
result$gibbs.mu2.means <- colMeans(mu2gibbs[range,])
result$gibbs.bias.means <- colMeans(biasgibbs[range,])
result$gibbs.var1.var2.var1b.varbias.means <- colMeans(vargibbs[range,])
if (plotconvg==1) {
plot(range, mu2gibbs[range, 1], type="l")
plot(density(mu2gibbs[range, 1], na.rm=T))}
p1 <- apply(forp1gibbs, 1, calculatep)
p2 <- apply(forp2gibbs, 1, calculatep)
Ip2.p1 <- ifelse(p2-p1 > -deltaf, 1, 0)
p1 <- p1[range]
p2 <- p2[range]
result$p1.mean <- .Internal(mean(p1))
result$p2.mean <- .Internal(mean(p2))
result$p2.p1.diff.mean <- .Internal(mean(p2-p1))
obspc2 <- mean(Ip2.p1[range])
result$obs.prob.decision <- obspc2
if (is.na(obspc2)==0 & obspc2 > pc2) {baysuccess2 <- 1
} else if (is.na(obspc2)==0 & obspc2 <= pc2) {baysuccess2 <- 0
} else if (is.na(obspc2)==1) {baysuccess2 <- NA}
result$bay.success2 <- baysuccess2
if ((freqp2-freqp1-qnorm(0.975)*sqrt((freqp2*(1-freqp2)/(ns12+ns22))
+(freqp1*(1-freqp1)/(ns11+ns21)))) > -(1-lambdaf)*(p1h-p0h-qnorm(0.975)
*sqrt((p1h*(1-p1h)/n1h)+(p0h*(1-p0h)/n0h)))) {freqsuccess <- 1
} else {freqsuccess <- 0}
result$freq.success <- freqsuccess
return(result)
}
probrejectnull2stage <- function(x1h, ns1, ns2, R, pc1, pc2, gammaf=0.9, triangle, lambdaf,
deltaf, thetaf, p0h, p1h, n0h, meanvec1h, thetafactual, var1, var2, nsim, plotconvg, nsimtrial) {
result <- list()
baytype1stg1 <- rep(NA, nsimtrial)
baytype1stg2 <- rep(NA, nsimtrial)
freqtype1 <- rep(NA, nsimtrial)
for (k in 1:nsimtrial) {
onetrial <- onetrialhier2stage(x1h=x1h, ns1=ns1, ns2=ns2, R=R, pc1=pc1, pc2=pc2,
gammaf=0.9, triangle=triangle, lambdaf=lambdaf, deltaf=deltaf, thetaf=thetaf, p0h=p0h,
p1h=p1h, n0h=n0h, meanvec1h=meanvec1h, thetafactual=thetafactual, var1=var1, var2=var2,
nsim=nsim, plotconvg=0)
baytype1stg1[k] <- onetrial$bay.success1
baytype1stg2[k] <- onetrial$bay.success2
freqtype1[k] <- onetrial$freq.success
}
result$baytype1stg1 <- baytype1stg1
result$baytype1stg2 <- baytype1stg2
result$baytype1sum <- baytype1stg1+baytype1stg2
result$baytype1error <- mean(baytype1stg1+baytype1stg2 > 0, na.rm=T)
result$expsamplesize <- (mean(baytype1stg1, na.rm=T))*ns1
+(1-(mean(baytype1stg1, na.rm=T)))*(ns1+ns2)
result$freqtype1error <- mean(freqtype1, na.rm=T)
return(result)
}
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5.6.2 Analysis Codes
# simulation setting
mu0h <- c(6, -7, 2, -3, -22, 2, -207)
mu1h <- c(56, 47, 44, 46, 53, 39, 31)
var0h <- 1600
var1h <- 1600
var1 <- 1600
var2 <- 1600
n0h <- 80
n1h <- 78
n <- c(60, 120)
R <- c(1, 2)
lambda <- c(0, 0.25, 0.5)
nsim <- 3000
nsimtrial <- 10000
range <- (ceiling(0.1*nsim)):nsim
# simulate historical trial
x0h <- matrix(rnorm(7*n0h, mu0h, sqrt(var0h)), c(7, n0h), byrow=F)
write.table(x0h, "x0h.txt", row.names=F, col.names=F, quote=F)
rowMeans(x0h)
px0h <- getpk(x0h)
px0h
x1h <- matrix(rnorm(7*n1h, mu1h, sqrt(var1h)), c(7, n1h), byrow=F)
write.table(x1h, "x1h.txt", row.names=F, col.names=F, quote=F)
rowMeans(x1h)
px1h <- getpk(x1h)
px1h
freqnimargin <- (px1h-px0h-qnorm(0.975)*sqrt((px1h*(1-px1h)/n1h)+(px0h*(1-px0h)/n0h)))
write.table(cbind(px0h, px1h, freqnimargin), "px0hpx1h.txt", quote=F, row.names=F, col.names=T)
px0hpx1h <- read.table("px0hpx1h.txt", header=T)
# determining non-inferiority margins, deltas
gibbs(xdata=x0h, nsim=nsim, outfile="x0hgibbs.txt")
gibbs(xdata=x1h, nsim=nsim, outfile="x1hgibbs.txt")
# producing trace plots and kernel plots
x0hgibbs <- read.table("x0hgibbs.txt", header=F); dim(x0hgibbs)
plotconvgmatrix(gibbssample=x0hgibbs, range=3:3000, outfile="traceplots0h.pdf")
plotkernelmatrix(gibbssample=x0hgibbs, range=range, outfile="kernelplots0h.pdf")
x1hgibbs <- read.table("x1hgibbs.txt", header=F); dim(x1hgibbs)
plotconvgmatrix(gibbssample=x1hgibbs, range=3:3000, outfile="traceplots1h.pdf")
plotkernelmatrix(gibbssample=x1hgibbs, range=range, outfile="kernelplots1h.pdf")
x0hgibbsmean <- colMeans(x0hgibbs[range,]); x0hgibbsmean
x1hgibbsmean <- colMeans(x1hgibbs[range,]); x1hgibbsmean
x1hmeans <- rowMeans(x1h)
x1hvar <- ((1/2)*sum(rowSums((x1h - x1hmeans)ˆ2)))/(((7*n1h)/2)-1)
x1hgibbsmean2 <- c(x1hmeans, x1hvar)
x1hgibbsmean2
dim(x1hgibbsmean2) <- c(1,8)
write.table(x1hgibbsmean2, "x1hgibbsmean.txt", quote=F, col.names=F, row.names=F)
p0h <- apply(x0hgibbs[range,], 1, calculatep); mean(p0h)
p1h <- apply(x1hgibbs[range,], 1, calculatep); mean(p1h)
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diffp01h <- p1h - p0h
mean(diffp01h)
pdf("histoprobdiff.pdf")
plot(density(diffp01h), main="Kernel plot of historial prob diff", xlab="p2-p1")
dev.off()
delta <- quantile(diffp01h, 0.025)
delta
nimargins <- delta*(1-lambda)
nimargins
# find corresponding thetas
gettheta <- findtheta(delta=nimargins, meanvec=mu1h, vari=var1h)
gettheta$theta
gettheta$thetaerror
margins <- cbind(rep(delta, length(lambda)), lambda, nimargins, gettheta$theta)
margins <- data.frame(margins)
names(margins) <- c("lowbound", "lambda", "delta", "theta")
margins
write.table(margins, "margins.txt", quote=F, col.names=T)
# figure of type 1 error vs triangle
n <- rep(60, 15)
R <- rep(1, 15)
pc <- rep(0.95, 15)
better <- c(-seq(2.8, 0.4, length=7), 0, seq(0.4, 2.8, length=7))
lambdaf <- rep(lambda[1], 15)
deltaf <- rep(margins$delta[1], 15)
thetaf <- rep(margins$theta[1], 15)
frame4inflat <- cbind(n, R, pc, better, lambdaf, deltaf, thetaf)
frame4inflat
write.table(frame4inflat, "frame4inflat.txt", quote=F, col.names=T, row.names=F)
frame4inflat <- read.table("frame4inflat.txt", header=T)
class(frame4inflat)
baytype1err <- rep(NA, length=nrow(frame4inflat))
freqtype1err <- rep(NA, length=nrow(frame4inflat))
file.con <- file("checkinflat.txt", "w")
for (s in 1:nrow(frame4inflat)) {
value <- probrejectnullhier(x1h=x1h, n=frame4inflat[s,1], R=frame4inflat[s,2],
pc=frame4inflat[s,3], triangle=frame4inflat[s,4],
lambdaf=frame4inflat[s,5], deltaf=frame4inflat[s,6],
thetaf=frame4inflat[s,7], p0h=px0hpx1h[1], p1h=px0hpx1h[2],
n0h=n0h, meanvec1h=mu1h, thetafactual=frame4inflat[s,7], var1=1600,
var2=1600, nsim=nsim, plotconvg=0, nsimtrial=nsimtrial)
check <- c(s, value$baytype1error, value$freqtype1error )
dim(check) <- c(1,3)
write.table(check, file.con, quote=F, row.names=F, col.names=F, append=T)
baytype1err[s] <- value$baytype1error
freqtype1err[s] <- value$freqtype1error
}
close(file.con)
frame4inflat$baytype1error <- baytype1err
frame4inflat$freqtype1error <- freqtype1err
frame4inflat
write.csv(frame4inflat, "frame4inflat.csv", quote=F, row.names=F)
inflat <- read.csv("frame4inflat.csv", header=T)
pdf("inflated.pdf")
plot(inflat$better, inflat$baytype1error, cex=0.7, type="b",
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main="Type 1 error by mean endpoint difference",
xlab=expression(paste(mu, "1j - ", mu, "1hj")), ylab="Type 1 error")
abline(h=0.025, col="blue")
lines(inflat$better, inflat$freqtype1error, cex=0.7, type="b", pch=3)
legend(1.5, 0.13, c("Bayesian", "Frequentist"), pch=c(1,3))
dev.off()
# table of type 1 error
n <- c(rep(60, 36), rep(120, 36))
R <- rep(c(rep(1, 18), rep(2, 18)), time=2)
pc <- rep(c(rep(0.95, 9), rep(0.975, 9)), time=4)
triangle <- rep(c(rep(-2, 3), rep(0, 3), rep(2, 3)), time=8)
lambdaf <- rep(lambda, time=24)
deltaf <- rep(margins$delta, time=24)
thetaf <- rep(margins$theta, time=24)
frame4type1 <- cbind(n, R, pc, triangle, lambdaf, deltaf, thetaf)
frame4type1
write.table(frame4type1, "frame4type1.txt", quote=F, col.names=T, row.names=F)
frame4type1 <- read.table("frame4type1.txt", header=T)
class(frame4type1)
baytype1err <- rep(NA, length=nrow(frame4type1))
freqtype1err <- rep(NA, length=nrow(frame4type1))
file.con <- file("checktype1.txt", "w")
for (s in 1:nrow(frame4type1)) {
value <- probrejectnullhier(x1h=x1h, n=frame4type1[s,1], R=frame4type1[s,2],
pc=frame4type1[s,3], triangle=frame4type1[s,4], lambdaf=frame4type1[s,5],
deltaf=frame4type1[s,6], thetaf=frame4type1[s,7], p0h=px0hpx1h[1],
p1h=px0hpx1h[2], n0h=n0h, meanvec1h=mu1h,
thetafactual=frame4type1[s,7], var1=1600, var2=1600, nsim=nsim,
plotconvg=0, nsimtrial=nsimtrial)
check <- c(s, value$baytype1error, value$freqtype1error )
dim(check) <- c(1,3)
write.table(check, file.con, quote=F, row.names=F, col.names=F, append=T)
baytype1err[s] <- value$baytype1error
freqtype1err[s] <- value$freqtype1error
}
close(file.con)
frame4type1$baytype1error <- baytype1err
frame4type1$freqtype1error <- freqtype1err
frame4type1
write.csv(frame4type1, "frame4type1final.csv", quote=F, row.names=F)
# table of power
# find corresponding thetas for half of the deltas under alternative
getthetahalf <- findtheta(delta=margins$delta*0.5, meanvec=mu1h, vari=var1h)
getthetahalf$thetaerror
getthetahalf <- getthetahalf$theta
n <- c(rep(60, 36), rep(120, 36))
R <- rep(c(rep(1, 18), rep(2, 18)), time=2)
pc <- rep(c(rep(0.95, 9), rep(0.975, 9)), time=4)
triangle <- rep(c(rep(-2, 3), rep(0, 3), rep(2, 3)), time=8)
lambdaf <- rep(lambda, time=24)
deltaf <- rep(margins$delta, time=24)
thetaf <- rep(margins$theta, time=24)
Ha_deltahalf <- rep(margins$delta*0.5, time=24)
Ha_thetahalf <- rep(getthetahalf, time=24)
Ha_deltazero <- rep(rep(0,3), time=24)
Ha_thetazero <- rep(rep(0,3), time=24)
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frame4power <- cbind(n, R, pc, triangle, lambdaf, deltaf, thetaf, Ha_deltahalf,
Ha_thetahalf, Ha_deltazero, Ha_thetazero)
frame4power
write.table(frame4power, "frame4power.txt", quote=F, col.names=T, row.names=F)
frame4power <- read.table("frame4power.txt", header=T)
class(frame4power)
baypowerhalf <- rep(NA, length=nrow(frame4power))
freqpowerhalf <- rep(NA, length=nrow(frame4power))
file.con <- file("checkpowerhalf.txt", "w")
for (s in 1:nrow(frame4power)) {
value <- probrejectnullhier(x1h=x1h, n=frame4power[s,1], R=frame4power[s,2],
pc=frame4power[s,3], triangle=frame4power[s,4],
lambdaf=frame4power[s,5], deltaf=frame4power[s,6],
thetaf=frame4power[s,7], p0h=px0hpx1h[1], p1h=px0hpx1h[2],
n0h=n0h, meanvec1h=mu1h, thetafactual=frame4power[s,9], var1=1600,
var2=1600, nsim=nsim, plotconvg=0, nsimtrial=nsimtrial)
check <- c(s, value$baytype1error, value$freqtype1error)
dim(check) <- c(1,3)
write.table(check, file.con, quote=F, row.names=F, col.names=F, append=T)
baypowerhalf[s] <- value$baytype1error
freqpowerhalf[s] <- value$freqtype1error
}
close(file.con)
frame4power$baypowerhalf <- baypowerhalf
frame4power$freqpowerhalf <- freqpowerhalf
frame4power
baypowerzero <- rep(NA, length=nrow(frame4power))
freqpowerzero <- rep(NA, length=nrow(frame4power))
file.con <- file("checkpowerzero.txt", "w")
for (s in 1:nrow(frame4power)) {
value <- probrejectnullhier(x1h=x1h, n=frame4power[s,1], R=frame4power[s,2],
pc=frame4power[s,3], triangle=frame4power[s,4],
lambdaf=frame4power[s,5], deltaf=frame4power[s,6],
thetaf=frame4power[s,7], p0h=px0hpx1h[1], p1h=px0hpx1h[2],
n0h=n0h, meanvec1h=mu1h, thetafactual=frame4power[s,11],
var1=1600, var2=1600, nsim=nsim, plotconvg=0, nsimtrial=nsimtrial)
check <- c(s, value$baytype1error, value$freqtype1error)
dim(check) <- c(1,3)
write.table(check, file.con, quote=F, row.names=F, col.names=F, append=T)
baypowerzero[s] <- value$baytype1error
freqpowerzero[s] <- value$freqtype1error
}
close(file.con)
frame4power$baypowerzero <- baypowerzero
frame4power$freqpowerzero <- freqpowerzero
frame4power
write.csv(frame4power, "frame4powerfinal.csv", row.names=F, quote=F)
# table of two-stage
n <- rep(120, 6)
ns1 <- rep(90, 6) # make sure ns1 and ns2 is divisible by (1+R)
ns2 <- rep(30, 6)
R <- rep(c(1,2), time=3)
pc1 <- rep(0.98, 6)
pc2 <- rep(0.95, 6)
triangle <- rep(c(rep(-2, 2), rep(0, 2), rep(2, 2)), time=1)
lambdaf <- rep(lambda[3], time=6)
deltaf <- rep(margins$delta[3], time=6)
thetaf <- rep(margins$theta[3], time=6)
Ha_deltahalf <- rep(margins$delta[3]*0.5, time=6)
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Ha_thetahalf <- rep(getthetahalf[3], time=6)
Ha_deltazero <- rep(0, time=6)
Ha_thetazero <- rep(0, time=6)
frame <- cbind(n, ns1, ns2, R, pc1, pc2, triangle, lambdaf, deltaf, thetaf,
Ha_deltahalf, Ha_thetahalf, Ha_deltazero, Ha_thetazero)
frame
write.table(frame, "frame4twostage.txt", quote=F, col.names=T, row.names=F)
frame <- read.table("frame4twostage.txt", header=T)
class(frame)
baytype1err <- rep(NA, length=nrow(frame))
freqtype1err <- rep(NA, length=nrow(frame))
expsstype1err <- rep(NA, length=nrow(frame))
file.con <- file("check2stagetype1.txt", "w")
for (s in 1:nrow(frame)) {
value <- probrejectnull2stage(x1h=x1h, ns1=frame[s,2], ns2=frame[s,3], R=frame[s,4],
pc1=frame[s,5], pc2=frame[s,6], gammaf=0.9, triangle=frame[s,7],
lambdaf=frame[s,8], deltaf=frame[s,9], thetaf=frame[s,10],
p0h=px0hpx1h[1], p1h=px0hpx1h[2], n0h=n0h, meanvec1h=mu1h,
thetafactual=frame[s,10], var1=1600, var2=1600, nsim=nsim,
plotconvg=0, nsimtrial=nsimtrial)
check <- c(s, value$baytype1error, value$freqtype1error, value$expsamplesize)
dim(check) <- c(1,4)
write.table(check, file.con, quote=F, row.names=F, col.names=F, append=T)
baypowerhalf[s] <- value$baytype1error
freqpowerhalf[s] <- value$freqtype1error
expsshalf[s] <- value$expsamplesize
}
close(file.con)
frame$baytype1error <- baytype1err
frame$freqtype1error <- freqtype1err
frame$expsstype1err <- expsstype1err
frame
write.csv(frame, "frame2stagetype1final.csv", quote=F, row.names=F)
baypowerhalf <- rep(NA, length=nrow(frame))
freqpowerhalf <- rep(NA, length=nrow(frame))
expsshalf <- rep(NA, length=nrow(frame))
file.con <- file("check2stagehalf.txt", "w")
for (s in 1:nrow(frame)) {
value <- probrejectnull2stage(x1h=x1h, ns1=frame[s,2], ns2=frame[s,3], R=frame[s,4],
pc1=frame[s,5], pc2=frame[s,6], gammaf=0.9, triangle=frame[s,7],
lambdaf=frame[s,8], deltaf=frame[s,9], thetaf=frame[s,10], p0h=px0hpx1h[1],
p1h=px0hpx1h[2], n0h=n0h, meanvec1h=mu1h, thetafactual=frame[s,12],
var1=1600, var2=1600, nsim=nsim, plotconvg=0, nsimtrial=nsimtrial)
check <- c(s, value$baytype1error, value$freqtype1error, value$expsamplesize)
dim(check) <- c(1,4)
write.table(check, file.con, quote=F, row.names=F, col.names=F, append=T)
baypowerhalf[s] <- value$baytype1error
freqpowerhalf[s] <- value$freqtype1error
expsshalf[s] <- value$expsamplesize
}
close(file.con)
frame$baypowerhalf <- baypowerhalf
frame$freqpowerhalf <- freqpowerhalf
frame$expsshalf <- expsshalf
frame
baypowerzero <- rep(NA, length=nrow(frame))
freqpowerzero <- rep(NA, length=nrow(frame))
expsszero <- rep(NA, length=nrow(frame))
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file.con <- file("check2stagezero.txt", "w")
for (s in 1:nrow(frame)) {
value <- probrejectnull2stage(x1h=x1h, ns1=frame[s,2], ns2=frame[s,3], R=frame[s,4],
pc1=frame[s,5], pc2=frame[s,6], gammaf=0.9, triangle=frame[s,7],
lambdaf=frame[s,8], deltaf=frame[s,9],
thetaf=frame[s,10], p0h=px0hpx1h[1], p1h=px0hpx1h[2], n0h=n0h,
meanvec1h=mu1h, thetafactual=frame[s,14], var1=1600, var2=1600,
nsim=nsim, plotconvg=0, nsimtrial=nsimtrial)
check <- c(s, value$baytype1error, value$freqtype1error, value$expsamplesize)
dim(check) <- c(1,4)
write.table(check, file.con, quote=F, row.names=F, col.names=F, append=T)
baypowerzero[s] <- value$baytype1error
freqpowerzero[s] <- value$freqtype1error
expsszero[s] <- value$expsamplesize
}
close(file.con)
frame$baypowerzero <- baypowerzero
frame$freqpowerzero <- freqpowerzero
frame$expsszero <- expsszero
frame
write.csv(frame, "frame4twostage.csv", row.names=F, quote=F)
# end of chapter code
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Chapter 6
Summary and Further Work
6.1 Summary
As the cost of clinical development increases while success rates still remain low, the bio-
pharmaceutical research community is widely embracing new adaptive methods across all
phases of the developmental process. Due to the complex dependent nature of the data
structure and uncharted properties of many adaptive design, extensive applications are still
rare. This dissertation aims to examine the characteristics of current adaptive methodolo-
gies used in phase 2 dose-ranging and phase 3 pivotal trials and proposing improved trial
designs.
As discussed in Chapters 1 and 2, such adaptive designs are sometimes known as the Seam-
less phase 2/3 clinical trials (Maca et al., 2006). These are deliberate designs that combine
the objectives of two traditionally separate trials into one single trial, such as the selection
of an optimal dose in a phase 2 dose-ranging trial and the confirmation of this selected
dose in a large-scale phase 3 randomized clinical trial. These designs aim at shortening the
wait time between trials and operationally combine these objectives within one single study
protocol. If these designs allow for early termination, then they are more efficient with
respect to the type I error allocated, compared to conducting two separate trials. Many
innovative and interesting approaches that classified themselves as Seamless study designs
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were found in the literature, which include, although are not restricted to, (1) incorporating
a parametric model (linear or non-linear) to aid the selection of either the minimum effec-
tive dose (MED) or the maximum biological dose (MBD) (Huang, Liu, and Hsiao, 2010),
(2) using a surrogate endpoint or an early outcome to inform the selection (Shun, Lan,
and Soo, 2008; Friede et al., 2011), (3) implementing response-adaptive randomization to
narrow down to one or two treatment arms (Wang and Cui, 2007), and others. In addition,
Bayesian Seamless 2/3 designs are also proposed and they elicit prior information to help
them improve overall performance (Schmidli, Bretz, and Racine-Poon, 2007). The analysis
of Seamless designs also presents challenges in controlling type I error. Statistical methods
such as different p-value Combination Tests have been proposed and they extended to tri-
als with multiple treatment arms, allowing for multiplicity adjustment (Bauer and Kieser,
1999).
In this dissertation, we have proposed an adaptive staggered dose design for both selecting a
dose and confirming the selected dose within a single trial. We recognize that if some qual-
itative information about the dose response is available such as monotonicity or downturn,
we can prioritize and stagger the candidate doses in such a way that the trial can explore
the doses of assumed better efficacy first before reaching to doses of uncertain efficacy later.
The application of an alpha spending function will be a good choice to favor the earlier
doses but this still allows the trial to proceed to the remaining doses if earlier doses do not
show evidence of efficacy. The operating characteristics of this design were examined and
discussed, and its strengths and weaknesses were also explored. We also discussed that in
some situations, we are not comparing and selecting doses of the same agent, but rather
different regimes or treatment modalities. In this case, staggered treatment modalities can
be explored one after the other with the assumed best one receiving favorable alpha spend-
ing. If we can assume that subjects who enter the trial are from a study population with a
relatively stable profile of characteristics over the study period, we do not have to continue
the control arm to the last arm of the experimental treatment and in this case, we can
further reduce the expected sample size. In Chapter 4, we also provide a brief discussion of
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how this adaptive staggered treatment design can be flexibly varied in order to optimize its
performance in dose selection and confirmation, as well as how it can be extended to binary
and survival endpoints. For example, if we are interested in locating the dose that gives
the lowest risk of a binary safety endpoint among doses that exhibit comparable efficacy,
under large sample condition and if the probability is not too close to either 0 or 1, then we
can use normal approximation to obtain the standardized test statistic and its distribution
under null hypotheses.
As for the proof of bioisimilarity, we have chosen to approach this testing problem from
a Bayesian perspective. As many innovator biological products in the market will have
their FDA licenses expiring in the next decade or so, pharmaceutical companies are in-
terested in developing generic versions of the same products. Therefore, many biosimilar
products, which are also known as follow-on biologics or subsequent-entry products, need to
demonstrate similarity in all aspects of the product’s characteristics: molecular structure,
functional assay, toxicity, and efficacy, against the backdrop of the original reference prod-
uct. We advocate for a Bayesian approach because it formally allows the incorporation of
historical trial information on the reference product into the analysis of the current biosim-
ilarity. We also choose the non-inferiority framework as it may require smaller sample size.
Within the hierarchical bias model proposed in the method, the elicitation of a skeptical
prior on the bias parameter allows the method to have good control on the Bayesian type
I error even when the constancy assumption does not hold slightly, and as a result, the
Bayesian power suffers moderately. However, when sample size increases in the case of true
biosimilarity, we confirm that the method can give better statistical power than the frequen-
tist approach. An adaptive two-stage design can shorten the biosimilarity trial and reduce
the expected overall trial sample size if biosimilarity is highly plausible. The simulation for
the two-stage trial design was computationally intensive as predictive probability was used
as a monitoring criterion. As of the writing of this dissertation, no Bayesian method has
yet been published for the establishment of biosimilarity.
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6.2 Further Work
Previously in Section 6.1, we have discussed some of the strengths and weaknesses of the
proposed adaptive methodologies. For the adaptive staggered treatment design, there are
at least two statistical properties of the design that may require further characterization.
1. Futility Analysis
In the proposed method, we did not consider early stopping due to futility. The
introduction of futility analysis into the design may allow it to drop inferior doses
earlier before they go through all of the pre-assigned M per-dose stages, therefore,
saving subjects from being randomizing to these inefficacious doses as well as getting to
the more efficacious faster, particularly when the a priori dose ordering fails to order
the more efficacious doses in earlier positions. In this case, one has to distinguish and
decide between the specification of either binding or non-binding futility. Binding
futility refers to the condition when the futility boundary is crossed, and the dose has
to be jettisoned from the study without affecting the type I error, otherwise, under
non-binding futility when the dose can be dropped or retained in the study even if
futility boundary is crossed. In this case, the corresponding efficacy boundary will
have to be adjusted upward to maintain the overall type I error. Futility analysis is
related to type II error and can be implemented using a beta spending function, β(t).
2. Maximum Likelihood Estimator (MLE)
In the usual two-arm group sequential clinical trial using a continuous endpoint, it is
well-known that the sampling distribution of the maximum likelihood estimator does
not follow exact normal distribution. An exposition of this point estimation problem
can be found in chapter 8 of “Group Sequential Methods with Applications to Clinical
Trials” by Jennison and Turnbull (2000). In order to investigate this problem, we can
look at Figure 6.1 which displays the sampling distributions of the MLE of the four
doses.
175
0.0 0.2 0.4 0.6 0.8 1.0
0
1
2
3
4
5
d=2, order=4
MLE of mu4=0.219, E(MLE)=0.368
Sa
m
pl
in
g 
di
st
rib
u
tio
n
0.0 0.2 0.4 0.6 0.8 1.0
0
1
2
3
4
5
d=4, order=3
MLE of mu3=0.292, E(MLE)=0.421
Sa
m
pl
in
g 
di
st
rib
u
tio
n
0.0 0.2 0.4 0.6 0.8 1.0
0
1
2
3
4
5
d=6, order=2
MLE of mu2=0.328, E(MLE)=0.442
Sa
m
pl
in
g 
di
st
rib
u
tio
n
0.0 0.2 0.4 0.6 0.8 1.0
0
1
2
3
4
d=8, order=1
MLE of mu1=0.35, E(MLE)=0.448
Sa
m
pl
in
g 
di
st
rib
u
tio
n
Emax / Informative / Rho=0.3 / 80% / c=63
Figure 6.1: The sampling distributions of the four doses for Emax dose response, informative
dose ordering, and Rho spending with ρ = 0.3. Cohort size c= 63 with power of 80%
We can see in each plot, the dashed curve represents the sampling distribution when
the dose crosses efficacy boundary at m = 1 and the dotted curve represents that
at m = 2. We notice that under informative ordering, d1 = 8 has the highest mean
outcome of µ1 = 0.350, and thus sample mean will have to be larger for m = 1
conditioned on the event that its value is large enough to allow the rejection of the null
hypothesis. The two conditional sampling distributions will be combined to obtain the
sampling distribution of the MLE conditioned on the rejection of the null hypothesis
for the dose. The blue vertical line represents the true value of the mean, while the red
vertical line represents the mean of combined sampling distribution. Therefore, the
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MLE itself is biased upward under this staggered dose design. As complete correction
of the estimation bias may not be possible, methods of reducing this bias for the group
sequential design have been proposed. This can be another area of further research,
but it is also important to caution that estimation upon selection will result in bias
in our proposed adaptive design and for the group sequential method in general.
For the Bayesian biosimilarity design, there are at least three areas that may warrant further
research and investigation.
1. Synthesis of Collective Biosimilarity Evidence
According to the guidance for the industry document on the scientific and statistical
considerations of biosimilarity presented by the FDA, two main principles of prov-
ing biosimilarity are succintly advocated, (1) totality-of-evidence approach, and (2)
stepwise approach (FDA, 2012). Although the document did not proceed to explain
these principles in detail, the industry is free to interpret them as an approach that
the proof of bisimilarity is not simply based on evidence from one or two clinical
studies. It is based on a collection of evidence that comprehensively shows that the
two polypeptides (reference and follow-on) are similar in major components despite
some dissimilarity in minor aspects. In fact, the Bayesian approach is still a desirable
method to collectively synthesize the evidence that is accumulated through a series
of studies. Perhaps a method that weighs the relative importance of the individual
studies (animal, toxicity, molecular, functional, bioavailability, and clinical studies)
and synthesizes the evidence collectively, may further help to reduce the sample size
needed to conduct the final clinical study.
2. Discounting the Historical Trials
Instead of modeling the heterogeneity of the historical trials hierarchically in the pro-
posed method, information accrued from historical trials may be discounted due to
discrepancies between the design and conduct of the historical trials and the current
trial of biosimilarity. Methods of discounting historical information have been pro-
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posed such as the power prior density (Ibrahim and Chen, 2000) and commensurate
prior density (Hobbs, Carlin, Mandrekar, and Sargent, 2011). In this case, additional
power parameter or commensurate parameters will be specified as well as their prior
distributions.
3. Dependence Between Individual ACR20 Endpoints
In the Bayesian method proposed, the seven individual ACR20 endpoints are assumed
to be separate and independent; however, in some cases, this assumption may not be
true, and therefore the Bayesian method can be updated to allow for the specifica-
tion of a correlation structure. Composite endpoints are useful and their statistical
properties are not fully known. It is important to have studies that can fully describe
the properties of a composite endpoint, which is usually defined based on a number
of individual endpoints, and can estimate their potential dependency structure. In
the Bayesian paradigm, for example, prior density for unstructured correlation matrix
can be flexibly modeled via the inverse-Wishart distribution.
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- Aug 2005
Provided clinical mental health services including individual, group, and family therapy. Con-
ducted intakes and assessments, furnished diagnostic, treatment, and outcome reports, and
provided multi-cultural counseling, mainly to Asian population but also to other cultural
groups.
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